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The roles of omega-3 long chain polyunsaturated fatty acids (n-3 LC-PUFA) on diverse 
physiological processes impacting health and chronic diseases have been well 
documented. Early intervention studies, such as GISSI (Gruppo Italiano per lo Studio 
della Sopravvivenza nell'Infarto Miocardico), reported a reduction in all-cause mortality 
and in sudden death after consuming n-3 LC-PUFA (Investigators, 1999). Furthermore, a 
consistent finding is that high intakes of n-3 LC-PUFA lowers plasma triglyceride levels 
(McKenney and Sica, 2007), reduces pain in subjects with rheumatoid arthritis (Goldberg 
and Katz, 2007) and can modestly reduce blood pressure (Colussi et al., 2014, Cabo et 
al., 2012).  
However, little scientific attention has been paid on the actual bioavailability of n-3 LC-
PUFA such as eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-
3) and docosahexaenoic acid (DHA, 22:6n-3) from food sources (fish, krill, fish oil and 
other sea foods) or dietary supplements. In most studies, bioavailability has been 
estimated by equating it with the blood levels achieved after consumption of fish or fish 
oil capsules. The results from such studies on the bioavailability of n-3 LC-PUFA have 
shown mixed results, depending on a number of factors including considerable 
variability in the experimental designs. The previous differences in findings generated 
the initial impetus for a review of the current literature reported in Chapter 2 of this 
thesis and published in Progress Lipid Research (2014). The review suggested specifically 
tailored future methodological and analytical approaches should be used when 
assessing the bioavailability of n-3 LC-PUFA dietary supplements in humans. This review 
paper further suggested that it is difficult to draw substantiated conclusions for 
14 
 
comparative bioavailability from available human and animal studies due to in first 
instance the loose definition of the term bioavailability and then also to a series of 
important factors, such as the highly heterogeneous nature of previous study designs 
including lack of standard analytical methodologies, failure to provide equal amounts of 
the n-3 LC-PUFA being compared, failure to provide the dose of n-3 LC-PUFA based on a 
body weight, failure to measure fatty acid excretion and failure to control the total fat 
intake. 
To fill this gap, the broad aim of this thesis was to investigate the bioavailability of n-3 
LC-PUFA in rats using a set of criteria outlined for conducted studies reported in the 
review paper (Chapter 2). It should be noted that there may be differences between rats 
and humans in terms of lipid metabolism, but in the literature many papers reported 
studies on the bioavailability of n-3 LC-PUFA in rats (Di Marzo et al., 2010, Rossmeisl et 
al., 2012, Batetta et al., 2009, Yang et al., 1990). Moreover, in this thesis, the specific 
method used was the “Whole Body Fatty Acid Balance Method”, and the intake, 
accumulation/deposition, metabolic fate and excretion of fatty acids was monitored. 
Indeed, in this method the whole rats’ body was used for analysis which couldn’t have 
been observed by running a “simple digestibility study” in humans. 
The recommendations for the intake of n-3 LC-PUFA vary from eating fish (‘once to twice 
per week’ for oily fish) to consuming specified amounts of EPA and DHA (‘250–500 mg 
per day’). It is not known if there is a difference in the uptake/bioavailability between 
consuming fish twice per week or taking supplements every day. Therefore, examining 
this question was the rationale for Chapter 3 with the objective to compare the 
15 
 
bioavailability of a daily dose (Constant) versus a large weekly dose (Spike) of n-3 LC-
PUFA. To investigate this question, six-week old healthy male Sprague Dawley rats were 
fed either the Spike, Constant, or Control treatment for six weeks and the results 
collected were to be analysed using the Whole Body Fatty Acid Balance Method. The 
Spike treatment was designed to contain 7-fold the n-3 LC-PUFA level of the Constant 
treatment and calculation by the Specialty Feeds showed that the ratio of DHA to EPA 
would be the same (0.68) for both Spike and Constant treatments since the same oil was 
being used in each of these diets. The results of this experiment showed that the ratio 
of DHA to EPA in the Constant group was considerably greater than this ratio in the Spike 
group, especially for white gastrocnemius muscle, heart, perirenal adipose tissue and 
whole body. In addition, the ratio of DHA to DPA differed greatly between the Constant 
and Spike groups – this ratio was higher in the Constant group compared with the Spike 
group in all tissues studied. These differences were unexpected. There were also more 
unexpected results from this study: 
x Rats fed the Constant treatment had greater levels of DHA than EPA, despite the 
Constant treatment providing more EPA (0.13%) than DHA (0.09%). 
x There were lower levels of DHA in tissues of the Spike group compared with the 
levels of DHA in tissues of the Constant group, so it was initially speculated that the 
Spike diet had less DHA than the Constant diet. 
x The EPA levels in Spike group were consistently higher than in the Constant group.  
These findings led the composition of the two diets to be questioned. Accordingly, the 
diets were then analysed at Deakin University in two different laboratories using 
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different Gas Chromatography (GC) instruments. The data showed that the Spike and 
Constant diets had different n-3 LC-PUFA proportion and ratios. To confirm the data 
obtained at Deakin University, the two diets were sent to “National Measurement 
Institute” in Melbourne. It was reported that the Spike diet contained only 3.5 times the 
omega-3 content of the Constant diet, which confirmed the results found in two 
different laboratories at Deakin University. In addition, the fatty acid profile and the 
ratios of DHA/EPA were not identical (0.6 in Spike treatment and 6 in the Constant 
treatment), strongly suggesting two different fish oils were used; the Constant diet was 
a DHA-rich oil (similar to a typical tuna oil) and the Spike diet was an EPA- rich oil (similar 
to a typical anchovy oil).  
As a result of the unexpected differences in fatty acid profiles of the Constant and the 
Spike treatments, the diet manufacturer (Specialty Feeds, WA) was contacted to 
ascertain what could have contributed to the wrong oils being included in these two 
treatments. After considerable discussion, the diet manufacturer admitted that two 
different fish oils had been used. Clearly, the experiment failed due to not checking the 
fatty acid composition of diets prior to conducting the study.   
Before the experiment was repeated, a considerable effort was made to ensure the diets 
would be made according to specification, including analysis of oils and test diet batches. 
The repeated experiment had the same design as before: six-week old healthy male 
Sprague Dawley rats were fed either the Spike, Constant, or Control diet for six weeks 
which contained total EPA+DHA+DPA levels of 8.0 mg/g/wk (Constant), 9.2 mg/g/wk 
(Spike) and 0 mg/g/wk of diet (Control) and the results collected were analysed using 
17 
 
the Whole Body Fatty Acid Balance Method. The whole body, tissues and collected 
faeces were analysed for fatty acid content. The findings suggested that a large dose of 
n-3 LC-PUFA once per week (Spike) was more effective in increasing whole body n-3 LC-
PUFA content compared with a smaller dose delivered daily (Constant). These results 
have been published in Nutrients (June 2015). 
The effects of krill oil as an alternative source of n-3 LC-PUFA have been investigated in 
the past several years. It has been claimed by various industry sources, with no clearly 
documented evidence, that n-3 LC-PUFA from krill oil are much more “bioavailable” than 
those from fish oil. This apparent difference has been attributed to differences in 
molecular structure and antioxidant content between these two marine n-3 LC-PUFA 
sources. In fish oil, the n-3 LC-PUFA are mostly esterified in triglycerides, whereas in krill 
oil the fatty acids are largely found in phospholipids, triglycerides and free fatty acids. 
There are conflicting results on differences in bioavailability from the few available 
studies comparing the effects of fish oil and krill oil. Therefore, the next aim of this thesis 
(Chapter 4) which has been published in British Journal of Nutrition (June 2015) was to 
compare the bioavailability and metabolic fate (absorption, β-oxidation and tissue 
deposition) of omega-3 fatty acids originating from krill oil (phospholipid-rich) or fish oil 
(triglyceride-rich) in rats of both sexes using the Whole Body Fatty Acid Balance Method. 
To do so, Sprague Dawley rats (36 male, 36 female) were randomly assigned to have 
either a krill oil diet (10% fat by weight, EPA+DHA+DPA=1.38 mg/g of diet) or a fish oil 
diet (10% fat by weight, EPA+DHA+DPA=1.61 mg/g of diet) to constant ration for 6 
weeks. The faeces, whole body and individual tissues were analysed for fatty acid 
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content. This study showed that significantly more n-3 LC-PUFA were deposited when 
originating from krill oil, than from fish oil, in both sexes, by a mean difference of 13.2%. 
Furthermore, and independently from the dietary treatment, it was found that female 
rats deposited a significantly higher proportion of the dietary n-3 LC-PUFA intake than 
did male rats, with the mean difference between females and males being 10.3%. 
In Chapter 5, the bioavailability of EPA and DPA was investigated and results of this study 
have been published in Prostaglandins, Leukotrienes & Essential Fatty Acids, 2014. The 
rationale for this study was based on findings from a human study that DPA and EPA had 
different and specific incorporation patterns in plasma lipids, red blood cell lipids and 
chylomicrons. Thus, this study was specifically designed to assess the relative loss of DPA 
or EPA in faeces after equal dietary intake, and whether there were different patterns 
of incorporation of dietary DPA or EPA into tissues. To do so, male Sprague Dawley rats 
were randomly assigned to three groups of six, and were fed a semi-synthetic high fat 
diet (23.5% fat) for 9 days. The test omega-3 fatty acids (EPA and DPA, 
250 mg/animal/day, free fatty acid form) or olive oil (250 mg/animal/day) were added 
to the high fat diet on days 5, 6 and 7. Findings from this chapter suggested that dietary 
DPA was less bioavailable than EPA, since proportionally more was excreted in faeces. 
However, there were similar deposition rates for the two n-3 LC-PUFA into tissues, which 
suggested that the EPA was more prone to catabolic processes compared with DPA.  
This thesis is submitted by publication, and it is structured with six chapters as follows. The 
literature review (Chapter 2) and each research question (Chapter 3, 4 and 5) are addressed 
by one publication. Therefore, chapters have been published in the form they are presented 
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here except table numbering which has been addressed per-chapter. The order of the papers 
presented corresponds with the order of the research questions. An introductory chapter 
(Chapter 1) and a conclusive chapter (Chapter 6) have also been included to complement the 
presentation of the published work.  
CHAPTER 1: Summary of thesis  
CHAPTER 2: Literature Review (Publication 1) 
CHAPTER 3: What is the most effective way of increasing the bioavailability of dietary Long 
Chain Omega-3 Fatty Acids - Daily vs Weekly Administration of Fish oil? (Publication 2) 
CHAPTER 4: Deposition of Long Chain Omega-3 Fatty Acids Is Influenced by the Oil Source 
(Krill Oil or Fish Oil) and by Sex in the Rat (Publication 3) 
CHAPTER 5: Comparison of the Bioavailability of Docosapentaenoic Acid (DPA, 22:5n-3) and 
Eicosapentaenoic Acid (EPA, 20:5n-3) in the Rat (Publication 4) 
CHAPTER 6: Conclusions and Future Directions. 
This research was conducted in the absence of any commercial or financial relationships that 
could be constructed as a potential of interest.  
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 Abstract 
This review considers the bioavailability of different forms of omega-3 long chain 
polyunsaturated fatty acids (n-3 LC-PUFA), including ethyl esters (EE), free fatty acids 
(FFA), triacylglycerols (TAG) and phospholipids (PL). The retrieved studies include short-
term and longer-term studies in humans, and a number of animal studies, which were 
highly heterogeneous in their design making it difficult to draw substantiated 
conclusions. The apparent bioavailability (as defined by the authors of these studies) 
seems to be lowest for the EE form and highest for the FFA form, whilst no conclusion 
can be made for TAG versus PL from human data. Animal studies suggest that there are 
substantial differences in the bioavailability of PL form of n-3 LC-PUFA compared with 
the TAG form. This apparent limited knowledge and understanding is fundamentally 
driven by methodological limitations of these studies. The major limitations with the 
studies to date include: (between studies) loose definition of the term bioavailability, 
lack of standardisation of analytical methodology, and differences in which blood 
compartment was analysed; (within a study) failure to provide equal amounts of the n-
3 LC-PUFA of the different forms being compared, failure to provide the dose of n-3 LC-
PUFA on a body weight basis, failure to measure fatty acid excretion, failure to control 
the total fat intake, and failure to adequately power the studies from a statistical point 
of view. This review has laid out a set of suggestions and criteria for conducting future 
studies on the bioavailability of different chemical forms of n-3 LC-PUFA. 
Key words: DHA; EPA; Ethyl esters; Fish oil; Free fatty acid; Krill oil; Omega-3 fatty acids; 
Phospholipids; Polyunsaturated fatty acids; Triacylglycerol.  
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 Introduction  
Omega-3 long chain polyunsaturated fatty acids (n-3 LC-PUFA) are highly unsaturated 
fatty acids which are particularly abundant in fish and other seafood. There are three 
main n-3 LC-PUFA: eicosapentaenoic acid (EPA; 20:5n-3), docosapentaenoic acid (DPA; 
22:5n-3) and docosahexaenoic acid (DHA; 22:6n-3); however, since there has been 
relatively little research on DPA (Kaur et al., 2011a), this review will focus on EPA and 
DHA. In the last five decades, it has been well documented by a plethora of studies that 
the ingestion of EPA and DHA can improve health and in some instances can contribute 
to preventing disease. Therefore, various national and international health authorities 
have made recommendations for n-3 LC-PUFA dietary intakes, which range from 250 mg 
per day up to 2 g per day of EPA plus DHA (FAO/WHO, 2008, Mozaffarian and Wu, 2012). 
In Australia, the daily required intake for healthy adults of approximately 500 mg of n-3 
LC-PUFA has been recommended by National Health and Medical Research Council of 
Australia; whilst the American Heart Association recommendation for patients with 
coronary heart disease is 1 g EPA plus DHA per day, and for patients with high plasma 
triglyceride levels, the recommendations range from 2 to 4 g EPA plus DHA per day 
(McKenney and Sica, 2007). The European Society of Cardiology recommended 1 g of 
EPA plus DHA for secondary prevention of coronary heart disease (Werf et al., 2003). 
However, the ingestion of a given quantity of n-3 LC-PUFA does not directly correlate 
with the actual quantity of n-3 LC-PUFA available for the body. As with all nutrients, the 
rate n-3 LC-PUFA digestion, absorption, excretion and retention in tissues (i.e. n-3 LC-
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PUFA bioavailability) can differ for n-3 LC-PUFA differently esterified (i.e. contained in 
different chemical macromolecules). 
Dietary supplements of n-3 LC-PUFA are widely available, and these are commonly in 
triglyceride (TAG; natural sources typically derived from fish oil) form, in free fatty acid 
(FFA) form, or in ethyl esters (EE) form, with both of the latter forms being derived from 
natural sources of fish oil TAG. More recently, krill oil derived sources, which contain a 
significant portion of their n-3 LC-PUFA in phospholipids (PL) and FFA form, are also 
increasingly found on the market, and marketed as being of “higher efficacy”, compared 
with traditional n-3 LC-PUFA supplements.  
The commercial interest in n-3 LC-PUFA dietary supplements has been fuelled by the 
almost overwhelming number of published studies on the potential effects of dietary n-
3 LC-PUFA. However, and quite surprisingly, little scientific attention has been paid on 
the actual bioavailability of n-3 LC-PUFA in various dietary supplements. This 
observation generated the initial impetus for this review paper, but at time of writing it, 
the first review paper by Schuchardt and Hahn (2013) on the topic of bioavailability of 
n-3 LC-PUFA was published. This elegantly presented review paper focused primarily on 
the sources and chemical forms of n-3 LC-PUFA, and the possible mechanisms 
responsible for different bioavailability values observed for different chemical forms of 
n-3 LC-PUFA. As concluded by the authors, the information available thus far is not fully 
clear and mixed results have been reported. Another comprehensive review which 
compliments the present review is that by Michalski et al (2013) which considered in 
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detail the influence of multiscale food / lipid structures (molecular and supramolecular) 
structures on fatty acid bioavailability and lipid metabolism.  
As a result, we chose to adopt a different approach to our review by focussing on 
methodological considerations of studies on bioavailability of omega-3 fatty acids, 
specifically in humans, but considering also relevant information available from animal 
studies. Thus the aims of this paper were to i) review the available scientific literature 
and knowledge relative to the bioavailability of n-3 LC-PUFA, when supplied in different 
chemical forms, ii) summarise the existing evidence of possible differences in 
bioavailability; and iii) carefully analyse the strengths and the limitations of these 
studies, paying specific attention to methodological considerations. 
The ultimate objective of this study was to complement the information provided by 
Schuchardt and Hahn (2013), and then suggest specifically tailored future 
methodological and analytical approaches to be used when assessing the bioavailability 
of n-3 LC-PUFA dietary supplements in humans - an area of research that clearly 
deserves a much more focused and substantiated scientific effort. 
 
 Literature search; methods and results of selected studies 
To retrieve the relevant studies to be used in this review paper, a search strategy using 
Medline/Pubmed, ScienceDirect, Web of Science, EMBASE was conducted using the 
following search terms: bioavailability, long chain fatty acids, omega-3, DHA, EPA, 
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formulation, omega-3 index, fish oil, krill oil, capsule, and matrix. Subsequently all 
retrieved studies were analysed by carefully reading the full-text articles.  
Of the 21 human studies reviewed, 4 articles were eliminated because they did not 
include a control group. Seventeen studies which reported on the association between 
bioavailability and n-3 LC-PUFA formulations in humans were selected. 
A total of 8 studies were found as postprandial or short-term trials of up to 72 hours and 
reported hereafter as Case Studies 1 to 8, respectively:  
x El Boustani et al (1987), Case Study 1; study length 24 hours; 
x Lawson and Hughes (1988a), Case Study 2;  study length 12 hours; 
x Lawson and Hughes (1988b), Case Study 3; study length 8 hours; 
x Beckermann et al (1990), Case Study 4; study length 32 hours; 
x Nordoy et al (1991), Case Study 5; study length 24 hours; 
x Wakil et al (2010), Case Study 6; study length 24 hours; 
x Schuchardt et al (2011b), Case Study 7; study length 72 hours; 
x Davidson et al (2012), Case Study 8; study length 24 hours; 
Nine longer-term studies were found which ranged in length from two weeks to six 
months reported hereafter as Case Studies 9 to 17, respectively. Of these nine studies, 
only 2 studies analysed red blood cell membranes (RBC) and the remainder analysed 
either serum/plasma fatty acid or whole blood; thus, direct comparison between these 
longer-term studies is difficult.  
x Reis et al (1990), Case Study 9, study length 6 months; 
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x Krokan et al (1993), Case Study 10,  study length 2 weeks; 
x Hansen et al (1993), Case Study 11, study length 7 weeks; 
x Maki et al (2009), Case Study 12, study length 1 month; 
x Dyerberg et al (2010), Case Study 13, study length 2 weeks; 
x Neubronner et al (2011), Case Study 14,  study length 6 months; 
x Ulven et al (2011), Case Study 15, study length 7 weeks; 
x Ramprasath et al (2013), Case Study 16, study length 1 month; 
x Laidlaw et al (2014), Case Study 17, study length 1 month; 
Of the 14 animal studies reviewed, 2 articles were eliminated because they did not 
include a control group. Six studies which reported on the association between 
bioavailability and n-3 LC-PUFA formulations in animals were selected, and six studies 
reported specifically on the bioavailability of PL form of n-3 LC-PUFA compared with TAG 
form were selected. These are reported in two separate sections. 
 
Animals studies - bioavailability of n-3 LC-PUFA formulations: 
x Hamazaki et al (1987), Animal Study 1, compared TAG, PL, EE; 
x Yang et al (1990), Animal Study 2 – compared TAG, EE and methyl esters; 
x Ikeda et al (1995), Animal Study 3 – compared TAG, FFA and EE; 
x Batetta et al (2009), Animal Study 4 – compared fish oil and krill oil;  
x Di Marzo et al (2010), Animal Study 5 – compared fish oil and krill oil; 
x Tou et al (2011), Animal Study 6 – compared fish oil  and krill oil; 
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Animal studies – bioavailability of LC-PUFA from PL forms and TAG forms: 
x Amate et al (2001), Animal Study 7, compared TAG and PL (arachidonic acid and DHA); 
x Cansell et al  (2003) , Animal Study 8, compared PL emulsion and TAG (n-3 LC-PUFA); 
x Cansell et al  (2006) , Animal Study 9, compared PL emulsion and TAG (n-3 LC-PUFA); 
x Rossmeisl et al (2012), Animal Study 10, compared TAG and PL (n-3 LC-PUFA); 
x Graf et al (2010), Animal Study 11, compared TAG and PL (DHA); 
x Wijendran et al (2002), Animal study 12, compared TAG and PL (arachidonic acid); 
 
In this review, human and animal studies are reported separately. The human studies 
are presented in two sections according to the length of study: i) postprandial (short-
term) studies (section 2.1); and ii) longer-term studies (section 2.2). In most studies, 
subjects were tested with more than two n-3 LC-PUFA preparations and in the case of 
cross-over studies there was usually a 1-2 week wash-out between different 
supplements, with the exception of Laidlaw (2014) and Ramprasath (2013), in which a 4 
and 8 week wash-out period between treatments was used, respectively. The animal 
studies are presented following the human studies, since they were not consistently 
directed at comparing the same outcomes as in the human studies. 
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2.3.1 Human studies   
2.3.1.1 Postprandial studies 
2.3.1.1.1 Methods of postprandial studies 
The measured outcomes for the assessment of the bioavailability of n-3 LC-PUFA 
included the concentration (or percentage relative to total fatty acids) of EPA and DHA 
in total lipids of plasma, serum, chylomicrons or in plasma lipid fractions such as TAG, 
PL, FFA and cholesterol esters (CE). A summary of the main data from these studies is 
reported in Table 2.1. 
Most studies were conducted giving from approximately 1 g (El Boustani et al., 1987) up 
to 3.1 g (Beckermann et al., 1990) of EPA or EPA plus DHA to healthy subjects (El Boustani 
et al., 1987, Lawson and Hughes, 1988a, Lawson and Hughes, 1988b, Beckermann et al., 
1990, Nordoy et al., 1991, Schuchardt et al., 2011b) or to overweight subjects (Davidson 
et al., 2012); amounts that are above the normally recommended intake levels. One 
study (Nordoy et al., 1991) used very large doses of n-3 LC-PUFA (14 g EPA plus 8 g DHA 
in TAG form versus 13.7 g EPA plus 10.4 g DHA in EE form), which were clearly well above 
recommended intakes.  
Most studies were conducted with a relatively small number of participants (between 5 
to 16 subjects of mixed gender), with the only exception being the study from Davidson 
et al (2012), which enrolled 54 subjects. 
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2.3.1.1.2 Results of postprandial studies 
An improved bioavailability of EPA and DHA when supplied in FFA form, compared with 
TAG or EE forms, was reported in several studies (El Boustani et al., 1987, Lawson and 
Hughes, 1988a, Lawson and Hughes, 1988b, Beckermann et al., 1990, Davidson et al., 
2012). Most trials also reported a significantly higher bioavailability of EPA and DHA from 
TAG (or randomised triglyceride) compared with EE (El Boustani et al., 1987, Lawson and 
Hughes, 1988a, Lawson and Hughes, 1988b, Beckermann et al., 1990, Schuchardt et al., 
2011b). However, one study suggested that the bioavailability of EPA and DHA was 
comparable when supplied in TAG form or EE form (Nordoy et al., 1991). Importantly, it 
should be noted that this study differed from the others not only for this conclusion, but 
also because it was conducted using substantially larger n-3 LC-PUFA doses.  
Overall, the findings of these short-term studies, and according to authors conclusions, 
suggested that the bioavailability of EPA and DHA from different chemical forms, as 
measured by incorporation into plasma lipids, was highest for FFA, followed by TAG (or 
randomised triglyceride), and lowest for the EE (Table 2.1). 
Case Study 1. In a study by El Boustani et al (1987), 8 healthy volunteers were given 1 g 
of EPA in four different forms (FFA, EE, Arginine salt and 1,3-dioctanoyl-2-
eicosapentaenoyl glycerol, a synthetic TAG). They concluded that the EPA was 
significantly less incorporated into plasma TAG after ingestion of the EE than after 
ingestion of the three other forms. The limitations of this study were the small number 
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of subjects, there was no indication of randomisation of the subjects to treatment, nor 
was the gender specified. 
Case Study 2. In a study by Lawson and Hughes (1988a), 16 male subjects were given 5 
g of fish oil co-ingested with a high fat meal (44 g total fat). The authors reported a 
greater bioavailability of EPA and DHA from the TAG form than from the EE form. In 
addition, their results showed that absorption of EE form was highly dependent on the 
amount of co-ingested fat. The strength of this study was the identical doses used 
between treatments, while a limitation of this study was the small number of subjects.  
Case Study 3. Lawson and Hughes (1988b) found a greater bioavailability of EPA and 
DHA from the TAG form than from the EE form when 5 g of fish oil with a low fat meal 
(8 g total fat) was given to 8 male volunteers. In this trial, they also studied the FFA form 
and found that the incorporation of the n-3 LC-PUFA into plasma TAG was significantly 
higher when supplied in FFA form compared with TAG and EE forms. A limitation of this 
study was the small number of subjects. 
Case Study 4. A randomized triple cross-over study by Beckermann et al (1990) in 8 
healthy female subjects demonstrated that the uptake of EPA and DHA in FFA form was 
significantly greater than that recorded for the TAG form. EPA and DHA in TAG form was 
in turn shown to have a significantly greater uptake than that in EE form. In this study, 
the interpretation of EPA and DHA uptake was based on area under the plasma 
concentration time curve over a 32 hour period after consumption. The limitations of 
this study were the small number of subjects and that the dose of n-3 LC-PUFA provided 
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in the various forms were different, with the dose from the EE being greater than that 
of the FFA, which was greater than that of the TAG form (Table 2.1).  
Case Study 5. Nordoy et al (1991) found there was no significant difference in absorption 
of n-3 LC-PUFA from both TAG and EE form, when approximately 20 g of EPA plus DHA 
was given to 5 healthy subjects (2 females, 3 males). They found that the levels of EPA 
and DHA in chylomicron TAG and plasma lipid fractions were similar for TAG and EE, 
compared with the placebo oil. The limitations of this study included the small number 
of subjects, the very large doses of the n-3 LC-PUFA and the fact that the TAG and EE 
forms contained different amounts of n-3 LC-PUFA. 
Case Study 6. The bioavailability over a 24 hour period of 4.5 g of TAG and re-constituted 
TAG containing 0.9 g EPA per day was studied by Wakil et al (2010) in 7 healthy subjects 
(4 females, 3 males). The TAG form was almost 100% triacylglycerol; however, the re-
constituted TAG form was a mixture of monoglyceride, diglyceride and more than 60% 
triglyceride. In the TAG form, EPA was mainly located in positions sn-1 and 3, and DHA 
in position sn-2, whereas EPA and DHA were randomly distributed in all three sn- 
positions in the re-constituted TAG. The results of this study showed that EPA 
bioavailability from re-constituted TAG was not significantly different to that obtained 
from normal TAG. The limitations of this study were the low number of subjects and the 
fact that the re-constituted TAG was only 60% TAG. 
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Case Study 7. Schuchardt et al (2011b) designed a study in which 1.6 g of EPA plus DHA 
in the form of TAG, EE and krill oil were given to 12 healthy male volunteers. Krill oil has 
a different composition to typical fish oils, in that this oil typically contains the n-3 LC-
PUFA in both re-esterified TAG and PL forms. They found no significant differences in 
the incorporation of EPA and DHA into plasma PL between the different n-3 LC-PUFA 
forms. The authors acknowledged that plasma PL was not the most appropriate lipid 
compartment to examine for bioavailability in a short-term study. A strength of this 
study was that the fish oil and krill oil treatment contained similar amount of EPA plus 
DHA; however, there was a difference in the total lipid content of the supplements 
between groups (3400 mg/d in the TAG and EE group vs 7000 mg/d in the PL group).  
Case Study 8. The bioavailability of EPA and DHA from single 4 g doses of n-3 LC-PUFA 
in FFA and EE forms was investigated in 54 overweight subjects (13 females; 41 males) 
in a prospective open-label randomized cross-over study (Davidson et al., 2012). They 
reported a 4-fold increased bioavailability of EPA plus DHA from FFA compared with EE 
after co-ingestion of these with a low fat meal. When the preparations were co-ingested 
with a high fat meal (containing 20 g of fat), there was also a smaller (1.2x) but still 
significant increase in bioavailability from the FFA form versus the EE form.  The 
limitations of this study included an uneven gender balance, the potential bias of 
authors as employees of the company supplying the supplements being tested and lack 
of detail on the EPA and DHA content of the different forms tested.  
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2.3.1.2 Longer-term studies  
2.3.1.2.1 Methods of longer-term studies  
Nine longer-term studies which were specifically designed to test the bioavailability of 
EPA and DHA from various n-3 LC-PUFA formulations were retrieved in the available 
scientific literature. The duration of the intervention for these studies varied from 2 
weeks to 6 months.  
In six out of nine of these studies (Krokan et al., 1993, Hansen et al., 1993, Maki et al., 
2009, Dyerberg et al., 2010, Ulven et al., 2011, Reis et al., 1990), the fatty acid 
composition of serum TAG and/or plasma fatty acids was analysed as the end point. In 
one study, the percentage of EPA plus DHA (relative to total fatty acids) in RBC was used 
as the end point (Neubronner et al., 2011), and in another study, the fatty acid 
composition of both plasma and RBC was analysed (Ramprasath et al., 2013). In a study 
by Laidlaw et al (2014), whole blood fatty acids were analysed as the end point. The total 
numbers of subjects participated in studies ranged from 24 to 129 (mixed gender). A 
summary of the main data from these studies is reported in Table 2.2. 
In the longer-term studies, the doses chosen ranged from 0.24 g (Laidlaw et al., 2014) 
up to 7.3 g (Krokan et al., 1993) of EPA plus DHA per day, and were administered to 
healthy subjects (Dyerberg et al., 2010, Hansen et al., 1993, Krokan et al., 1993, 
Ramprasath et al., 2013, Laidlaw et al., 2014), to overweight subjects (Maki et al., 2009), 
to hyperlipidemic subjects (2011), to subjects with normal or slightly elevated total 
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blood cholesterol and/or triglyceride levels (Ulven et al., 2011) and to subjects with 
coronary artery disease (Reis et al., 1990). 
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Table 2-1. A summary of experimental design and results from eight postprandial (short-term) studies 
Reference  Number of 
participants 
Type of 
study 
Test formulation Period of 
study  
Tissue / blood  Results reported in the papers Limitation  
(El Boustani et 
al., 1987) 
8 healthy subjects  
Gender was not 
specified 
Unspecified  FFA, EE, Arg-FFA, C8-
TAG 
1 g dose of EPA from 
FFA, EE,  
Arginine salt,  
1,3-dioctanoyl-2-
eicosapentaenoyl 
glycerol (TAG) 
 
Postprandial 
study (24 h) 
following by a 
week wash out 
between 
studies 
Blood sampling at 
times 0, 1, 2,3, 4, 5, 
6, 9, 12 & 24 h 
 
Plasma triglyceride 
analysed 
 
The incorporation of EPA into plasma 
TAG was significantly lower from ethyl 
ester compared with FFA form, TAG 
form or arginine salt of EPA. 
 
No indication of 
randomisation or gender 
of subjects.  
Small sample size. 
(Lawson and 
Hughes, 
1988a) 
16 M  
healthy subjects 
 
 
Randomised, 
parallel 
groups  
design, n=8 
per group 
TAG, EE 
5 g fish oil TAG or EE 
containing 1.00g EPA 
and 0.65 g DHA 
consumed together 
with 3.5 g linseed oil. 
Capsules were taken 
with high fat breakfast  
(44 g fat) 
Postprandial 
study (24 h) 
Blood sampling at 
times 0, 3, 5, 6, 7, 8, 
10 & 12 h  
 
Plasma triglyceride 
fatty acids analysed 
 
The maximum increases in omega-3 
fatty acids occurred at 5-6h in most 
subjects. 
EPA absorption, relative to ALA, in 
plasma TAG significantly higher after 
fish oil compared with EE.  
No difference in the absorption of 
DHA in plasma TAG between the two 
oil supplements. 
 
Low number of subjects 
(Lawson and 
Hughes, 
1988b) 
8 M 
healthy subjects  
Randomized 
design to 3 
treatments  
TAG, FFA, EE 
5 g fish oil TAG, FFA, or 
EE containing 1.00g EPA 
and 0.67 g DHA 
Postprandial 
study following 
by 1-2 weeks 
wash out 
Blood sampling at 
times 0, 2,3, 4, 5, 6, 7 
& 8 h  
The incorporation of EPA and DHA 
into plasma TAG from EE was 
significantly lower than that from 
TAG, and in turn the incorporation of 
Low number of subjects   
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consumed together 
with 2.0 g linseed oil. 
Capsules were taken 
with low fat breakfast 
(8 g fat) 
 
between 
treatments  
 
Plasma TAG fatty 
acids analysed 
EPA and DHA from FFA was 
significantly greater than from TAG 
 
 
 
(Beckermann 
et al., 1990) 
8 F 
healthy subjects 
Randomized 
triple cross-
over trial 
TAG, FFA, EE 
G1: TAG (1.68 g EPA and 
0.72 g DHA). 
G2: FFA (1.35 g EPA and 
1.065 g DHA). 
G3: EE (1.86 g EPA and 
1.27 g DHA). 
 
Postprandial 
study (32 h) 
Blood samples taken 
at 0, 1, 2, 3, 4, 5, 6, 7, 
8, 10, 12, 24 and 32 
hours. 
Plasma analysed for 
area under the curve 
for EPA and DHA. 
Plasma level was significantly greater 
for the FFA form compared with TAG 
form, which in turn was significantly 
greater than EE form. 
  
The three treatments 
contained different 
amounts of EPA and DHA. 
 
 
(Nordoy et al., 
1991) 
2 F, 3 M  
healthy subjects  
 
Unspecified TAG, EE 
G1: 40 g TAG (14 g EPA 
and 8 g DHA). 
G2: 28 g EE (13.7 g EPA 
and 10.4 g DHA). 
G3:28 g EE (13.7 g EPA 
and 10.4 g DHA) + 12 g 
olive oil, 
G4: 40 g olive oil 
 
 
Postprandial 
study (24 h), 
each test was 
conducted 1 to 
2 weeks apart.  
Blood sampling at 
times 0, 2, 4, 6, 8 & 
24 h 
 
Plasma TAG, PL and 
CE and chylomicron 
triglyceride analysed 
EPA & DHA peak concentration in 
chylomicrons reached 6 hours after 
supplementation. 
 
There were no significant difference 
in the incorporation of EPA and DHA 
from TAG and ethyl ester form in 
plasma lipids and chylomicron TAG. 
 
 
Very large dose of n-3 fatty 
acids and low number of 
subjects. 
The amounts of n-3 fatty 
acids varied between TAG 
and EE. 
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(Wakil et al., 
2010) 
4 F, 3 M healthy 
subjects 
Double blind 
cross-over 
trial, 
sequence of 
supplements 
chosen 
randomly.  
 
TAG, rcTAG, eTAG, DG, 
MG 
All subjects provided 
with 4.5 g of the each 
formulation (0.89 g EPA 
and 0.35 g DHA) 
 
Postprandial 
study (24 h) 
following by a 
7-day washout 
between 
studies   
Blood sampling at 
times 0, 2, 4, 6, 8 & 
24 h  
 
Serum EPA levels 
analysed 
Serum EPA peak concentration 
reached 6-8 hours after 
supplementation. 
Bioavailability based on area under 
the curve measurements showed 
that rcTAG and nTAG were 
significantly greater than eTAG and 
MG 
rcTAG (where EPA is randomly 
distributed) were not less absorbed 
than those taken from natural fish oil 
 
Low number of subjects 
lead to high variability of 
data.  
Four of the five 
preparations were >90% 
pure compounds, but 
rcTAG was a mixture of 
TAG (61%) and DG (33%). 
Lack of data on the 
position of PUFA in the 
glyceride molecule. 
 (Schuchardt 
et al., 2011b) 
12 M 
healthy subjects 
 
Double- 
blinded 
crossover trial  
EE, PL, reTAG 
G1: Fish oil reTAG 
(1.008 g EPA and 0.672 
g DHA) 
G2: Ethyl Esters (1.008 g 
EPA and 0.672 g DHA) 
G3: Krill oil, mainly PL 
(1.050 g EPA and 0.630 
g DHA) 
Capsules were taken 
with breakfast. The 
total fat intake 
(breakfast + capsules) 
was 33.5 g for the 
reTAG and the EE 
treatment and 37.1 g 
for the krill oil 
treatment 
 
Postprandial 
study (72 h) 
following by 2 
weeks wash out 
between 
treatments 
Blood sampling at 
times 0, 2,4, 6, 8, 24, 
48 & 72 h 
 
Plasma phospholipid 
EPA, DHA & total n-3 
FA analysed 
Plasma PL levels peaked at 24 hours 
for EPA. DHA levels did not show 
obvious peak in absorption. 
 
Data showed variability (high SD) and 
there were no significant differences 
in the incorporation of EPA or DHA 
into the plasma PL between 
treatments. 
 
 
Plasma PL not regarded as 
best indicator of 
postprandial absorption. 
 
Different amounts of fat 
consumed between krill oil 
and other groups. 
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(Davidson et 
al., 2012) 
41 M, 13 F 
overweight adults  
 
Randomized, 
open-label, 
single dose, 4-
way crossover 
trial; subjects 
consumed 
low fat meal 
for each 
treatment 
followed by 
high fat meal 
for each 
treatment. 
EE, FFA 
G1: 4 g FFA (2.2 g EPA 
and 0.8 g DHA) 
G2: 4 g EE (1.7 g EPA 
and 1.38 g DHA). 
 
There were two low 
and two high fat 
periods for the study.   
 
The meals for the low-
fat periods were no 
breakfast, a no-fat 
lunch (0 g fat; 600 kcal) 
and a low-fat dinner (9 
g fat; 900 kcal) 
For the high-fat periods 
the meals were a high-
fat breakfast (20 g fat; 
600 kcal), a high-fat 
lunch (30 g fat; 900 
kcal), and a high fat 
dinner (30 g fat; 900 
kcal) 
Postprandial 
study (24 h) 
following by at 
least a week 
wash out 
between 
treatments  
Blood sampling at 
times 0, 1, 2,3, 4, 5, 
6, 7, 8, 10, 12 & 24 h 
 
 
Total plasma fatty 
acids analysed 
The peak increase in EPA+DHA was at 
5 hours post ingestion for low fat and 
high fat periods. 
There was a significantly greater 
increase in the area under curve for 
plasma EPA plus DHA for the FFA form 
versus EE form in the low fat 
consumption period, by a factor of 
4.2. 
There was a significantly greater 
increase in the area under curve for 
plasma EPA plus DHA for the FFA form 
versus the EE form in the high fat 
consumption period, by a factor of 
1.2. 
 
Differences between low 
and high fat periods (no 
breakfast in low fat) 
period). 
There was almost 
negligible increase in 
plasma EPA+DHA in low fat 
period for the EE form. 
Differences in the two oils 
used - the FFA preparation 
was encapsulated and 
coated with polyacrylate 
which facilities a delayed 
release in gut (to avoid 
unpleasant GI effects). The 
EE were not claimed to be 
encapsulated. 
No details were provided 
on the EPA and DHA 
content of the 
preparations. 
Authors are employed by 
fatty acids provider 
company  
 
        
Abbreviations - FA: fatty acid, FFA: free fatty acids, EE: ethyl esters, PL: phospholipids, TAG: triglycerides, rcTAG: re-constituted triglyceride, reTAG: re-
esterified TAG, nTAG: natural triglyceride, eTAG: Enzymatic Triglyceride, DG: Diglyceride, MG: Monoglyceride.
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2.3.1.2.2 Results of longer-term studies 
The bioavailability of EPA and DHA from EE and TAG was investigated in most longer-
term studies retrieved (Table 2.2). The bioavailability of EPA and DHA in FFA form was 
also compared with the other two forms (EE and TAG) in the study by Dyerberg et al 
(2010); the bioavailability of EPA and DHA from PL and TAG forms was investigated in 
three studies (Maki et al., 2009, Ulven et al., 2011, Ramprasath et al., 2013). Some 
conflicting results were observed when comparing these studies. In two trials, EPA and 
DHA in TAG form were reported to be significantly more bioavailable compared with 
those originating from EE form (Dyerberg et al., 2010, Neubronner et al., 2011); whilst 
three studies found no difference in bioavailability for these two forms of n-3 LC-PUFA 
(Reis et al., 1990, Krokan et al., 1993, Hansen et al., 1993). Maki et al (2009) showed no 
difference in bioavailability for fish oil and krill oil treatments; while two studies (Ulven 
et al., 2011, Ramprasath et al., 2013) suggested krill oil was more bioavailable than fish 
oil by a factor of up to 1.6 times.  
Overall, these nine studies were of different designs and, not surprisingly, the results 
achieved were mixed and somewhat inconsistent between studies. 
Case Study 9. Reis et al (1990) designed a randomised double blind study in which 6.2 g 
per day of EPA plus DHA (7 g of total n-3 LC-PUFA) in the form of EE and 4.8 g per day of 
EPA plus DHA (6 g of total n-3 LC-PUFA) in the form of TAG were given to 32 and 36 
patients with coronary artery disease for six months, respectively. The results of this 
study showed that there were no significant differences between treatments in the 
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levels of EPA at 3-months and 6-months in plasma PL, which rose in both groups five 
times higher compared with the control group who received 12 g per day olive oil. They 
also reported that there were no differences between the two forms of n-3 LC-PUFA for 
DHA levels in the plasma PL, but the data were not shown. The strengths of this study 
are the length of time and the number of subjects, while the limitations were that 
different doses of n-3 LC-PUFA were given to each group and the fact that the gender of 
the subjects was not specified.  
Case Study 10. In a parallel group design study by Krokan et al (1993), 5 groups of 8 
healthy male subjects consumed between 4 and 24 g of n-3 LC-PUFA preparation in EE 
or TAG form per day. These preparation contained different amounts of n-3 LC-PUFA 
from either EE (G1: 2.2 g EPA plus 1.2 g DHA; G2: 4.4 g EPA plus 2.4 g DHA; G3: 7.7 g EPA 
plus 4.2 g DHA) or from TAG (G4: 2.2 g EPA plus 1.4 g DHA; G5: 4.4 g EPA plus 2.9 g DHA), 
which were administered twice daily with meals for two weeks. The author concluded 
that there were no significant differences in the concentrations of EPA and DHA in both 
serum total lipid fatty acids and serum PL fatty acids after 14 days. The limitations of this 
study included the fact that different doses of n-3 LC-PUFA were used for the 
preparations, the relatively short length of the study and the low number of subjects 
studied. 
Case Study 11. Hansen et al (1993) conducted a randomized double blind study with 31 
healthy male volunteers provided with 2.2 g of EPA plus 1.2 g of DHA in EE form or 2.2 g 
of EPA plus 1.4 g of DHA in TAG form, for seven weeks. The authors reported that there 
were no statistically significant differences in the incorporation of EPA and DHA into 
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plasma phospholipid between the EE and TAG forms; however, there was a significantly 
higher proportion of EPA in the plasma CE fraction in the TAG group versus the EE group. 
The strengths of this study include the length of time and the number of subjects, while 
the limitation was that the doses of DHA were different between the groups. 
Case Study 12. In a randomized, double-blind parallel arm study by Maki et al (2009), 76 
obese men and women consumed 2 g of either fish oil (n=26, 0.212 g EPA plus 0.178 g 
DHA per day), krill oil (n=25, 0.216 g EPA plus 0.09 g DHA per day) or olive oil (n=21) for 
4 weeks. The results showed that plasma EPA and DHA concentrations increased 
significantly in the krill oil group (178.4 ± 38.7 and 90.2 ± 40.3 μmol/L, respectively) and 
fish oil group (131.8 ± 28.0 and 149.9 ± 30.4 μmol/L, respectively) compared with the 
olive oil group (2.9 ± 13.8 and -1.1 ± 32.4 μmol/L, respectively); however, there was no 
significant differences between fish oil and krill oil groups. Limitation of this study 
related to the failure to have identical doses of n-3 LC-PUFA between treatments and 
the lack of information on the lipid composition of fish oil and krill oil.  
Case Study 13. Another randomised double blind trial compared the apparent 
bioavailability of TAG, re-esterified TAG, EE or FFA forms (Dyerberg et al., 2010). In this 
study, 3.1-3.6 g of EPA plus DHA in encapsulated preparations were given to 72 healthy 
subjects (36 females, 36 males), twice daily, for 14 days. They found a significantly lower 
bioavailability in serum lipids (TAG, CE and PL) of EPA plus DHA from EE compared with 
FFA, TAG and re-esterified TAG. The strength of this study was the number of subjects 
used, while the limitations included the fact that the doses of n-3 LC-PUFA were different 
between groups and the relatively short duration of the study. 
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Case Study 14. A double-blind placebo controlled trial was conducted by Neubronner et 
al (2011) in which 1.68 g of EPA plus DHA in the form of re-esterified TAG and EE were 
given to 86 out of 129 hyperlipidemic subjects (65 females and 64 males), for six months. 
In this study, RBC membrane fatty acid composition was analysed. Their results showed 
there was a significantly greater incorporation of EPA and DHA into RBC membrane lipids 
from the re-esterified TAG form compared with EE form, which was already evident at 
3 months’ time, and this difference was maintained out to the completion of the trial at 
6 months. Within each treatment, no significant increase in the EPA and DHA levels 
between 3- and 6-months was recorded. The strengths of this study were that the doses 
used were identical between treatments, the large number of subjects, the length of the 
study and the choice of RBC n-3 LC-PUFA as a marker of longer-term n-3 LC-PUFA status 
(Harris and Thomas, 2010).  
Case Study 15. Ulven et al (2011) conducted an open single-center, randomized parallel 
study with 113 healthy male and female volunteers with normal or slightly elevated total 
blood cholesterol and/or triglyceride levels provided with 3 g of krill oil or 1.8 g of fish 
oil for seven weeks. They found that the daily dose of krill oil containing 0.543 g EPA plus 
DHA increased the plasma level of EPA and DHA to the same extent as the dose of fish 
oil containing 0.864 g EPA plus DHA, which suggested krill oil was more bioavailable than 
fish oil by a factor of 1.59. The limitation was that the doses of n-3 LC-PUFA were 
different between the groups. 
Case Study 16. A randomised double-blind crossover trial compared the apparent 
bioavailability of PL and TAG forms from krill oil and fish oil (Ramprasath et al., 2013). In 
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this study, 3 g of either krill oil (0.777 g of EPA plus DHA), fish oil (0.663 g EPA plus DHA) 
or corn oil were daily given to 24 healthy subjects (12 females, 12 males) for 4 weeks. 
The authors reported that plasma and RBC EPA and DHA proportions increased 
significantly in the krill oil group compared with fish oil group. In the RBC, the increase 
in EPA plus DHA proportions in the krill oil treatment was a factor of 1.09 times that of 
the fish oil group. The limitations of the study were that the doses of EPA plus DHA were 
different, and the atypical fish oil composition which contained a very high level of 
linoleic acid (32%), in contrast the krill oil has only 2% linoleic acid. In a commentary 
following the release of this article, this concern was highlighted and it was suggested 
that the trial could have been biased by the use of an unusual a fish oil, which appeared 
to be a mixture of a fish oil product diluted or blended with an oil enriched in linoleic 
acid (Nichols et al., 2014). 
Case Study 17. An open-label, randomized, cross-over study by Laidlaw et al (2014) in 
35 healthy subjects (17 females, 18 males) demonstrated that the mean whole blood 
EPA and DHA percentage increased significantly in concentrated TAG group compared 
with that recorded for the EE, TAG and PL forms. In this study, either fish oil in 
concentrated TAG form (1.1 g of EPA plus DHA), fish oil in EE from (0.984 g of EPA plus 
DHA), krill oil in PL form (0.24 g of EPA plus DHA), or salmon oil in TAG form (0.4 g of EPA 
plus DHA) were given daily to subjects for 4 weeks. The daily dose of each supplement 
was chosen based on the label by the manufacturer; as a result of the large difference 
in intake per day from the four different forms there was as expected a large difference 
in the whole blood n-3 LC-PUFA levels. The limitation of this study was that the doses of 
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n-3 LC-PUFA were considerably different between the groups (240 mg per day up to 
1100 mg per day). 
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Table 2-2. A summary of experimental design and results from nine longer-term studies. 
Reference  Number of 
participants 
Type of study Test formulation Period of 
study  
Tissue / blood  Results reported in the papers Limitation  
(Reis et al., 
1990) 
89 subjects with 
coronary artery 
disease.  
Gender was not 
specified 
 
Randomized 
double-blind 
study, n=36 TAG, 
n=32 EE and n=21 
olive oil. 
EE, TAG 
G1: 7 g EE (3.7 g EPA 
and 2.5 g DHA/d) 
G2: 6 g TAG (3.4 g EPA 
and 1.4 g DHA) 
G3: 12 g olive oil/day 
 
6 months  Blood sampling at 
day 0, 6 & 6 months. 
 
Plasma PL analysed  
No significant differences in the 
incorporation of EPA and DHA into 
plasma PL from the two formulations 
found.  
Doses of EPA and DHA 
were not identical 
between ethyl ester and 
TAG groups. 
(Krokan et 
al., 1993) 
40  M  
healthy subjects 
Unspecified  
n= 8 
 
EE, TAG 
G1: 4 g EE (2.2 g EPA 
and 1.2 g DHA/d) 
G2: 8 g EE (4.4 g EPA 
and 2.4 g DHA/day) 
G3: 14 g EE (7.7 g EPA 
and 4.2 g DHA/day) 
G4: 12 g TAG (2.2 g EPA 
and 1.4 g DHA/day) 
G5: 24 g TAG (4.4 g EPA 
and 2.9 g DHA/day) 
 
14 days  Blood sampling at 
days 0, 8 & 15 h after 
intake the last 
supplementation  
 
Total serum fatty 
acids and  
phospholipids 
analysed 
The amounts of EPA and DHA in total 
serum lipids and in serum 
phospholipids were essentially 
identical for the two ester forms of 
the n - 3 fatty acids 
 
In vitro hydrolysis of natural fish oil 
was faster than synthetic ethyl ester 
while the enteral absorption of EPA & 
DHA from these two were similar 
 
Doses of EPA and DHA 
were not identical 
between ethyl ester and 
TAG groups. 
 
Randomisation of subjects 
not specified. 
 
Did not compare blood 
levels of EPA and DHA 
between TAG and ethyl 
ester forms. 
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(Hansen et 
al., 1993) 
31 M 
healthy subjects 
Randomized 
double-blind 
study, n=10 TAG, 
n=11 EE and n=10 
placebo. 
EE, TAG 
G1: 12 g TAG (2.2 g EPA 
and 1.4 g DHA/day) 
G2: 4 g EE (2.2 g EPA 
and 1.2 g DHA/day) 
G3: 4 g corn oil 
(placebo) 
 
7 weeks  Blood sampling at 0, 
1, 3 and 7 weeks. 
 
Plasma PL and CE 
fatty acids analysed 
EPA in plasma CE was significantly 
greater at 7 weeks in TAG v EE group. 
No significant differences in the 
incorporation of EPA and DHA into 
plasma PL from the two formulations 
were found 
 
The doses of DHA were 
different between the 
groups 
(Maki et al., 
2009) 
 
76 obese men & 
women 
Randomized, 
double-blind 
parallel arm trial 
n=25 krill, n=26 
fish, n=25 control  
 
Krill oil, Fish oil  
G1: 2 g krill oil (0.216 g 
EPA and 0.09 g 
DHA/day) 
G2: 2 g fish oil (0.212 g 
EPA and 0.178 g 
DHA/day) 
G3: 2 g olive oil - control   
 
1 month Blood sampling at 
week 0 & 4.  
 
Total plasma fatty 
acids was analysed 
No significant differences in EPA and 
DHA concentration between treated 
groups.   
 
Doses of DHA were not 
identical between 
experimental  groups 
 
(Dyerberg et 
al., 2010) 
36 M, 36 F 
healthy subjects 
Randomised 
double blind 
design for fish oil 
formulations and 
placebo groups. 
Single blind design 
for cod liver oil 
and fish body oil 
Six groups with 
n=12/group. 
FFA, reTAG, nTAG, FFA 
G1: 6.5 g reTAG (1.85 g 
EPA and 1.29 g 
DHA/day), 
G2: 6.5 g FFA (2.18 g 
EPA and 1.40 g 
DHA/day, 
G3: 6.5 g EE (1.87 g EPA 
and 1.39 g DHA/day), 
14 days Blood sampling at 
days 0 & 14.  
 
Serum TAG, CE & PL 
analysed 
Bioavailability of EPA+DHA was 
significantly greater for reTAG 
compared with FFA and EE. There 
was no difference in bioavailability 
between reTAG and FBO. 
The randomization of EPA and DHA in 
the triacylglycerols had no bearing on 
the bioavailability of n-3 LC-PUFA  
 
Doses of EPA and DHA are 
not identical between 
ethyl ester and TAG groups 
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 G4: 13.0 g fish body oil 
(2.04 g EPA and 1.48 g 
DHA/day), 
G5: 12.0 g Cod liver oil 
(1.38 g EPA and 1.87 g 
DHA/day), 
G6: 6.5 g corn oil/day. 
 
(Neubronne
r et al., 
2011) 
64 M, 65 F 
hyperlipidaemic 
subjects  
 
 
Randomised 
double-blinded 
placebo-controlled 
parallel design 
trial, all on statins; 
subjects were 
from 4 different 
cities.  n=41 
reTAG, n=45 EE, 
n=43 placebo. 
reTAG, EE 
G1: x g of reTAG (1.01 g 
EPA and 0.67 g 
DHA/day),  
G2: x g of EE (1.01 g EPA 
and 0.67 g DHA/day), 
G3: x g Corn oil placebo. 
 
 
 
6 months  Blood sampling at 
days 0, 3 & 6 
months.  
 
RBC membrane total 
FA was analysed  
EPA+DHA consumed as reTAGs 
resulted in a significantly greater 
increase in the proportions of EPA and 
DHA compared with EE at both 3- and 
6-months. DPA levels were not 
different between treatments. 
Three months of n-3 FA treatment 
resulted in significant increases of 
EPA, DPA & DHA content in RBC 
membranes compared with the 
placebo group. There was further 
increase of EPA & DHA between 
months three and six but was not 
significant. 
 
Total weight of oil 
consumed per day (in 
capsules) not specified. 
(Ulven et al., 
2011) 
113 men & 
women 
Subjects with 
normal or 
slightly elevated 
total blood 
cholesterol 
and/or TAG 
levels 
An open single-
center, 
randomized, 
parallel 
group designed 
study 
n=36 krill, n=40 
fish, n=37 control  
Krill oil, Fish oil  
G1: 3 g krill oil (0.543 g 
EPA+DHA/day) 
G2: 1.8 g fish oil (0.864 g 
EPA+DHA/day) 
G3: control – no 
supplement    
7 weeks  Blood sampling at 
week 0 & 7 
 
Total plasma lipid 
analysed 
Bioavailability of EPA+DHA was 
significantly greater for krill oil 
compared with fish oil treatment. 
Doses of n-3  LC-PUFA 
were not identical 
between experimental  
groups 
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(Ramprasath 
et al., 2013) 
12 M, 12 F 
healthy subjects 
Double blinded, 
randomized, 
crossover trial 
Krill oil, Fish oil  
G1: 3 g krill oil (0.33 g 
EPA and 0.19 g 
DHA/day) 
G2: 3 g fish oil (0.28 g 
EPA and 0.18 g 
DHA/day) 
G3: 3 g corn oil  
 
1 month study 
following by a 
8-weeks 
washout period 
 
 
Blood sampling at 
week 0 & 4 
Total plasma and 
RBC fatty acid 
analysed 
Krill oil consumption increased 
significantly plasma and RBC n-3 
PUFA proportions, including 
EPA and DHA compared with fish oil 
consumption. 
Doses of EPA+DHA were 
not identical between 
experimental groups while 
two treatment provided 
the identical n-3 PUFA.   
 
(Laidlaw et 
al., 2014) 
18 M, 17 F 
healthy subjects 
 
Open-label, 
randomized, 
crossover trial 
 
TAG, EE, krill oil (PL)  
G1: x g of concentrated 
TAG (0.65 g EPA and 
0.45 g  DHA/day),  
G2: x g of EE (0.756 g 
EPA and 0.228 g 
DHA/day), 
G3: x g of PL (0.15 g EPA 
and 0.09 g DHA/day) 
G4: x g of TAG (0.18 g 
EPA and 0.22 g 
DHA/day) 
4 weeks Blood sampling at 
days 0 & 28 
 
Whole blood FA was 
analysed 
Bioavailability of EPA+DHA was 
significantly greater for fish oil 
compared with krill oil treatment 
Doses of EPA and DHA 
were very different 
between groups. 
 
Total weight of oil 
consumed per day (in 
capsules) not specified. 
        
Abbreviations – FA: fatty acid, FFA: free fatty acids, EE: ethyl esters, PL: phospholipids, TAG: triglycerides, reTAG: re-esterified TAG, nTAG: natural 
triglyceride, eTAG: Enzymatic Triglyceride, DG: Diglyceride, MG: Monoglyceride.
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2.3.2 Animal studies  
2.3.2.1 Methods of animal studies 
Twelve animal studies which compared the bioavailability of EPA and DHA from various 
n-3 LC-PUFA formulations were retrieved in the available scientific literature. Of these, 
three studies (Batetta et al., 2009, Di Marzo et al., 2010, Tou et al., 2011) compared the 
bioavailability of fish oil and krill oil in which Batetta et al (2009) and Di Marzo et al 
(2010) focused on the comparison of the production of endocannabinoids from fish oil 
and krill oil in Zucker rats.  
In nine studies, rats were chosen as an animal model; however, other authors used mice, 
piglets and baboons in their research (Rossmeisl et al., 2012, Wijendran et al., 2002, 
Amate et al., 2001). In these animal studies the following criteria were used: animal per 
group, length of study, applied dose, gender of animals, and the end-point outcomes. 
The number of animals per group in studies ranged from 2 to 10. In animal studies, the 
doses chosen ranged from 0.2 g EPA or DHA in the test diet (Ikeda et al., 1995) up to 30 
g of EPA plus DHA per kg of the diet (Rossmeisl et al., 2012). The duration of the 
intervention for these studies varied from 24 hour to 4 weeks.  
 
2.3.2.2 Results of animal studies – bioavailability and n-3 LC-PUFA formulations 
Animal Study 1. Hamazaki et al (1987) implemented a study to evaluate the efficiency 
of oral administration of TAG, phosphatidylcholine (PC) and EE forms of EPA on the 
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proportions of EPA in plasma PL and cholesterol ester in 18 male Wistar rats weighing 
about 500 g in two different lengths of feeding (4 days and 10 days).  In this study, 400 
mg/kg of EPA in the form of liquid (5 ml) was given to rats daily through a gastric tube. 
The results showed that, there was no significant increase in the EPA level of plasma PL 
and cholesterol ester among groups in the short-term feeding. However, after 10 days 
treatment, EPA content of both plasma PL and cholesterol ester of rats supplemented 
with EPA in EE form was significantly higher than that PC forms. There were no 
significant differences between EE-form and TAG-form. A possible explanation for the 
lower incorporation of EPA from the PC form was that it contained a high proportion of 
linoleic acid as well as EPA, and may have competed with the EPA for incorporation into 
the lipid classes.   
Animal Study 2. Yang et al (1990) designed a study in which 1-3 ml of menhaden oil or 
rapeseed oil or 1-3 ml of their fatty acid ethyl or methyl esters (ME) were given by 
stomach tube to male rats (n= 4, 2, 4, 5, respectively) and the lymph was collected for 
24 h. They found that there was a similar recovery of fatty acids from enterocytes 
following administration of EE and ME. They also found the lymphatic appearance of 
fatty acids from the digestion and absorption of the EE and ME was nearly 50% lower 
than that of TAG.  
Animal Study 3. In a study by Ikeda et al (1995), male Sprague Dawley rats (6 rats per 
group) were given 3 ml of a test emulsion through a gastric tube and the lymph was 
collected for the following 24 h. The 3-ml test emulsion contained 200 mg of sodium 
taurocholate, 50 mg of fatty acid-free albumin, and 200 mg of either TriEPA, TriDHA, 
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free EPA, free DHA, ethyl EPA, ethyl DHA or triolein. They found that the 24-hour 
lymphatic recovery of EPA and DHA in EE was significantly lower (approximately 30% 
and 40%, respectively) compared with that of FFA and TAG forms.  
Animal Study 4. In a study by Batetta et al (2009), low doses of n-3 LC-PUFA (0.5 g of 
EPA plus DHA per 100 g of diet) in the form of either fish oil (GC Rieber Oils) or krill oil 
(Superba, Aker BioMarine) were fed to 18 obese Zucker rats for 4 weeks. It was shown 
that in liver and heart tissues, EPA and DHA concentrations in the PL fraction were 
significantly increased in the krill fed rats compared with fish oil fed rats.  
Animal Study 5. Di Marzo et al (2010) reported the effects of the administration of 0.5% 
of EPA plus DPA in the form of either fish oil (GC Rieber Oils, AS, Kristiansand, Norway) 
or krill oil (SuperbaTM, Aker BioMarine, Oslo, Norway) to 18 obese Zucker rats for 4 
weeks. They reported that a significantly higher DHA level was found in brain PL of rats 
provided with krill oil compared with fish oil.  
Animal Study 6. Tou et al (2011) reported a study comparing the effects of different 
sources of n-3 LC-PUFA on digestibility and tissue deposition. In this trial, female Sprague 
Dawley rats were randomly assigned (10 rats per group) to be fed a high fat diet (12% 
lipid by weight) consisting of either corn oil, flaxseed oil, krill oil (Enzymotec Ltd.), 
menhaden oil, salmon or tuna oil for 8 weeks. The authors found that overall total lipid 
digestibility was lowest in krill oil fed rats (93.1%) compared with other groups (97%). 
Rats fed krill oil had significantly lower DHA digestibility and brain DHA incorporation, 
than rats fed salmon oil.  
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2.3.2.3 Animal studies – bioavailability of LC-PUFA from PL and TAG forms 
Animal Study 7. Amate et al (2001) implemented a study to evaluate the effects of TAG 
or PL forms of DHA and arachidonic acid (ARA; 20:4n-6) on plasma and plasma 
lipoproteins in Yorkshire piglets. Thirty infant pigs (5 day old) were bottle fed with either 
control diet (3.3 g fat per 100 g diet), or formulas enriched with DHA and ARA from either 
tuna and fungal (TAG form), or egg yolk (PL form) for 4 weeks. Both supplemented diets 
had 0.6 of ARA plus 0.3 g of DHA. It was shown that there were significant differences 
between the partitioning of ARA and DHA in the PL fraction of LDL and HDL; the TAG 
form led to significantly greater incorporation of ARA and DHA in LDL-PL, while the PL 
form led to significantly greater incorporation of ARA and DHA into the HDL-PL, thus 
emphasising the potential for different biological tissue fates of these PUFA from 
different sources. 
Animal Study 8. Cansell et al (2003) designed a study in which 0.4 g lipid in the form of 
either traditional fish oil (TAG) or specifically prepared marine lipid liposomes 
(containing 69% PL) (both with and without alpha-tocopherol) were given orally to male 
Wistar rats (n=5, 6) and the lymph was collected for 24 h. There was a significantly higher 
lymphatic bioavailability of PUFA from the PL form compared with the TAG form, and 
accordingly a significantly higher faecal excretion of PUFA from the TAG form. The EPA 
and DHA proportion in the lymph was higher after liposome ingestion (95% and 78%, 
respectively) compared with fish oil ingestion (42% and 47%, respectively). The two 
different forms of n-3 LC-PUFA (TAG and PL) led to different positional distributions of 
EPA and DHA in the chylomicron TAG. 
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Animal study 9. Cansell et al (2006) conducted a 13-day rat study, in which PL rich in n-
3 LC-PUFA delivered in micellar form showed significantly great incorporation of DHA in 
plasma TAG and plasma PL than the incorporation of DHA from the TAG form. A possible 
confounding factor in this study was that the PL micelles were also enriched in palmitic 
acid, whereas the TAG preparation was enriched in C12:0 and C14:0.   
Animal study 10. Rossmeisl et al (2012) implemented a study to assess the bioavailability 
of EPA and DHA originating from PL or TAG in 3 month-old male mice (8-9 mice per 
group) fed increasing intakes of DHA plus EPA for 2 weeks (from 1.2 up to 30.7 g/kg diet 
of EPA plus DHA); in this study, the plasma concentration was significantly higher in the 
PL-fed group especially for EPA and at higher dietary intakes. They also measured the 
EPA and DHA content in total plasma lipids, liver and white adipose tissue following a 9 
weeks period of feeding a high fat diet supplied with 30 g DHA plus EPA per kg either as 
PL or TAG, and found EPA levels in liver PL were nearly double in the PL-fed group 
compared with the TAG-fed group.  
Animal Study 11. In a study by Graf et al (2010), male Sprague Dawley rats (2, 4 and 10 
week old) were gavaged with 2 mg 14C-DHA/kg body weight, either in the form of PL, 
TAG or PL plus TAG. After 24 h, the distribution of radioactivity in body and brain regions 
was determined using quantitative whole body autoradiography. The authors found that 
the highest accumulation of 14C-DHA was found in the liver (14–30% of the dose) and 
very little (0.07–0.67%) of the 14C-DHA was found in brain at 24 h after the dose. In 10-
week-old rats, tissues such as liver, brain, kidney and retina accumulated 2–3 more 14C-
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DHA derived radioactivity after 14C-DHA in form of PL compared with 14C-DHA in form of 
TAG.  
Animal study 12. In a study by Wijendran et al (2002), female pregnant baboons 
received a single oral dose of 13C-ARA in form of either TAG (n=3) or PL (n=4) at 18–19 
day of age. Isotopic enrichment was measured 10 days after the treatment in various 
tissues (brain, lung, liver, retina, heart, plasma, RBC). Their results showed that 
significantly more label from PL form in tissues than TAG form. For example, in the brain, 
4.5% of the ARA in PL form and 2.1% of that in TAG from were recovered as brain 13C-
ARA indicating brain accumulated 2.1 more 13C-ARA derived radioactivity after 13C-ARA 
in form of PL compared with 13C-ARA in form of TAG. 
 
 Discussion  
The first and quite salient observation achieved by this review of evidence was that, 
despite the importance of the field and the constantly increasing and almost 
overwhelming number of publications focusing on biological effects and health 
interactions of n-3 LC-PUFA intake, surprisingly only few studies were found to deal 
directly with n-3 LC-PUFA bioavailability. The recent review paper dealing with the topic 
of n-3 LC-PUFA bioavailability by Schuchardt and Hahn (2013) comprehensively 
discussed this topic from the following points of view: mechanism of action, matrix 
effects, galenic effects (emulsification, micro-encapsulation), different foods, enteric 
coating, and also briefly referred to the issue of biological variability. This review covered 
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human studies, and readers are suggested to refer to it, as a useful complement to the 
present review. 
In our review of evidence, the human studies identified were of two different kinds, 
short-term (postprandial) and longer-term (from 2 weeks up to 6 months) interventions, 
slightly differently and inconsistently designed, and all fundamentally based on an 
estimation of bioavailability via the measurement of the levels or proportions of the n-
3 LC-PUFA in plasma lipids or RBC lipids, after administration of different preparations 
containing n-3 LC-PUFA in different chemical forms. Thus, it has been difficult, if not 
impossible, to compare the outcomes of the studies because of differences [a] in study 
design, [b] in the number of participants (which was commonly much smaller for short-
term studies), [c] in the length of the studies, [d] in the gender of participants, [e] in the 
total amount of fat and the actual concentration of n-3 LC-PUFA administrated (which 
was commonly higher in longer-term studies), [f] in the end-point outcome assessed for 
bioavailability estimation, and [g] in whether or not the different forms of n-3 LC-PUFA 
were given in equal amounts. It is also likely that many of the human studies considered 
in this review were underpowered from a statistical point of view, as discussed below. 
In spite of these limitations, it seems to be clear that the chemical form of n-3 LC-PUFA 
affects its bioavailability, but there is confusion and a lack of strong, substantiated and 
consistent evidence to directly address this issue and to, at least tentatively, quantify 
the extent of the differences in bioavailability. Therefore, the following discussion is 
divided into sections: the first one briefly addressing current knowledge and evidence 
on n-3 LC-PUFA bioavailability as affected by their chemical form, and the second one 
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specifically addressing a series of methodological considerations that are envisaged to 
be responsible for the current lack of robust evidence and that are hoped to be useful 
in designing future studies. 
 
2.4.1 Summary on current knowledge on n-3 LC-PUFA bioavailability 
In pharmacology, bioavailability is a well-defined and standardised term referring to the 
measurement of the rate and extent to which a drug reaches the systemic circulation 
(Kwan, 1997). However, when used with reference to nutrients, there is no agreed 
definition for the term bioavailability, and it is a term used more or less loosely to 
broadly describe how much of a given nutrient administered orally is then actually 
retained in the body, after its digestion and absorption; and thus in essence it is not 
different from the term “digestibility”. Nevertheless, whilst “digestibility” is well-defined 
term and its methods of evaluation are agreed and standardised, the term bioavailability 
is increasingly being used in nutrition science, and even more so specifically for n-3 LC-
PUFA. For this reason, in this review paper we decided to refer to the term 
bioavailability, even if, as it will be described in following sections, it should be better 
defined and standardised.  
The biochemical aspects potentially underpinning the possible differences observed in 
the bioavailability of n-3 LC-PUFA as affected by their chemical form were discussed and 
reviewed by Schuchardt and Hahn (2013). Accordingly, the present review of evidence 
suggests that overall, most of the short-term postprandial studies reported that the 
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bioavailability of EPA and DHA in EE form was significantly lower than the bioavailability 
of EPA and DHA in TAG form. Briefly, independently from the actual quantity provided, 
there are a number of different factors that could affect the bioavailability of different 
forms of n-3 LC-PUFA. These include pancreatic lipase activity, lymphatic recovery of 
fatty acids, the position of fatty acids in the glycerol backbone of triglyceride, the 
position of double bond from carboxyl-end, the molecular weight of n-3 LC-PUFA 
formulations, and the actual matrix in which the n-3 LC-PUFA were provided (Schuchardt 
and Hahn, 2013). The animal studies which compared different forms of n-3 LC-PUFA 
also found the EE form to be less bioavailable than FFA or TAG forms. However, 
Hamazaki et al (1987) showed that EPA in EE form and TAG form had similar 
bioavailability. Furthermore, two out of the three animal studies where krill oil was 
compared with fish oil for a variety of biological outcomes, the tissue incorporation of 
EPA and DHA was higher in krill oil fed animals than fish oil fed animals. Since the 
composition of krill oil varies, in terms of proportions of PL, FFA and TAG, the ability to 
compare between studies using different sources of krill oil is difficult, as is the reason 
for any apparent increase in the bioavailability of n-3 LC-PUFA. 
The animal studies comparing essential pure PL preparations with TAG form were 
generally consistent in showing different patterns of incorporation of n-3 LC-PUFA into 
different chylomicron and plasma lipids or lipoprotein fractions (Amate et al., 2001, 
Cansell et al., 2003, Cansell et al., 2006, Rossmeisl et al., 2012). This emphasises that the 
data do not support the simplistic view that PL and TAG fatty acids are metabolised in a 
similar fashion. In fact, the studies on PL versus TAG showed significantly greater 
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incorporation of the n-3 LC-PUFA into tissues from PL compared with TAG form. The 
difference in metabolic fates of DHA in PL or TAG form was highlighted in a 72 hour 
postprandial study in humans using 13C-DHA in the phosphatidylcholine (PC) form; this 
study revealed that the lipid form (PC versus TAG) markedly affected the kinetics and 
metabolic fate of the DHA in this time frame (Lemaitre-Delaunay et al., 1999). The 
authors considered that the supply of 13C-DHA to platelets occurred through non-
esterified fatty acids, in contrast to erythrocytes where the 13C-DHA was carried by both 
lyso-PC and non-esterified fatty acids. This kinetic analysis revealed a difference with an 
earlier study by this group which observed, after intake of triglycerides labeled with 13C-
DHA, that lyso-PC was the only source of 13C-DHA for erythrocytes (Brossard et al., 1997). 
Furthermore, it was reported that there was a delay in the peak labelling of plasma FFA 
and TAG after the labelled PC form (6 hours) compared with the labelling of these lipids 
following the labelled TAG form (2 hours). 
The above data is pertinent to the issue of whether krill oil n-3 LC-PUFA might be more 
bioavailable than that from fish oils; however, it should be noted that there are 
substantial differences in the relative proportions of PL, FFA and TAG in various krill oil 
preparations. Krill oil has been reported with different proportion of PL (from 34% to 
58%), FFA (from 6% to 22%) and TAG (from 23% to 36%) in several studies (Winther et 
al., 2011, Bottino, 1975, Tandy et al., 2009, Schuchardt et al., 2011b). The proportion of 
FFA in krill oil was only reported in one human study (Schuchardt et al., 2011b). As krill 
oil was manufactured for these human studies by different companies (Neptune 
Technologies & Bioressources Inc. (Schuchardt et al., 2011b), Enzymotec Ltd. 
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(Ramprasath et al., 2013), Source Naturals ArcticPure (Laidlaw et al., 2014), Aker 
BioMarine ASA (Maki et al., 2009, Ulven et al., 2011), and also as krill oil composition is 
variable from batch to batch, as affected by processing technologies and by seasonal 
variations (Saether et al., 1986), it is important that detailed information on lipid 
composition of krill oil should be provided in any study using it and aiming at assessing 
the bioavailability of EPA and DHA in PL. In this way, it may be possible to determine 
whether the relative proportions of PL, TAG, and FFA are responsible for any reported 
changes in EPA and DHA availability. Thus far, there have been only 5 human studies 
comparing the bioavailability of n-3 LC-PUFA found in fish oil vs krill oils (Maki et al., 
2009, Ulven et al., 2011, Ramprasath et al., 2013, Schuchardt et al., 2011b, Laidlaw et 
al., 2014). Given the very limited number of studies available, their mixed results, and 
the great market interest in krill oil, as a speculated more “efficient” and more 
sustainable source of n-3 LC-PUFA compared with traditional fish oil, further 
experimental investigations are clearly needed, for any possible conclusions to be drawn 
regarding comparative bioavailability of n-3 LC-PUFA from fish oil and krill oil.  
Though outside the specific scope of this review paper, a subsequent and important 
aspect to be considered is whether the differences found in incorporation of EE versus 
TAG versus FFA into blood fractions have any biological relevance, especially in terms of 
lowering plasma TAG concentrations. For example, consider the randomized double-
blind placebo controlled trial conducted by Schuchardt et al (2011a) in which corn oil as 
a placebo or fish oil either as TAG or EE in identical doses (1.01 g EPA plus 0.67 g DHA) 
were given to 150 dyslipidemic statin-treated participants for six months. They reported 
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that a significant decrease in serum TAG level from baseline value was only seen in the 
TAG-group compared with the EE-group (18.7% and -8.8%, respectively); suggesting that 
the measurable physiological effects of different preparations could be directly relative 
to their actual n-3 LC-PUFA bioavailability, or that the study was underpowered to 
establish an effect of the EE treatment. In contrast to a lack of data on EE versus 
TAG/FFA, there has been a plethora of studies in the biological impact of krill oil feeding, 
focussing on endocannabinoids, brain function, fatty liver, bone mass/architecture, 
gene regulation and so on as reviewed by Burri et al (2012). 
 
2.4.2 Methodological issues and considerations for future studies 
2.4.2.1  Overall experimental design: short-term versus longer-term studies 
Most of the available studies used plasma or serum lipid fractions for measuring the 
incorporation of the n-3 LC-PUFA, as an estimate of body retention, referring to this as 
an indication of n-3 LC-PUFA bioavailability. However, there is a very important question 
that has not yet been addressed: does a higher plasma concentration indicate a higher 
bioavailability, as the majority of the authors assert, or does it indicate an actual lower 
availability to tissues because transport and tissue’s uptake are slower? Overall then, 
the concept of bioavailability as measured only by blood levels, either as a concentration 
at specific time, or area under the curve, is deeply flawed as an indicator of 
bioavailability. Lands and others have argued that the important issue is to measure the 
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omega-6 and omega-3 fatty acids in tissues in order to ascertain the biological potency 
(Lands, 2014). 
The basis for using short-term studies is that digested fatty acids are absorbed and then 
transported in chylomicrons (as TAG) to the liver and then the fatty acids, including the 
n-3 LC-PUFA are either stored there or exported in very low density lipoprotein to extra-
hepatic tissues (muscle, adipose tissue, RBC and so forth). Thus, it can be envisaged that 
in short-term studies, the monitoring of n-3 LC-PUFA level in plasma TAG or chylomicron 
TAG could be an appropriate way to determine their uptake, as these are reflective of 
short-term changes in intake. One needs to bear in mind that the plasma or chylomicron 
level at a point in time post-prandially is a function of the rate of absorption and the rate 
of tissue uptake or metabolism. On this basis, one might expect that differences that 
were apparent in short-term studies would also manifest themselves in longer-term 
studies; but in the latter, different metabolic considerations are involved, not just the 
fatty acid digestion, absorption and transport, but also their retention and or 
incorporation into tissues; and thus different endpoints to estimate n-3 LC-PUFA uptake 
should be used. In fact, in longer-term studies (several weeks or months), it has been 
widely accepted that the most appropriate way of determining n-3 LC-PUFA status is to 
examine the n-3 LC-PUFA levels in the RBC, since the n-3 LC-PUFA are found only in PL 
of their membranes; and thus are a better representation of the longer-term effect of 
different n-3 LC-PUFA supply. Accordingly, it has been shown that the RBC n-3 LC-PUFA 
content had the lowest biological variability, which was lower by a factor of 10 compared 
with that recorded for the variability in total plasma fatty acids or plasma PL (Harris and 
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Thomas, 2010). Despite this being the accepted wisdom, the actual mechanism of how 
RBC acquire their n-3 LC-PUFA is not clear although Brossard et al (1997) argued that 
lyso-PC is a source of DHA for RBC. Alternatively, other methods which are likely to be a 
more accurate description of the actual n-3 LC-PUFA status of an organism as affected 
by dietary supply can be achieved by analysing the fatty acid composition of different 
tissues. However, whilst this can be easily achieved in animal models, human studies 
have to rely on the use of biopsies of selected tissues such as skeletal muscle, liver or 
adipose tissue, which of course may pose a series of logistic difficulties and do not reflect 
the bioavailability in all the tissues/organs.  
The results of longer-term studies will therefore be inclusive of the combined effect of 
n-3 LC-PUFA bioavailability, as digestion and absorption, and their subsequent metabolic 
fate, such as catabolism towards energy production, and/or anabolism such as direct 
deposition into stored TAG, membrane PL, bioconversion into different fatty acids or 
eicosanoids and docosanoids. Thus, a longer-term study can be envisaged to be more 
informative about the overall biological effect of n-3 LC-PUFA administration, but not 
ideal for evaluating the actual direct bioavailability of dietary n-3 LC-PUFA. On the other 
hand, short-term (postprandial) studies are a useful tool towards assessing directly the 
bioavailability (digestion and absorption) of n-3 LC-PUFA, but do not provide any 
information about the resultant metabolic transformations and deposition in tissues. 
Pertinent to this issue is a study by Sadou et al (1995) which examined the incorporation 
of n-3 LC-PUFA into plasma lipids over an 8-hour period and also over the longer-term 
(30 days) following supplementation with 2 g EPA and 1.3 g DHA daily. The difference in 
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incorporation at 8 hours and 30 days was marked – for example, for EPA the ratio of 
incorporation into TAG, CE and PL was (TAG value = 1), 1: 0.04: 0.67 whereas the 
equivalent values at 30 days were 1: 1.65: 3.29. Similar to EPA, large difference between 
8 hours and 30 days existed for DHA. Thus 8 hours data (short-term) do not mirror the 
30 days data and this highlights how comparisons between short-term and longer-term 
studies are very difficult. The fact is that the turnover rates and metabolic processing 
are likely to be quite different between these 2 time points. 
It can be concluded that both approaches are useful, as they bring different information, 
and they should be considered as being complementary, rather than alternative, and 
possibly they should be implemented simultaneously, to achieve a complete 
understanding of factors and mechanisms affecting n-3 LC-PUFA bioavailability in 
humans.   
  
2.4.2.2 Dietary fat and bioavailability of n-3 LC-PUFA  
It is known that the matrix of food, meaning the actual physical structure of the food, 
can affect the bioavailability of the nutrients contained in it (Parada and Aguilera, 2007), 
and such an effect could clearly also influence the bioavailability of n-3 LC-PUFA, as also 
discussed by Schuchardt and Hahn (2013).  
Importantly, very significant effects on bioavailability of the n-3 LC-PUFA have been 
shown to be related to the amount of dietary fat. However, none of the longer-term 
studies reported dietary fat intakes. In the short-term studies, the amount of fat in the 
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diets during the intervention days was only reported in four of these studies (Lawson 
and Hughes, 1988b, Lawson and Hughes, 1988a, Schuchardt et al., 2011b, Davidson et 
al., 2012) as noted in Table 2.1. For example, Lawson and Hughes (1988b) showed that 
a fat-rich meal (44 g of fat) significantly improved the absorption from both the EE form 
and TAG form in human volunteers, compared with a low-fat meal (8 g of fat). In another 
study, the bioavailability of n-3 LC-PUFA in FFA was markedly greater by a factor of 4 
times compared with the EE form when the n-3 LC-PUFA were taken with a very low fat 
breakfast and lunch (Davidson et al., 2012). The authors suggested that this might be 
due to the EE form requiring pancreatic lipase for digestion prior to absorption.  
Additionally, it should be noted that several studies have shown that a high fat breakfast 
containing n-3 LC-PUFA, followed by a high fat lunch (devoid of n-3 LC-PUFA), can lead 
to a second peak in the appearancbe of these n-3 LC-PUFA in plasma lipids, suggesting 
that some of the PUFA from the breakfast were stored in the enterocytes and released 
after the high fat lunch (Heath et al., 2007). Thus post-prandial studies, examining the 
appearance of n-3 LC-PUFA in plasma lipids which extend beyond lunch might be 
influenced by the fat content of the lunch. 
Thus, it is clear that when it comes to studying the potential differences in n-3 LC-PUFA 
bioavailability, both, the food matrix and the total dietary fat provided to participants 
should always be considered, and ideally, the experimental design should be properly 
developed towards controlling/considering, or even better standardizing, these two 
factors. This will help in reducing the variability of the results achieved, will increase the 
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statistical power of the test, and will ultimately contribute to obtaining more robust, 
more substantiated and more easily interpretable findings.    
 
2.4.2.3 Statistical considerations  
It is likely that many of the studies considered in this review were underpowered from 
a statistical point of view, given that there is a very large variability between individuals 
in the response to n-3 LC-PUFA as measured in plasma PL (Reis et al., 1990). In this 
context, the readers are referred to a recent series in The Lancet which discussed in 
detail issues related to study design, conduct and analysis, including the issue of 
adequately powered studies (Ioannidis et al., 2014). In the short-term studies, the 
median number of subjects per group studied in the papers cited in the present review 
was 8 with the range being from 5 to 54, while in the longer-term studies the median 
number was 74 with the range being from 24 to 129 subjects. Thus, from a statistical 
point of view, type II errors are likely to be commonly present in this collection of 
studies, and the often reported lack of statistical significant effect is likely not a 
substantiated evidence of the actual biological effect. For this reason, when no 
statistically significant differences were reported, the power of the statistical test should 
always be reported and considered, and it could be more appropriate to cautiously 
observe and refer to the actual numerical results. For example, observing the results 
reported by Ulven et al (2011), the study with 113 subjects, and for this example only 
considering as the endpoint the plasma DHA content after 7 weeks of daily 
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administration of either 3 g of krill oil or 1.8 g of fish oil, the reported values (plasma 
DHA as μmol/L; mean ± SD) were: 70.4 ± 25.7 (for fish oil, n=40), and 64.2 ± 26.2 (for krill 
oil, n=36). Thus, despite the numerical difference of 6.2 μmol/L, almost 10% of the actual 
DHA value, which could clearly suggest different bioavailability and also could have 
important biological significance, no statistically significant difference could be 
observed. However, by implementing a power analysis, it could be seen that the power 
of the statistical test was lower than 20%, and that assuming a true difference of 6.2 
μmol/L, 200 subjects per treatment would have been required to achieve a power of the 
statistical test equal to 80% (which is the power normally accepted to validate results). 
This example clearly shows the issue of the under-power of most of the studies 
conducted thus far in evaluating n-3 LC-PUFA bioavailability. The need for such a large 
number of subjects is simply driven by the relatively large variability of the outcomes 
measured, typically plasma or RBC fatty acid levels, and further highlights the need for 
trying to minimise this variability as much as possible. 
  
2.4.2.4 Analytical chemistry methodologies 
The high variability of outcomes measured (fatty acid composition) within a single study 
and between different studies is one of the most significant constraints resulting in the 
current lack of reliable evidence, and this makes it very difficult to compare results, 
which are ultimately limiting our current knowledge of possible existing differences in 
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n-3 LC-PUFA bioavailability. Within this context, some analytical chemistry 
considerations are important. 
Thanks to technological advances in the last few decades, the analysis of fatty acid via 
chromatography is nowadays a simple analysis for almost all laboratories. Consequently, 
less attention is given to its proper implementation, interpretation of results and 
reporting, with, for example, almost all cases analysed in this review providing 
fundamentally no detailed information about the methodology used to achieve the final 
fatty acid results. Though conceptually a simple analysis, the risks of improper 
implementation are high, particularly when the so called fast-chromatography 
approach, typically conducted with non-polar phase columns, is used. Without entering 
into tedious technical details, which is outside the scope of this review, it is well known 
that a series of factors involved in the process of fatty acid analysis can be responsible 
for imprecise results, typically due to co-elution or incomplete resolution of peaks, and 
or creation of artefacts and/or non-complete trans-methylation during sample 
preparation (Eder, 1995).  
Assuming there is a proper separation and identification of peaks, another commonly 
used approach is that of reporting fatty acid data as percentage of total fatty acids based 
on area percentage, without any individual peak calibration or the use of correction 
factors to adjust for detector response and the difference of molecular weight of methyl 
esters compared with free fatty acids (Ackman, 2002, Karakatsouli, 2012). These 
analytical considerations and concerns have been, for example, recently raised 
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specifically for fish and seafood products, where typically n-3 LC-PUFA are the key 
objects of the analysis of the studies (Karakatsouli, 2012).  
The reporting of fatty acid as percentage of total fatty acids is conceptually limited as it 
does not take into consideration that 1 g of lipid does not contain 1000 mg of fatty acid, 
and that the percentages themselves are directly affected by the number of fatty acid 
that are separated, identified and reported. In fact, often several minor fatty acids are 
omitted, or not considered, with the logical resultant over-estimation of the one which 
are reported.  
For example, and paradoxically, imagine two subjects were provided with the same 
amount of EPA, but one consuming large amount of lamb and beef meat (reported to 
contain up to 2.5% of odd-chain saturated straight chain and branched chain fatty acids, 
like 15:0 and 17:0) and the other not consuming any red meat products. Then imagine 
that EPA would be equally deposited in both subjects at 3% of total pool of plasma fatty 
acids, and that 15:0 plus 17:0 will be deposited, in the first subject, at 2.5% of the total 
pool of plasma fatty acids. If in the final chromatograms 15:0 and 17:0 are omitted, and 
not reported as considered minor, the final EPA % in plasma measured for the subject 
consuming more red meat would be 3.1%, and thus erroneous conclusions, and/or 
unexpected large variability, will be reported.  
As mentioned above, the second important limit of fatty acids analysis as simple 
percentages is that it excludes any possible consideration of total fatty acids content for 
a given weight of tissue, and even for a given weight of total lipid. For example, 
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imagining the same tissue from two different individuals (A and B) having the same 
recorded EPA %, but tissue of A containing double the amount of total lipid than tissue 
of B, it is evident that in actuality the total EPA content in subject A is double than that 
in subject B; but yet completely overlooked by using simple fatty acid percentage. The 
same problem applies also to tissues with rather consistent total lipid content, as for 
example RBC, as total fatty acids per unit weight of total lipids is affected by the 
proportional contribution of different lipids (ie TAG/PL ratio) and also by the quantity of 
nonsaponifiable lipids (ie in the case of RBC, PL/cholesterol ratio). As an example, it 
would be possible to observe a difference between two individuals for their EPA levels, 
as % of total fatty acids, even if the actual quantity of EPA is the same, but the two 
individuals have very different cholesterol content. In RBC membranes, the 
cholesterol/phospholipid molecular ratio can vary from 0.9 to 2 (Cooper, 1978), and thus 
fatty acid percentages could likely be very different to fatty acid quantities. This could 
also help explaining the variability observed in the omega-3 index (Von Schacky, 2009), 
which even if accurately standardised in terms of laboratory protocols (Harris et al., 
2013), it still fundamentally reports only the percentage content of EPA plus DHA in RBC. 
In summary, whilst reporting fatty acids as percentage has the advantage of being very 
simply carried out, and also easier to mentally and visually grasp and discuss, it has so 
many limitations that fundamentally renders results of little value. The solution to 
overcome these issues is to use a quantitative fatty acid analysis. To do so, relatively 
minor and easily implemented modifications to commonly used laboratory protocols 
have to be considered, and briefly including: accurate weight of samples, complete lipid 
extraction, use of known amounts of proper selected internal standard, complete 
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chromatography resolution and reporting, appropriate transformations and/or 
calibration with external standards. These are technical, but important, aspects that 
have been widely discussed and detailed information are readily available (Eder, 1995, 
Ackman, 2002, Karakatsouli, 2012, Christie, 2003). Therefore, a proper quantitative fatty 
acid analysis is absolutely necessary, even before attempting a study on this topic, and 
also detailed information about methodologies used should always be reported, so that 
reviewers, and then readers, would be able to fully understand and ponder the results 
proposed in the study itself. 
 
2.4.2.5 Doses and basic chemistry considerations 
A significant issue common in many of these studies, and likely one of the most stringent 
ones limiting the possible interpretation of the findings, was that the actual amounts of 
EPA and DHA administered to subjects in the various studied forms often varied amongst 
treatments, and even within the one study (as shown in Table 2.3). Only five studies 
considered this issue and were designed to provide a balanced and equal amount of n-
3 LC-PUFA in the different forms studied. Clearly, providing n-3 LC-PUFA in unequal 
doses is a major methodological fault, and results obtained from these studies cannot 
be considered as being substantiated, and thus cannot provide any reliable information 
on the possible differences in n-3 LC-PUFA bioavailability. 
Additionally, in the studies where doses of different n-3 LC-PUFA preparation were 
balanced, another major limitation can occur. In fact, as suggested by Davidson et al 
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(2012), the molecular weight of different forms of n-3 LC-PUFA, could affect the 
recorded apparent bioavailability of different n-3 LC-PUFA, since for a given quantity of 
preparation, the actual number of moles provided are different. For example, using EPA 
as example, 1 g of EPA as FFA (C20H30O2, formula weight = 302.45) contains 1 g, or 3.31 
mmol of EPA. But 1 g of EPA as EE (C22H34O2, formula weight = 330.51) contains 3.03 
mmol of EPA (88.2% of that found in 1 g of FFA), 1 g of EPA as TAG (triecosapentaenoin, 
C66H92O6, formula weight = 981.44) contains 3.06 mmol of EPA (89.1% of that found in 1 
g of FFA), and 1 g of EPA as PL (an hypothetical phosphatidylcholine with EPA in both sn-
1 and sn-2, C48H76NO8P, formula weight = 826.10) contains 2.42 mmol of EPA (69.9% of 
that found in 1 g of FFA). Additionally, when different n-3 LC-PUFA are studied, the same 
concept applies as different fatty acids have different molecular weights. Thus, for 
example, 1 g of DHA as FFA (C22H32O2, formula weight = 328.49) contains 3.04 mmol of 
DHA, which equates to only 88.7% of the EPA moles found in 1 g of EPA as FFA. 
Consequently, it is clear that a gram for gram comparison of n-3 LC-PUFA provided in 
different forms is inappropriate, and likely to increase variability and to generate 
misleading results.  
It is therefore recommended that future studies should be conducted so that the total 
amount (mg or even better the actual number of moles) of each fatty acid under 
examination to be administered via the different preparations should be balanced and 
consistent across all treatments. Consistently, and as discussed in the previous section 
relative to analytical chemistry methodologies, fatty acids should be measured and 
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reported, in administered doses and in any target tissues as moles per gram of 
tissue/sample.  
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Table 2-3. The amounts of EPA and DHA provided to subjects in the different trials reported in this review. 
Reference  Type of 
study  
Intervention group / dose (g/day) EPA/DHA 
Ratio1 
Fatty acid content2  
(El Boustani et al., 
1987) 
 
STS 1 g of EPA in four different forms 
(FFA, TAG, EE, Arginine salt) 
Gram of DHA 
is unspecified 
0.9 g EPA as EE & TAG, 1 g 
EPA as FFA 
(Lawson and Hughes, 
1988a) 
 
STS G1: 5 g of TAG (1 g EPA+0.65 g DHA as TAG) 
G2: 5 g of EE (1 g EPA+0.65 g DHA as EE) 
G1:1.53 
G2:1.53 
 
G1: 0.9 g EPA+0.62 g DHA 
G2: 0.9 g EPA+0.62 g DHA 
(Lawson and Hughes, 
1988b) 
STS G1: 5 g of TAG (1 g EPA+0.67 g DHA as TAG) 
G2: 5 g of EE (1 g EPA+0.67 g DHA as EE) 
G3: 5 g of FFA (1 g EPA+0.67 g DHA as FFA) 
 
G1:1.49 
G2:1.49 
G3:1.49 
G1: 0.9 g EPA+0.62 g DHA 
G2: 0.9 g EPA+0.62 g DHA 
G3: 1 g EPA+0.67 g DHA 
(Beckermann et al., 
1990) 
 
 
STS G1: 1.68 g EPA+0.72 g DHA  as TAG  
G2: 1.35 g EPA+1.065 g DHA as FFA  
G3: 1.86 g EPA+1.27 g DHA as EE 
G1: 2.33 
G2: 1.27 
G3: 1.46 
G1: 1.52 g EPA+0.66 g DHA 
G2: 1.35 g EPA+1.06 g DHA 
G3: 1.70 g EPA+1.17 g DHA 
(Nordoy et al., 1991) STS G1: 40 g TAG (14 g EPA and 8 g DHA) 
G2: 28 g EE (13.7 g EPA and 10.4 g DHA) 
G3: 28 g EE (13.7 g EPA and 10.4 g DHA) + 12 g olive oil 
G4: 40 g olive oil 
 
G1: 1.75 
G2: 1.32 
G3: 1.32 
G1: 12.7 g EPA+7.3 g DHA 
G2: 12.5 g EPA+9.5 g DHA 
G3: 12.5 g EPA+9.5 g DHA 
(Wakil et al., 2010) STS 4.5 grams of  nTAG, rcTAG, eTAG, DG, MG 
(0.89 g EPA and 0.35 g DHA) 
 
G1-5: 2.54 
 
Calculation not possible 
because the composition 
was unspecified 
 
(Schuchardt et al., 
2011b) 
STS G1: Fish oil reTAG (1.008 g EPA and 0.672 g DHA) 
G2: Ethyl Esters (1.008 g EPA and 0.672 g DHA) 
G3: Krill oil, mainly PL (1.050 g EPA and 0.630 g DHA) 
 
G1: 1.50 
G2: 1.50 
G3: 1.66 
G1: 0.9 g EPA+0.62 g DHA 
G2: 0.9 g EPA+0.62 g DHA 
G3: Calculation not 
possible 
(Davidson et al., 2012) STS G1: 4 g of n-3 (2.2 g EPA + 0.8 g DHA as FFA) G1: 2.75 G1: 2.2 g EPA+0.8 g DHA 
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G2: 4 g of n-3 (1.7 g EPA + 1.38 g DHA as EE) 
 
G2: 1.29 G2: 1.55 g EPA+1.27 g DHA 
(Reis et al., 1990)               LTS G1: 7 g EE (3.7 g EPA and 2.5 g DHA) 
G2: 6 g TAG (3.4 g EPA and 1.4 g DHA) 
G3: 12 g olive oil 
 
G1: 1.48 
G2: 2.4 
 
G1: 3.38 g EPA+2.30g DHA 
G2: 3.08 g EPA+1.28 g DHA 
 
(Krokan et al., 1993)          LTS G1: 4 g EE/d (2.2 g EPA + 1.2 g DHA) 
G2: 8 g EE/d (4.4 g EPA + 2.4 g DHA) 
G3: 14 g EE/d (7.7 g EPA + 4.2 g DHA) 
G4: 12 g TAG/d (2.2 g EPA + 1.4 g DHA) 
G5: 24 g TAG/d (4.4 g EPA + 2.9 g DHA) 
 
G1: 1.83 
G2: 1.83 
G3:1.83 
G4: 1.57 
G5: 1.51 
G1: 2.01 g EPA+1.11 g DHA 
G2: 4.03 g EPA+2.21 g DHA 
G3: 7.05 g EPA+3.87 g DHA 
G4: 2 g EPA+1.28 g DHA 
G5: 3.81 g EPA+2.65 g DHA 
 
(Hansen et al., 1993)         LTS G1: 2.2 g EPA + 1.2 g DHA as EE 
G2: 2.2 g EPA+ 1.4 g DHA as TAG 
G1: 1.83 
G2: 1.57  
 
G1: 2.01 g EPA+1.11 g DHA 
G2: 2.0 g EPA+1.28 g DHA 
 
(Maki et al., 2009) 
 
LTS G1: 2 g krill oil/d (0.216 g EPA + 0.09 g DHA) 
G2: 2 g fish oil/d (0.212 g EPA + 0.178 g DHA) 
G3: 2 g olive oil/d - control  
 
G1: 2.04 
G2: 1.19  
Calculation not possible 
because the composition 
was unspecified  
(Dyerberg et al., 2010) LTS G1: 1.85 g EPA+1.29 g DHA  as reTAG 
G2: 2.18 g EPA+1.4 g DHA  as FFA 
G3: 1.87 g EPA+1.39 g DHA  as EE 
G4: 2.04 g EPA+1.48 g DHA  as Fish body oil  
G5: 1.38 g EPA+1.87 g DHA  as Cod liver oil 
G6: Corn oil (CO, no EPA+DHA)-Place 
 
G1: 1.83 
G2: 1.83 
G3:1.83 
 
G1: 1.68 g EPA+1.18 g DHA 
G2: 2.18 g EPA+1.4 g DHA 
G3: 1.71 g EPA+1.28 g DHA 
 
(Neubronner et al., 
2011)              
LTS G1: 1.01 g EPA + 0.67 g DHA as reTAG  
G2: 1.01 g EPA + 0.67 g DHA as EE  
G3:Corn oil –Placebo 
 
G1: 1.51 
G2: 1.51 
G1: 0.9 g EPA+0.62 g DHA 
G2: 0.9 g EPA+0.62 g DHA 
 
(Ulven et al., 2011)     LTS G1: 3 g krill oil/d (0.543 g EPA+DHA) 
G2: 1.8 g fish oil/d (0.864 g EPA+DHA) 
G3: control – no supplement  
   
G1: ---- 
G2: ----- 
 
Calculation not possible 
because the composition 
was unspecified.  
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(Ramprasath et al., 
2013)            
LTS G1: 3 g krill oil (0.33 g EPA and 0.19 g DHA/day) 
G2: 3 g fish oil (0.28 g EPA and 0.18 g DHA/day) 
G3: 3 g corn oil 
 
G1: 1.74 
G2: 1.55 
 
Calculation not possible 
because the composition 
was unspecified 
(Laidlaw et al., 2014) LTS G1: x g of concentrated TAG (0.65 g EPA and 0.45 g  
DHA/day),  
G2: x g of EE (0.756 g EPA and 0.228 g DHA/day), 
G3: x g of PL (0.15 g EPA and 0.09 g DHA/day) 
G4: x g of TAG (0.18 g EPA and 0.22 g DHA/day) 
G1: 1.1.43 
G2: 3.28 
G3: ----- 
G4: 0.8 
 
G1: 0.59 g EPA+0.41 g DHA 
G2: 0.69 g EPA+ 0.21 g 
DHA 
G3: Calculation not 
possible 
G4: 0.16 g EPA+0.20 g DHA 
 
Abbreviations: STS: short-term study, LTS: longer-term study, FFA: free fatty acids, EE: ethyl esters, PL: phospholipids, TAG: triglycerides, rcTAG: re-
constituted triglyceride, reTAG: re-esterified TAG, nTAG: natural triglyceride, eTAG: Enzymatic Triglyceride, DG: Diglyceride, MG: Monoglyceride. 
1 EPA/DHA ratio is based on the fatty acid content reported in studies. 
 2 This is the actual fatty acid content used in studies, calculated as described in section 3.2.4. 
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2.4.2.6 Dose rate, age and gender 
As mentioned earlier, variability in plasma/serum and red blood cells is one of the major 
limiting factors directly impacting on the power of the statistical test, and thus impacting 
on the resultant data interpretation. Different from studies based on animal models, 
where specific and consistent dietary treatments can be easily imposed prior and during 
the study, and also much higher genotypic and phenotypic homogeneity of subjects 
(animals) can be achieved, studies in humans are unquestionably more challenging. This 
was highlighted in the research on the omega-3 index in a paper by Von Schacky (2009) 
where a highly variable RBC response to supplementation of 1 g per day of EPA plus DHA 
for approximately 3 months was reported for 69 individuals. From the data provided in 
some individuals, EPA plus DHA of RBC was elevated by more than 4-fold while in others 
showed very little response. The mean EPA plus DHA levels (% of total fatty acids in RBC) 
prior to supplementation was 6.13 ± 1.43% (mean ± SD) and 8.13 ± 2.30% after 
supplementation.  
However, a simple strategy to minimise the inter-individual variability would be to use 
different doses of the tested n-3 LC-PUFA preparation relative to the body weight of the 
subject. For example, if 1 g of EPA in TAG form, is administered to subject A (a person of 
60 kg body weight) and subject B (a person of 90 kg body weight), the two subjects will 
receive a dose of EPA equating to 0.0017% and 0.0011% of their body weights, for 
subject A and subject B, respectively. Thus subject A would actually be provided with a 
dose 50% higher than that provided to subject B; clearly contributing to remarkably 
increasing the variability of the final end point measured for the assessment of EPA 
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bioavailability. Thus, doses should be provided not as a fixed quantity, but proportionally 
to body weight of the subjects. It is recognised that if this approach was adopted it would 
impose practical challenges to health recommendations, since fish oil is typically 
available in 1 g capsules, but this approach could be relatively easily addressed when 
conducting scientific studies, for example by selecting participants of similar body 
weight or by re-capsuling tested oils accordingly.  
A second important aspect to be considered towards reducing variability is the age of 
subjects. This topic has not been covered in any detail in the literature; however, there 
are a few papers that are worth noting. First, in an animal study referred to earlier by 
Graf et al (2010), the incorporation of 14C-DHA was studied in different rat tissues in rats 
of 3 different ages (2, 4 and 10 weeks). It is of interest that only in the oldest animals 
there were significant differences in the uptake of 14C-DHA in PC form compared with 
14C-DHA in TAG from (2-fold). In a human study, volunteers aged 24 (n=9, 5M, 4F) and 
74 years (n=10, 5M, 5F) were provided with 680 mg DHA per day and 320 mg EPA per 
day for 3 weeks. It was noted that while DHA levels in plasma which started at the same 
value for each age group increased in both groups, but 42% more in the elderly group 
than the young group (Vandal et al., 2008) . There was no similar effect for EPA values. 
These two studies emphasise that age should be taken into account in future 
bioavailability studies.  
Carver et al (2001) implemented a study to assess the relationship between cerebral 
cortex and erythrocyte fatty acid composition in 40 subjects with ages ≤18 and >18 
years. They found that among subjects ≤18 years of age, there was no significant 
relationship between cerebral cortex and erythrocyte fatty acid levels, while in the older 
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group, there was a significant relationship between brain and erythrocyte levels for 
several fatty acids, particularly 16:0.  
A third important aspect to consider is gender, and particularly for longer-term studies, 
where also n-3 LC-PUFA retention and incorporation into tissues is assessed. In a 
systematic review by Lohner et al (2013), it has been shown that women have a 
significantly higher proportion of ARA and DHA in plasma/serum, RBC and adipose tissue 
lipids compared with men. It is therefore suggested that single gender studies should be 
conducted, or if there is the intention of assessing n-3 LC-PUFA bioavailability in both 
genders, clearly separating subjects, by gender, prior to any statistical test is a 
requirement.  
 
2.4.2.7 The missed opportunity: faeces analysis  
As mentioned earlier the term bioavailability is rather loosely defined when used in 
nutrition studies. The commonly intended meaning for bioavailability is in actuality 
exactly the same as the term “digestibility”, and specifically an estimate of how much of 
the nutrient taken would then be retained in the body, after digestion and absorption. 
Accordingly, in animal nutrition science “digestibility” is likely one of the first and more 
important parameters normally measured and reported, whilst bioavailability is 
fundamentally very seldom mentioned or used. Thus it appears that the term 
bioavailability is a sort of synonym used primarily in human nutrition science, and the 
reasons of why this is happening were recently masterfully summarised by Clemens von 
Schacky who, replying to the question of why digestibility, and thus the simple analysis 
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of fatty acid content of faeces of subjects under different treatments, is never 
considered in human studies, said “nobody wants to do this sort of job” (2013, personal 
communication at Q&A time at AOCS, Australasian section biennial meeting, 6-8 
November 2013, Newcastle, NSW, Australia). It is well established that excess dietary 
fat can be excreted in faeces (steatorrhea) as the result of certain medical cases 
(malabsorption, exocrine pancreatic insufficiency, pancreatitis and so on). However, 
even in healthy individuals the amount of fat in faeces can vary between 5.8 - 12.4 g per 
day for adults (Bijoor et al., 2004). Furthermore, Lorenzen and Astrup (2011) have shown 
that diet rich in dairy calcium (1977 mg per 10 megajoule) increased faecal excretion of 
fat by up to 30% compared with diet low in calcium (504 mg per 10 megajoule). Gabert 
et al (2011) validated the analysis of lipid tracers in stools during 3 days post a single 
dose of a mixture of 300 mg of 1,1,1-13C3-tripalmitin and 210 mg of 1,1,1-13C3-triolein 
with a fat-rich meal in 8 healthy men. The objective of this study was to evaluate the 
proportion of 13C-labelled lipids that were eliminated in stools after ingestion. The 
authors concluded that the faecal elimination is of great importance when establishing 
dietary lipid fate and total lipid distribution, since the cumulative tracer recovery of the 
administered dose was approximately 7%, with significant individual variability. In fact, 
digestibility can be accurately measured by analysing the fatty acid content of faeces, 
following only a few elementary standardised computations. There are several animal 
studies where the measurement of the coefficient of fat digestibility, by measuring fat 
excretion, has been implemented (Kritchevsky et al., 2000, Kritchevsky, 1994, Carroll, 
1958). Carrol et al (1958) showed that fatty acid containing 4-10 carbon atoms were 
100% digested in male Sprague Dawley rats weighing 80 to 90 grams; while, the 
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digestibility of lauric, palmitic and stearic acid was 86%, 48% and 12%, respectively. 
Kritchevsky et al (2000) showed that fat excretion was higher in male rabbits fed stearic 
acid rich fats (47 ± 4 mg/g faeces) than in those fed the palmitic acid rich fats (28 ± 3 
mg/g faeces). In a study on male Wistar rats where the in vivo absorption of traditional 
fish oil (TAG) was compared with that of specifically developed marine lipid derived 
liposomes (containing 69% PL), it was recorded that the total lipid absorption was 
remarkably different, and varied from 73 ± 6% for fish oil to 98 ± 1% for liposomes 
(Cansell et al., 2003). Additionally, by comparing the estimated absorption values as 
measured by analysing faecal or lymph lipid content (24 h collection for both), it was 
observed that the absorption of SFA and MUFA were consistent and similar using the 
two approaches, whilst different results were obtained for PUFA. Specifically, the 
authors observed that absorption was overestimated with faecal lipid compared to 
lymph lipid, and this was suggested to be due to in vivo PUFA oxidation process during 
digestion. However, derivatives of PUFA oxidation in faeces were not quantified in this 
study, which could confirm this point and contribute towards the correct quantification 
of total not-absorbed PUFA.  
Thus, whilst routinely used in animal nutrition sector, the logistics, safety and technical 
issues associated with handling human faeces are likely the main causes of discouraging 
researchers in measuring faecal fat levels, with the subsequent need of replacing this 
fundamental, and easily achievable, piece of information with the somewhat undefined 
bioavailability concept.  
The analysis of faecal lipids can easily and simply be seen as a missed opportunity. All 
the analysed studies reported in this review would have likely achieved robust and 
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informative results about the efficacy of the different n-3LC-PUFA preparations studied, 
if a simple digestibility analysis, and thus the quantitative fatty acid analysis of the 
faeces, had been carried out. It is therefore suggested that the actual digestibility of n-
3 LC-PUFA should be reported in future studies trying to shed light on this topic, 
especially in view of the data from the animal study above which reported 73% lipid 
absorption from fish oil (Cansell et al., 2003), which is in agreement with Chen et al 
(1987) who have demonstrated in rats where lymph was collected for 24 hours following 
doses of corn oil, menhaden oil or fish oil concentrate that the recovery of fatty acids in 
the lymph was significantly less for the two fish oil treatments compared with corn oil 
group. 
 
 Conclusion  
The intention of this review has been to critically consider the short-term (postprandial) 
and longer-term studies which have examined the bioavailability of different chemical 
forms of n-3 LC-PUFA in humans, with also the consideration of evidence originating 
from animal studies.  
Firstly, it was shown how postprandial and longer-term studies bring different 
information, which makes conclusions achieved by the two different approaches 
difficult to compare. It was therefore suggested that both are useful and 
complementary, thus they should be implemented simultaneously, to achieve a better 
understanding of factors and mechanisms affecting n-3 LC-PUFA bioavailability. 
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In general, despite many apparently underpowered studies, the results revealed that 
there seems to be a difference in the apparent bioavailability of n-3 LC-PUFA, such that 
FFA form is more bioavailable than the TAG form, which in turn is more bioavailable than 
the EE form. The review did not consider whether these differences in bioavailability led 
to differences in plasma TAG levels in subjects with hypertriglyceridaemia or in normo-
triglyceridaemic subjects, mainly because there was a paucity of data on the topic. When 
it comes to bioavailability of n-3 LC-PUFA in PL versus TAG, the human studies available 
thus far could not provide any neither robust nor conclusive result; whilst animal studies 
showed that n-3 LC-PUFA in PL form seem to be more bioavailable than those in TAG 
form. 
This review specifically highlighted the strengths and weaknesses of the human studies 
conducted to date pointing out several common limitations, including that many studies 
did not use the same dose of n-3 LC-PUFA when comparing different forms; most studies 
did not correct for the molecular weights of the different forms of n-3 LC-PUFA used; 
most studies did not report sufficient details of the analytical and quality control matters 
related to the measurements of levels/concentrations in plasma or red blood cells; most 
of the studies did not report the fat content of the subjects’ diets; none of the studies 
reported details on the statistical power of the study; none of the studies adjusted the 
dose given to subjects on a body weight basis; the confounding factors relative to gender 
and age of participants were commonly overlooked; and finally, none of the studies 
measured the faecal excretion of the n-3 LC-PUFA. This review has thus laid out a set of 
criteria for conducting future studies on the bioavailability of n-3 LC-PUFA of different 
chemical forms. 
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 Abstract 
The recommendations on the intake of long chain omega-3 polyunsaturated fatty acids 
(n-3 LC-PUFA) vary from eating oily fish (‘once to twice per week’) to consuming 
specified daily amounts of EPA and DHA (‘250–500 mg per day’). It is not known if there 
is a difference in the uptake/bioavailability between regular daily consumption of 
supplements versus consuming fish once or twice per week. In this study, the 
bioavailability of a daily dose of n-3 LC-PUFA (Constant treatment), representing 
supplements, versus a large weekly dose of n-3 LC-PUFA (Spike treatment), representing 
consuming once or twice per week, was assessed. Six-week old healthy male Sprague 
Dawley rats were fed either a Constant treatment, a Spike treatment or Control 
treatment (no n-3 LC-PUFA), for six weeks. The whole body, tissues and faeces were 
analysed for fatty acid content. The results showed that the major metabolic fate of the 
n-3 LC-PUFA (EPA+DPA+DHA) was towards catabolism (β-oxidation) accounting for over 
70% of total dietary intake, whereas deposition accounted less than 25% of total dietary 
intake. It was found that significantly more n-3 LC-PUFA were β-oxidised when 
originating from the Constant treatment (84% of dose), compared with the Spike 
treatment (75% of dose). Conversely, it was found that significantly more n-3 LC-PUFA 
were deposited when originating from the Spike treatment (23% of dose), than from the 
Constant treatment (15% of dose). These unexpected findings show that a large dose of 
n-3 LC-PUFA once per week is more effective in increasing whole body n-3 LC-PUFA 
content in rats compared with a smaller dose delivered daily.  
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of intake. 
 
 Introduction 
A vast body of literature exists on the effect of long chain omega-3 polyunsaturated fatty 
acids (n-3 LC-PUFA) in the areas of infant development (Sherry et al., 2015), 
cardiovascular disease, platelet aggregation (Guichardant et al., 2015), cancer (Turunen 
et al., 2014), dementia, Alzheimer’s disease, depression (Denis et al., 2015, Salem et al., 
2015), and inflammation (Lorente-Cebrian et al., 2015, Skulas-Ray, 2015).  
Recommendations for eicosapentaenoic acid (EPA; 20:5n-3) plus docosahexaenoic acid 
(DHA; 22:6n-3) intake have been put forth by several organizations globally, with ranges 
from 250 mg to 500 mg per day for adults with an additional 200 mg of DHA per day for 
pregnant and lactating women (Mozaffarian and Wu, 2012). The recommendation for 
patients with coronary heart disease generally is 1 g EPA plus DHA per day, and for 
patients with high triglycerides the recommendations range from 1.2 to 4 g EPA plus 
DHA per day (Mozaffarian and Wu, 2012). Some organisations including the American 
Heart Association and Australian National Health and Medical Research Council 
recommend foods (oily fish) once to twice per week (NHMRC, 2006), whereas others 
like the National Heart Foundation of Australia deal with nutrients daily based on daily 
intake (250–500 mg per day of EPA plus DHA) (NHF, 1999). Accordingly, despite the 
actual quantity of recommended intake, it appears to be important to understand what 
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feeding strategy, such as a constant daily dose or large doses fewer times per week, is 
more efficient to fulfil dietary requirements of EPA and DHA.  
There are two human studies which have compared a constant daily dose of n-3 LC-
PUFA versus twice weekly doses of n-3 LC-PUFA (Browning et al., 2014, Harris et al., 
2007). Harris et al (2007) compared the bioavailability of EPA and DHA from twice 
weekly consumption of oily fish (3.40 g/week EPA+DHA) with daily fish-oil capsule 
supplementation (3.37 g/week EPA+DHA) in a 16 week study in 23 women; they found 
that there were no treatment differences in the EPA and DHA content of red blood cell 
membranes or plasma phospholipids. Browning et al (2014) compared the 
bioavailability of EPA and DHA from fish oil capsules (twice per week) with daily fish oil 
consumption. Male and female participants (n=65) were given capsules (containing 6.54 
g of EPA and DHA per week) either twice weekly or daily for one year. They found that 
there was no difference between treatments in the plasma phosphatidylcholine level of 
EPA and DHA, but that there were significantly higher levels of EPA and DHA in platelets 
and higher levels of EPA in mononuclear cells in continuous daily supply compared with 
the weekly supply over the course of a 12-month intervention. Both studies used blood 
(plasma or red cell) levels of n-3 LC-PUFA as a proxy for bioavailability, which as 
discussed previously has significant limitations (Ghasemifard et al., 2014). The aim of the 
present study was to compare the bioavailability and efficiency (as metabolic fate) of 
the same amount of dietary n-3 LC-PUFA administered either as a constant daily dose 
(Constant treatment) versus a single weekly dose (Spike treatment). It was hypothesized 
that a single weekly dose of n-3 LC-PUFA would not be as bioavailable as a continuous 
daily dose of n-3 LC-PUFA.  
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 Materials and Methods 
3.3.1 Diet and study design 
This study was performed following the Australian code for the care and use of animals 
for scientific purposes and approved by the Deakin University Animal Welfare 
Committee (G29-2012). 
Forty eight 6-week old, sexually mature, healthy male Sprague Dawley rats were 
purchased from Animal Resources Centre, Western Australia. Rats were housed in pairs 
(2 rats per cage; 24 cages in total) and acclimatised for a week on ad libitum normal 
chow diet. The 24 cages of rats were randomly divided into four groups of six cages each. 
One group (six cages) was sacrificed via CO2 overdose at day 0 for the baseline data. The 
other three groups (six cages each) were randomly allocated to three different dietary 
treatments (feeding regimes), named “Control”, “Constant” and “Spike”. To achieve 
these three different dietary treatments, three specifically formulated diets were 
designed and manufactured to be iso-proteic, iso-lipidic (10% fat by weight, Speciality 
Feeds, Western Australia), and named: “No n-3 LC-PUFA diet”, “Constant diet” and 
“Spike diet”. The “No n-3 LC-PUFA diet” was formulated to contain no fish oil, and thus 
no n-3 LC-PUFA; the “Constant diet” was formulated to contain 0.7% of fish oil (mixed 
fish oils), and the “Spike diet” was formulated to contain a 4.9% of the same fish oil (a 
7-fold higher level of n-3 LC-PUFA compared with the “Constant diet”) (Table 3.1). Based 
on these three experimental diets, three different dietary treatments (feeding regimes) 
Control, Constant and Spike were implemented. In the “Control” treatment rats were 
fed only with the “No n-3 LC-PUFA diet”, in the “Constant” treatment rats were fed only 
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with the “Constant diet”, and in the “Spike” treatment the rats were fed 6 days/week 
with the “No n-3 LC-PUFA diet”, and one day per week with the “Spike diet”. To ensure 
equal intake amongst dietary treatments during the experimentation, animals were fed 
to fixed predetermined ration, which was adjusted weekly relative to body weight, for 6 
weeks. To determine the appropriate food ration, a preliminary short trial was 
implemented over a three-week period, where 15 rats of similar size were fed ad libitum 
normal chow diet and total feed consumption was recorded. Then, using a regression 
equation comparing body weight (BW), the daily ration in grams, was estimated as:  
Ration (% BW) = -0.0283 BW + 16.6 
Therefore, the experimental design for the rats in the Constant and Spike treatments 
was to consume exactly the same amount of fish oil (and therefore n-3 LC-PUFA) over a 
7-day period, in order to establish if there was a difference in whole body bioavailability 
between these two feeding strategies (daily versus weekly).  
Throughout the 6 weeks trial period, the rats were weighed (twice per week), and faeces 
were collected every day during the last two weeks. The coprophagy in rats was not 
prevented nor estimated. After the 6 weeks, the rats were humanely sacrificed via CO2 
overdose. Six rats from each treatment (one per cage) were used for analysis of whole 
body lipids and the other six rats (one per cage) were used for the analysis of the 
individual tissue lipid content. The collected faeces, whole body and tissues (liver, heart, 
white gastrocnemius muscle and perirenal adipose tissue) were analysed for fatty acid 
content. 
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Table 3-1. Experimental diet formulation, proximate composition and selected fatty 
acid concentrations 
Composition No n-3 LC-PUFA diet Constant diet Spike diet 
 a) Diet formulation and Proximate composition *  
Diet formulation (%)   
Sucrose 10.00 10.00 10.00 
Casein (acid) 20.00 20.00 20.00 
Starch 37.44 37.44 37.44 
Dextrinised starch 13.20 13.20 13.20 
Safflower oil 0.05 0.13 0.64 
Palm oil 9.88 9.11 4.45 
Linseed oil 0.07 0.06 0.01 
Fish oil ** 0.00 0.07 4.90 
Proximate composition (mg/g of diet)   
Protein 194.00 194.00 194.00 
Fibre 84.00 84.00 84.00 
Fat 100.00 100.00 100.00 
 
b) Fatty acid concentration of the diet after formulation (mg/g of diet) 
16:0 43.00 38.50 26.40 
18:0 4.00 3.81 3.10 
18:1n-9 28.20 26.90 18.21 
18:2n-6 7.71 7.82 7.20 
20:4n-6 0.00 0.05 0.27 
18:3n-3 0.50 0.50 0.30 
18:4n-3 0.00 0.10 0.71 
20:5n-3 (EPA) 0.00 0.90 4.50 
22:5n-3 (DPA) 0.00 0.12 0.51 
22:6n-3 (DHA) 0.00 0.60 2.92 
EPA (eicosapentaenoic acid), DHA (docosahexaenoic acid), DPA (docosapentaenoic acid). * Diet 
formulation and proximate composition reported from data from the feed company. ** Fish oil 
was a mixture of fish oils used in diet manufacture. The mixture was made at the diet 
formulators premises before use. 
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3.3.2 Lipid analysis  
The whole body, tissues and faeces samples were homogenized, and the lipids extracted 
by dichloromethane:methanol (2:1), a modification of the method described by Folch et 
al (1957). Fatty acids derived from the lipids were methylated using an acid-catalysed 
trans-methylation (Christie, 2003). In brief, an aliquot of fatty acids derived from the 
lipids plus a known amount of internal standard of tricosanoic acid (C23:0 >99%; Nu-
Chek Prep, Inc.) were reacted with acetyl chloride/methanol to form fatty acid methyl 
esters (FAME). The resulting FAME were separated, identified and quantified using an 
Agilent Technologies 7890A gas chromatography system (Agilent Technologies; Santa 
Clara, CA, USA) equipped with a BPX70 capillary column (120m, 0.25 mm internal 
diameter, 0.25 μm film thickness; SGE Analytical Science, Australia), an Agilent 
Technologies 7693 autosampler, a split injection system and a flame ionisation detector 
using established protocols (Norambuena et al., 2013). 
 
3.3.3 Lipid and fatty acid apparent digestibility  
Apparent digestibility of total lipid was measured according to Tou et al (2011) as [(lipid 
intake -faecal lipid)/(lipid intake)] × 100. Similarly, apparent digestibility of individual 
fatty acids was measured using the formula [(fatty acid intake - fatty acid excretion in 
faeces)/(fatty acid intake)] × 100. Lipid intake was determined as diet consumed per 
week × % lipid in the diet. Likewise, fatty acid intake was determined as diet consumed 
per week × % fatty acid in the diet. Faecal lipid and fatty acids were determined as total 
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faeces excreted per week (pooled 7 days faecal samples) × % lipid and % fatty acids in 
the faeces respectively.  
 
3.3.4 Whole Body Fatty Acid Balance Method  
The fatty acid metabolism of rats was determined using the Whole Body Fatty Acid 
Balance Method, as conceived and described by Turchini et al (2007) with subsequent 
developments (Turchini and Francis, 2009). Briefly, the first step of the method required 
that the net appearance or disappearance of each individual fatty acid be determined 
by the difference between total fatty acid accumulation (=final fatty acid content-initial 
fatty acid content) and the net fatty acid intake (=total fatty acid intake-fatty acid 
excretion in faeces), as initially proposed by Cunnane’s group (Cunnane et al., 1995, 
Cunnane and Yang, 1995, Cunnane and Anderson, 1997). Then, after the transformation 
of data from gram per animal per the duration of the trial to mol of fatty acid per gram 
of body weight per day, the subsequent second step involved a series of backwards 
computations along all the known fatty acid bioconversion pathways, therefore the fate 
of each individual fatty acid towards bioconversion, β-oxidation or deposition was 
determined and quantified. Eventually, data relative to apparent in vivo enzyme activity 
could be reported as nmol of enzyme’s product per gram of body weight per day, and 
the in vivo metabolic fate (absorption, β-oxidation, bioconversion and deposition) of 
each dietary fatty acid could be reported as a % relative to the dietary intake. This 
method has proven to be a simple and effective method that can be used in any 
laboratory equipped with a gas chromatography unit (Turchini et al., 2011). 
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3.3.5 Statistical analysis  
All data are reported as mean ± SD of the 6 cages per treatment (n=6, N=18). The 
experimental unit was the cage (with two rats per cage). Significant differences between 
experimental treatments were tested using one-way ANOVA, assessing the effects of 
diets, with an exception of using T-test for the n-3 LC-PUFA apparent digestibility (as 
only two treatments were considered). Paired tests were performed with Tukey’s test. 
Statistical significance was considered for P<0.05. Data analysis was performed with 
Minitab Statistical Software (Version 14; Minitab Inc., USA). 
 
 Results 
3.4.1 Feed and n-3 LC-PUFA intake  
As described in the methods, rats were fed to fixed predetermined ration, which was 
adjusted weekly relative to body weight, for 6 weeks. Rats in the Control and Spike 
treatments consumed all the diet provided each week; however, rats in the Constant 
treatment left some food uneaten, especially in week three, and this was recorded and 
accounted for (Table 3.2). 
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Table 3-2. Actual feed intake over the six weeks of the experiment in the three 
treatments. 
Total diet intake 
(g/rat/6wk) 
Control Constant Spike 
No n-3 LC-PUFA diet 938 ± 32 --- ---- 
Constant diet ---- 931 ± 44 804 ± 25 
Spike diet ---- ---- 134 ± 11 
Values are expressed as the mean ± SD of 6 cages per group. 
 
An important result that has to be noted and carefully considered was the fatty acid 
concentration of the experimental diets. Despite the prescribed formulation with 0.7% 
of fish oil in the “Constant diet”, and 4.9% fish oil in the “Spike diet” (and fish oil being 
the only source of dietary n-3 LC-PUFA), the resulting manufactured diets had slightly 
different total amounts of n-3 LC-PUFA than expected (Table 3.1). The “Constant diet” 
recorded EPA+DHA+DPA=1.6 mg/g of diet, and the “Spike diet” recorded 
EPA+DHA+DPA=8.0 mg/g of diet (a 5-fold difference, rather than the expected 7-fold 
difference).  
 
3.4.2 n-3 fatty acid apparent digestibility 
The effect of Constant and Spike treatments on apparent digestibility is shown in Table 
3.3. There were small, but significant differences observed in EPA and DHA apparent 
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digestibility between these two treatments, which was higher in the Constant, 
compared with the Spike treatment. However, DPA apparent digestibility was similar 
between Constant and Spike treatments.  
 
Table 3-3. The effect of Constant and Spike treatments on apparent digestibility (%) of 
n-3 LC-PUFA. 
n-3 LC-PUFA Constant Spike  P value 
20:5n-3 (EPA) 99.4 ± 0.0 99.0 ± 0.9 0.021 
22:5n-3 (DPA) 96.9 ± 1.0 96.5 ± 0.4 0.753 
22:6n-3 (DHA) 98.8 ± 0.5 98.2 ± 0.2 0.042 
Values are expressed as the mean ± SD of 6 cages per group. Control treatment not 
reported as no n-3 LC-PUFA was provided by the diet. 
 
 
 
3.4.3 Growth and biometrical parameters 
There was no significant difference (P=0.856) in the body weight of rats between the 
three experimental treatments during the six weeks of the experiment. The average 
body weights (± SD) of animals in the Control, Constant and Spike treatments were 412 
± 6 g, 413 ± 6 g, and 409 ± 11 g respectively, at the end of the experiment (Table 3.4). 
In regard to the tissue weight, there was no significant difference in the tissue weight of 
rats between the three dietary treatments at the end of the experiment. In addition, the 
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Hepatosomatic Index and Perirenal adipose-somatic index showed no significant 
difference in the Constant and Spike treatments compared with the Control (Table 3.4). 
 
Table 3-4. The effect of Constant and Spike treatments on rat tissue weight and 
biometric parameters. 
Weight (g) Control Constant Spike P value 
Whole body 412.4 ± 6.2 412.6 ± 6.2 409.3 ± 10.8 0.714 
Liver 17.9 ± 2.5 17.3 ± 2.1 17.0 ± 0.8 0.914 
Heart 1.5 ± 0.2 1.5 ± 0.1 1.5 ± 0.1 0.547 
Perirenal adipose 7.6 ± 2.9 6.8 ± 2.9 8.5 ± 1.9 0.225 
Muscle 0.8 ± 0.1 0.7 ± 0.1 0.7 ± 0.1 0.856 
HSI * 4.3 ± 0.6 4.2 ± 0.6 4.0 ± 0.3 0.432 
PASI  ** 1.8 ± 0.7 1.7 ± 0.7 2.0 ± 0.4 0.543 
Control, Constant and Spike treatments provided 0 mg, 9.2 mg and 8 mg per week of 
EPA+DPA+DHA, respectively. Values are expressed as the mean ± SD of 6 cages per group. * HSI 
(Hepatosomatic Index, liver weight/whole body weight*100). ** PASI (Perirenal adipose-
somatic index, Perirenal adipose weight/ whole body weight *100)  
 
3.4.4 Lipid content of rat whole body and tissues  
Whole body and tissue lipid content (mg/g tissue wet weight) of all rats at the conclusion 
of the study were significantly higher compared with the baseline data (P<0.001). There 
was no significant difference in the total lipid content of the whole body or tissues 
between the three dietary treatments (Table 3.5).  
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Table 3-5. Lipid content of tissues of rats fed the different experimental treatments. 
Lipid content Control Constant  Spike  P value 
Whole body  
(mg/g whole body) 
133.7 ± 17.1 119.1 ± 12.6 111.4 ± 28.8 0.199 
Tissues (mg/g tissue)     
Liver  53.3 ± 16.9 51.6 ± 6.4 51.1 ± 8.1 0.942 
Heart  29.8 ± 2.6 28.8 ± 0.8 30.7 ± 1.4 0.168 
Perirenal adipose 831.2 ± 89.4 893.0 ± 27.4 931.2 ± 67.9 0.640 
Muscle 19.5 ± 3.5 20.0 ± 2.8 24.7 ± 8.0 0.209 
Values are expressed as the mean ± SD of 6 cages per group. 
 
 
 
3.4.5 The fatty acid concentration of the rat whole body and tissues  
As shown in Table 3.6, the whole body fatty acid concentration for rats that received the 
Constant treatment was significantly higher for all n-3 LC-PUFA compared with rats on 
the Spike treatment at the end of experiment (P<0.05). In addition, n-6 PUFA 
concentrations were significantly lower in the Spike compared with the Constant 
treatment at the end of the study period (P=0.003). It should be recalled that rats in the 
Spike treatment received a relatively smaller amounts of n-3 LC-PUFA each week 
compared with the Constant treatment, because the manufactured diet slightly 
deviated from expected final fatty acid concentration.  
Supplementation with n-3 LC-PUFA diets (both Constant and Spike treatments) led to a 
significant increase (P<0.005) in whole body EPA+DPA+DHA concentrations compared 
with Control treatment and the baseline data, by a factor of 50% increase, over the six 
weeks of the experiment (data not shown).  
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In terms of tissue concentrations, no significant differences were observed in EPA and 
DHA concentration between these two feeding strategies in any of these four tissues. In 
contrast, rats under the Spike treatment had significantly higher concentrations of DPA 
than those under the Constant treatment in liver and muscle tissue, but not in heart or 
adipose tissue (Table 3.6). 
Although EPA was the main n-3 LC-PUFA in the Constant and Spike diets, DHA was the 
predominant n-3 LC-PUFA in all tissues analysed except perirenal fat. DPA was the next 
most deposited n-3 LC-PUFA in tissues, except in the liver, where EPA levels were 
significantly higher than DPA levels. 
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Table 3-6. Selected fatty acid content of whole body (mg/g whole body) and tissues 
(mg/g tissue) from rats fed different dietary treatments. 
 PUFA n-6 PUFA n-3 EPA DPA DHA EPA+DPA+DHA 
Whole body (mg/g whole body)     
Control 11.23 ± 1.50b 0.83 ± 0.12a n.d 0.06 ± 0.01a 0.30 ± 0.08a 0.37 ± 0.09a 
Constant 10.88 ± 1.12b 1.76 ± 0.08c 0.16 ± 0.02b 0.22 ± 0.02c 0.88 ± 0.06c 1.26 ± 0.08c 
Spike 9.30 ± 1.38a 1.49 ± 0.13b 0.12 ± 0.02a 0.19 ± 0.02b 0.75 ± 0.05b 1.07 ± 0.07b 
P value 0.003 0.001 0.001 0.001 0.001 0.001 
Liver (mg/g liver)      
Control 7.1 ± 1.7b 1.1 ± 0.2a 0.03 ± 0.01a 0.05 ± 0.01a 0.61 ± 0.19a 0.68 ± 0.19a 
Constant 5.7 ± 1.1a 2.2 ± 0.3b 0.31 ± 0.03b 0.14 ± 0.02b 1.47 ± 0.32b 1.92 ± 0.37b 
Spike 7.8 ± 1.0b 2.6 ± 0.5b 0.28 ± 0.08b 0.19 ± 0.05c 1.72 ± 0.50b 2.20 ± 0.56b 
P value 0.049 0.001 0.001 0.001 0.001 0.001 
Heart (mg/g heart)      
Control 6.01 ± 0.34b 0.96 ± 0.08a 0.02 ± 0.01a 0.08 ± 0.00a 0.65 ± 0.07a 0.74 ± 0.07a 
Constant 4.70 ± 0.32a 2.34 ± 0.13b 0.11 ± 0.01b 0.25 ± 0.03b 1.86 ± 0.11b 2.21 ± 0.13b 
Spike 5.24 ± 0.39b 2.27 ± 0.23b 0.11 ± 0.00b 0.29 ± 0.03b 1.73 ± 0.21b 2.12 ± 0.20b 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
Perirenal adipose (mg/g Perirenal)     
Control 4.6 ± 0.7a 0.3 ± 0.0a n.d 0.01 ± 0.01a 0.01 ± 0.00a 0.03 ± 0.01a 
Constant 7.7 ± 2.6a 0.7 ± 0.2b 0.06 ± 0.02a 0.12 ± 0.06b 0.09 ± 0.03b 0.28 ± 0.09b 
Spike 7.1 ± 0.6a 0.7 ± 0.1b 0.07 ± 0.01a 0.16 ± 0.03b 0.11 ± 0.04b 0.34 ± 0.06b 
P value 0.543 0.001 0.001 0.001 0.001 0.001 
Muscle (mg/g muscle)      
Control 3.37 ± 0.70b 0.92 ± 0.38a 0.08 ± 0.05a 0.09 ± 0.01a 0.34 ± 0.13a 0.51 ± 0.19a 
Constant 2.37 ± 0.30a 1.36 ± 0.14b 0.14 ± 0.04b 0.15 ± 0.02b 0.92 ± 0.10b 1.22 ± 0.15b 
Spike 2.91 ± 0.69b 1.47 ± 0.06b 0.13 ± 0.02b 0.21 ± 0.02c 0.95 ± 0.04b 1.30 ± 0.05b 
P value 0.036 0.003 0.050 0.001 0.001 0.001 
Values are expressed as the mean ± SD of 6 cages per group. Values with different letters 
in each column differ significantly (P<0.05. n.d = not detected. 
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3.4.6 EPA, DPA and DHA—Mass Balance 
Intake and excretion: The Constant treatment provided significantly more EPA, DPA and 
DHA to rats compared with the Spike treatment over the duration of the experiment, as 
noted earlier. Rats under the Constant treatment excreted significantly more DPA 
(P<0.001) and less EPA (P<0.001) and DHA (P<0.001) compared with those in the Spike 
treatment. In addition, n-6 PUFA intake and excretion were higher in rats in the Constant 
compared with the Spike treatment. 
Accumulation: The total n-3 LC-PUFA content in whole body in both n-3 enriched 
treatments over the 6 weeks of the experiment was significantly higher compared with 
the Control treatment (P<0.05), with no effect between the two feeding strategies being 
observed (Table 3.7).  
Appearance/disappearance: There was a net disappearance of all n-3 LC-PUFA over the 
duration of the experiment (intake greater than accumulation) in both Spike and 
Constant treatments; with the exception of the Control treatment where a small net 
appearance was observed, due to formation from the dietary 18:3n-3 (Table 3.7). A 
statistically significant difference in the net disappearance of all n-3 LC-PUFA were 
observed as a result of dietary treatment, with values for the Constant treatment being 
higher than for the Spike treatment (P<0.05). 
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Table 3-7. Selected fatty acids and fatty acid classes balance (mg/animal) in rats fed 
under the different dietary treatments. 
 PUFA n-6 PUFA n-3 EPA DPA DHA EPA+DPA+DHA 
Total Intake (mg/animal)      
Control 12812 ± 0a 807 ± 0a n.d n.d n.d n.d 
Constant 14685 ± 84c 4256 ± 24c 1662 ± 10b 237 ± 1b 1104 ± 6b 3003 ± 17b 
Spike 13115 ± 9b 3161 ± 10b 1208 ± 5a 145 ± 1a 779 ± 3a 2132 ± 9a 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
Excretion (mg/animal)      
Control 84 ± 0a 4 ± 0a n.d n.d n.d n.d 
Constant 64 ± 0b 46 ± 0c 10 ± 0a 8 ± 0b 13 ± 0a 31 ± 0a 
Spike 84 ± 0a 45 ± 0b 12 ± 0b 5 ± 0a 14 ± 0b 31 ± 0b 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
Net Intake (mg/animal)      
Control 12728 ± 0a 807 ± 0a n.d n.d n.d n.d 
Constant 14621 ± 84c 4210 ± 24c 1652 ± 9b 230 ± 1b 1090 ± 6b 2972 ± 17b 
Spike 13031 ± 9b 3117 ± 10b 1196 ± 5a 140 ± 1a 764 ± 3a 2101 ± 9a 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
Initial body content (mg/animal)      
Control 1331 ± 79a 167 ± 10a 4 ± 0a 18 ± 1a 44 ± 3a 66 ± 4a 
Constant 1292 ± 107a 162 ± 13a 3 ± 0a 18 ± 1a 43 ± 4a 64 ± 5a 
Spike 1274 ± 75a 160 ± 9a 3 ± 0a 18 ± 1a 42 ± 3a 63 ± 4a 
P value 0.236 0.127 0.118 0.090 0.417 0.236 
Final body content (mg/animal)      
Control 5183 ± 1214a 386 ± 108a 3 ± 3a 28 ± 9a 144 ± 67a 175 ± 76a 
Constant 4450 ± 384 a 723 ± 28b 66 ± 25b 89 ± 30b 360 ± 27b 616 ± 36b 
Spike 4930 ± 1042a 801 ± 204b 67 ± 15b 100 ± 21b 416 ± 133b 582 ± 168b 
P value 0.346 0.001 0.001 0.001 0.001 0.001 
Accumulation (mg/animal)      
Control 3852 ± 1285a 219 ± 117a n.d 9.5 ± 10a 100.2 ± 69a 109 ± 80a 
Constant 3158 ± 227a 561 ± 26b 63 ± 9a 71 ± 9b 317 ± 28b 452 ± 38b 
Spike 3656 ± 1045a 641 ± 204b 63 ± 15a 82 ± 21b 373 ± 133b 519 ± 168b 
P value 0.476 0.001 0.001 0.001 0.001 0.001 
Appearance/disappearance (mg/animal)     
Control -8876 ± 1285a -584 ± 117a 0.3 ± 3a 10 ± 10a 100 ± 69a 109 ± 80a 
Constant -11463 ± 441a -3649 ± 34c -1589 ± 13c -158 ± 9c -772 ± 23c -2520 ± 30c 
Spike -9375 ± 1043a -2475 ± 198b -1133 ± 13b -58 ± 21b -391±131b -1582 ± 162b 
P value   0.871 0.001 0.001 0.001 0.001 0.001 
Values are expressed as the mean ± SD of 6 cages per group. Values with different letters 
differ significantly in each column (P<0.05). n.d = not detected; PUFA n-6: 18:2n-6, 20:2n-
6, 22:2n-6, 18:3n-6, 20:3n-6, 20:4n-6, 22:4n-6, 24:4n-6, 24:5n-6, 22:5n-6; PUFA n-3: 18:3n-
3, 20:3n-3, 22:3n-3, 18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3, 24:5n-3, 24:6n-3, 22:6n-3. 
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3.4.7 EPA, DPA and DHA - Apparent in vivo metabolism 
The Whole Body Fatty Acid Balance Method allowed the calculation of apparent in vivo 
fatty acid metabolism (excretion, β-oxidation, bioconversion and deposition) as shown 
in Table 3.8. The two most important pathways identified for the n-3 LC-PUFA in this 
study were β-oxidation and deposition, which together accounted for more than 98% of 
the apparent in vivo metabolism (Table 3.8). 
Based on calculation, the main fate of EPA, DPA and DHA in both n-3 LC-PUFA 
supplemented treatments was β-oxidation, except for DPA in rats fed the Spike 
treatment where deposition was observed as the main fate. β-oxidation was 
approximately 95% for EPA, while for DPA and DHA it ranged between 40 to 70%. There 
was a significant effect of the dietary treatment on the β-oxidation for EPA, DPA and 
DHA, which was higher for rats fed the Constant compared with Spike treatment.  
Apart from β-oxidation, deposition was the next main fate of the EPA and DHA in both 
treatments and DPA in the Constant treatment. In the case of EPA, deposition amounted 
to less than 6% of the total metabolic activity, whereas in the case of DPA and DHA, 
deposition accounted for between 30 to 56% and 28 to 48%, respectively (Table 3. 8). 
The whole body deposition of all n-3 LC-PUFA was significantly higher (P<0.05) in rats 
fed the Spike treatment compared with those fed the Constant treatment.   
For EPA and DHA there were very similar trends between Spike and Constant 
treatments; however, this was not the case for DPA. The main fate of DPA differed 
between the two n-3 LC-PUFA supplemented treatments. DPA was likely not further bio-
converted to other n-3 LC-PUFA (namely 24:5n-3, 24:6n-3 or DHA) in any treatment. In 
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the control group, 18:3n-3 was bioconverted at a significantly higher rate compared with 
the other two treatments.  
The n-6 fatty acid β-oxidation, bioconversion and deposition were similar between all 
three dietary treatments. However, the n-6 fatty acid excretion was significantly higher 
(P<0.001) in the Spike compared with the Constant treatment. In the Constant and Spike 
treatments mostly 18:3n-6 and 20:4n-6 were bioconverted, 20:3n-6 was bioconverted 
only in the Spike treatment. In the Constant treatment mostly 18:2n-6 and 20:4n-6 were 
deposited while in the Spike treatment more n-6 fatty acids (18:2n-6, 20:4n-6, 22:4n-6, 
22:5n-6) were deposited in the rat’s whole body (data not shown). 
The apparent in vivo enzyme activities (expressed as mmol of product per g of body 
weight per day) are reported in Table 3.9. The apparent total elongase activity and 
desaturase activities (Δ5-Desaturase and Δ6-Desaturase) were similar in rats under the 
Constant and the Spike treatment. The apparent Δ9-Desaturase enzyme activity was 
higher in rats under the Spike treatment compared with those on the Constant 
treatment.  
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Table 3-8. Metabolic fate of fatty acid (% of the intake) in rats under the three dietary 
treatments. 
 PUFA n-6 PUFA n-3 EPA DPA DHA EPA+DPA+DHA 
Excreted (% of intake)      
Control 0.65 ± 0.00c 0.52 ± 0.00a n.d n.d n.d n.d 
Constant 0.43 ± 0.00a 1.07 ± 0.00b 0.57 ± 0.00a 3.18 ± 1.01a 1.23 ± 0.50a 1.00 ± 0.00a 
Spike 0.62 ± 0.00b 1.40 ± 0.00c 1.02 ± 0.00b 3.52 ± 0.00b 1.84 ± 0.00b 1.44 ± 0.00b 
P value 0.001 0.001 0.001 0.001 0.001 0.001 
β-oxidised (% of intake)      
Control 69.78 ± 9.75a 74.81 ± 12.84a n.d n.d n.d n.d 
Constant 78.23 ± 2.74a 86.30 ± 0.74a 95.66 ± 0.57b 66.61 ± 3.62b 69.98 ± 2.43b 84.44 ± 1.20b 
Spike 71.80 ± 7.83a 79.29 ± 6.11a 93.78 ± 1.24a 40.00 ± 14.60a 50.21±17.01a 75.14 ± 7.49a 
P value 0.096 0.081 0.012 0.008 0.037 0.001 
Bio-converted (% of intake)     
Control 4.90  ± 2.81b 15.72 ± 10.10b n.d n.d n.d n.d 
Constant 1.56 ± 0.08a 0.16 ± 0.02a n.d n.d n.d n.d 
Spike 3.07 ± 1.60ab 0.05 ± 0.08a n.d n.d n.d n.d 
P value 0.026 0.001 ---- ---- ----- ----- 
Deposited (% of intake)      
Control 24.67 ± 7.05a 8.95 ± 3.28a n.d n.d n.d n.d 
Constant 19.78 ± 2.70a 12.47 ± 0.75a 3.76 ± 0.57a 30.21 ± 3.87a 28.79 ± 2.43a 14.51 ± 1.21a 
Spike 24.51 ± 6.32a 19.26 ± 6.04b 5.24 ± 1.24b 56.50 ± 14.60b 47.9 ± 17.0b 23.42 ± 7.49a 
P value 0.269 0.002 0.033 0.008 0.042 0.034 
Values are expressed as the mean ± SD of 6 cages per group. Values with different letters differ 
significantly in each column (P<0.05). n.d = not detected; PUFA n-6: 18:2n-6, 20:2n-6, 22:2n-6, 
18:3n-6, 20:3n-6, 20:4n-6, 22:4n-6, 24:4n-6, 24:5n-6, 22:5n-6; PUFA n-3: 18:3n-3, 20:3n-3, 22, 3n-
3, 18:4n-3, 20:4n-3, 20:5n-3, 22:5n-3, 24:5n-3, 24:6n-3, 22:6n-3. 
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Table 3-9. Apparent in vivo enzyme activities in rats fed the three dietary 
treatments. 
 Ƹ Elongase 
Ƹ Δ9- 
Desaturase 
Ƹ Δ6- 
Desaturase 
Δ6- 
Desaturase 
for n-6 
Δ6- 
Desaturase 
for n-3 
Ƹ Δ5- 
Desaturase  
Δ5- 
Desaturase 
for n-6 
Δ5- 
Desaturase 
for n-3 
Control 629 ± 335
b 1305 ± 245c 298 ±192b 228 ±142b 69 ± 49 227 ± 147b 195 ± 122b 31 ± 24 
Constant  97 ± 15a 375 ± 134a 48 ± 4a 48 ± 4a n.d 56 ± 5a 56 ± 5a n.d 
Spike  219 ± 146
a 722 ± 240b 114 ± 67ab 114 ± 67ab n.d 108 ± 61ab 108 ± 61ab n.d 
P value  0.001 0.001 0.006 0.012 ---- 0.017 0.025 ---- 
Values are expressed in mmol/g/day as the mean ± SD of 6 cages per group.  
Values with different letters differ significantly in each column (P<0.05). n.d = not detected. 
 
 
 Discussion 
The present study sought to examine the whole body bioavailability and efficiency (as 
n-3 LC-PUFA metabolic fate) of the same overall dose of n-3 LC-PUFA, provided from the 
same source (fish oil), at the same overall weekly dose, but at different frequencies: 
daily versus weekly. It was found that the growth of the animals was not different 
between treatments and no mortalities were recorded amongst the three experimental 
treatments (Constant, Spike and Control). There were significant but small differences 
in the excretion of the n-3 LC-PUFA between the Spike and Constant treatment groups, 
which are unlikely to be nutritionally relevant.  
The results obtained by simply comparing tissue FA concentrations (mg/g tissue) were 
interesting, but they are admittedly of limited value towards achieving a better 
understanding of n-3 LC-PUFA “bioavailability”. While the dietary intake of n-3 LC-PUFA 
provided by the two diets were similar, but not identical, there were some differences 
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between treatments that might be independent of the difference in dietary intake. For 
example, the DPA concentration in liver and muscle was significantly greater in the Spike 
treatment than in the Constant treatment, despite the dietary DPA intake being 
significantly greater for the Constant treatment. This has no obvious explanation, but 
reveals that metabolic processing of dietary n-3 LC-PUFA is more complex than simply 
looking at dietary intake values or tissue levels.  
A much greater and more accurate understanding of the actual metabolic fate of n-3 LC-
PUFA provided by different oils can be achieved by observing the results of the Whole 
Body Fatty Acid Balance Method, which takes into account, and thus balances out, any 
differences in dietary intake. 
 This data showed that the major metabolic fate of the n-3 LC-PUFA (EPA+DPA+DHA) 
was towards catabolism (β-oxidation) accounting for over 70% of total dietary intake, 
whereas deposition accounted less than 25% of total dietary intake. It was found that 
significantly more n-3 LC-PUFA were β-oxidised when originating from the Constant 
treatment (84% of dose), compared with the Spike treatment (75% of dose). Conversely, 
it was found that significantly more n-3 LC-PUFA were deposited when originating from 
the Spike treatment (23% of dose), than from the Constant treatment (15% of dose). 
This result suggests that the n-3 LC-PUFA provided by the Spike treatment was more 
deposited (bioavailable), compared with those provided by the Constant treatment. 
The differences in β-oxidation and deposition were not the same for each of EPA, DPA 
and DHA for either the Spike or the Constant treatment. That is, EPA was more 
extensively β-oxidised than DPA and DHA on both treatments, but the difference 
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between the 20 carbon and the 22 carbon PUFA was accentuated in the Spike treatment. 
In the case of β-oxidation, the Constant/Spike ratios were 1.7 for DPA and 1.4 for DHA, 
but only 1.0 for EPA. In terms of deposition, the Constant/Spike ratios were 0.5 for DPA, 
0.6 for DHA, and 0.7 for EPA. This suggests that EPA is preferentially directed towards β-
oxidation almost independent of whether the EPA is provided daily or once per week. 
This is consistent with data showing high affinity of EPA to catabolism (β-oxidation) in 
animal models (Madsen et al., 1999). It has been reported using Wistar rats that EPA-
CoA was a good substrate for mitochondrial carnitine acyl-transferase-I and DHA was a 
poor substrate for both mitochondrial and peroxisomal β-oxidation, which could explain 
the high rate of β-oxidation for EPA (Madsen et al., 1999). 
In contrast to EPA, it would appear that DHA and DPA are somewhat spared from β-
oxidation when consumed, as observed previously (Kaur et al., 2013) but especially 
when a large dose of dietary n-3 LC-PUFA is provided weekly. This is consistent with the 
finding of Kaur et al (Kaur et al., 2013) in rodents who showed, using radiolabelled EPA, 
DPA and DHA in rats, that six hours after dosing 19% of the EPA was β-oxidized and 
expired as CO2 compared with 5% in case of DPA and 7% of DHA. However, these data 
do not shed any light on why providing a bolus dose of n-3 LC-PUFA leads to a greater 
partitioning of DPA and DHA towards deposition. With the Spike treatment, it is 
therefore possible to speculate that this ‘flood’ of n-3 LC-PUFA could have saturated the 
capacity of the mitochondria to uptake and β-oxidise any DPA and DHA, resulting in a 
greater retention and deposition of these fatty acids in tissues. 
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To our knowledge, this is the first study to compare the whole body bioavailability of n-
3 LC-PUFA in rats fed a constant daily dose versus a larger and less frequent dose of the 
same dietary source of n-3 LC-PUFA. From the two available human studies comparing 
a weekly dose of n-3 LC-PUFA with daily dose, only one study used the same source of 
n-3 LC-PUFA (capsules not fish meal) (Browning et al., 2014). Both studies used blood 
levels (plasma, platelets or mononuclear cells) as a proxy for bioavailability. The 
limitations of these studies include a failure to provide the dose adjusted on a body 
weight basis, the failure to measure excretion and the failure to measure the EPA and 
DHA levels in the red blood cells (which are widely regarded as the best measure of 
EPA+DHA tissue status). Furthermore, because of the known high level of variability in 
the response of subjects to the same dose of fish oil (as noted by Kohler et al (2010)), 
these studies have limitations because the data was not adjusted for by gender, body 
weight or exercise level (Flock et al., 2013). In the present rat study, rats were fed to 
fixed predetermined ration, which was adjusted weekly relative to body weight, for 6 
weeks which helped in reducing the variability of the results achieved, increased the 
statistical power of the test (greater than 80% for the vast majority of data recorded), 
and ultimately contributed to obtaining more robust, more substantiated and more 
easily interpretable findings. 
The possible difference in bioavailability of n-3 LC-PUFA when provided in different 
edible sources has received some research attention. Specifically, the blood levels of n-
3 LC-PUFA derived from daily fish oil capsules compared with either a  daily fish meal or 
daily fish oil enriched food have been reported in a few studies (Schram et al., 2007, 
Visioli et al., 2003, Wallace et al., 2000, Higgins et al., 1999).  
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In the current study, the Constant and the Spike treatment showed lower levels of 
apparent in vivo enzyme activity for elongase, Δ6-desaturase and Δ5-desaturase 
compared with the Control treatment. Lower Δ6-desaturase activity with fish oil feeding 
has been previously reported (Garg et al., 1988); however, there is no data looking at a 
weekly versus daily dose to compare with. These desaturases and elongases are 
required for the biosynthesis of LC-PUFA and their inter-conversion. High availability of 
these fatty acids in the Constant and the Spike treatments can act via a negative 
feedback control mechanism and reduce the gene transcription rate and the actual 
activity of the desaturase and elongase enzymes in these treatments, possibly via sterol 
regulatory element binding protein (SREBP-1c) (Kaur et al., 2011b, Matsuzaka et al., 
2002). On the other hand, the lack of n-3 LC-PUFA intake in the diet of the Control rats 
has likely increased their elongase and desaturase enzyme activities in order to increase 
endogenous n-3 LC-PUFA synthesis. Dietary n-3 LC-PUFA deprivation has previously 
been shown upregulated liver mRNA levels of Δ6-desaturase and Δ5-desaturases as well 
as activities of Δ6-desaturase and Δ5-desaturases (Igarashi et al., 2007, Hofacer et al., 
2011). Overall, there were no significant differences in the assessed enzyme activities 
between the Spike and Constant treatments, with the exception of Δ9-desaturase 
(required for the biosynthesis of monounsaturated fatty acids), which was significantly 
higher in the Spike treatment. 
Admittedly, one of the limitations of the present study includes being an animal study 
in only male rats, and the results may have been different in female rats as well as in 
humans. Nevertheless, these preliminary, novel and highly interesting findings warrant 
further investigations, and in particular the need to be substantiated by conducting 
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appropriate trials in humans. It is worth noting that the dose of n-3 LC-PUFA used in the 
Constant treatment equates to 1012 mg/day for a 70 kg human (Reagan-Shaw et al., 
2008), which is in the range of human recommendations for these fatty acids. Another 
limitation, as previously mentioned, was the slightly different total amounts of n-3 LC-
PUFA administered by the two n-3 LC-PUFA enriched dietary treatments used in this 
study. However, these differences are relatively minimal, and unlikely to be responsible 
of any major modification in the overall n-3 LC-PUFA metabolism, and have been 
accounted for in the Whole Body Fatty Acid Balance Method. A third limitation is that 
these results do not apply on comparative effects of consumption of daily fish oil 
capsules versus a sporadic meal with fish or seafood, since the study investigated the 
bioavailability of the same food source of n-3 LC-PUFA; but this was intentional to 
exclude the possible effect of the food source of the dietary n-3 LC-PUFA. In addition, a 
limitation of the constant dose approach is that it does not mimic what happens in 
humans where supplements are usually consumed once or twice per day.  
In conclusion, our data show that there was a significantly greater deposition of the n-3 
LC-PUFA associated with a single large dose of dietary n-3 LC-PUFA compared with the 
smaller daily doses in rats, due to less β-oxidation and greater deposition, and not due 
to differences in excretion (digestibility). The results from this animal study provide a 
suitable platform for further human studies towards developing substantiated evidence 
for advising consumers on the most efficient way to increase their n-3 LC-PUFA status. 
These findings suggest that a large dose of n-3 LC-PUFA once per week is more effective 
in increasing whole body n-3 LC-PUFA content compared to a smaller dose delivered 
daily. This observation, if validated in humans, could have remarkable effects on the 
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possible development of more effective and sustainable utilisation strategies of these 
limited and metabolically important nutrients, currently derived primarily from the 
dwindling oceanic fish stocks. 
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 Abstract 
The effects of krill oil as an alternative source of long chain omega-3 fatty acids (n-3 LC-
PUFA) have been investigated recently. There are conflicting results from the few 
available studies comparing fish oil and krill oil. The aim of this study was to compare 
the bioavailability and metabolic fate (absorption, β-oxidation and tissue deposition) of 
omega-3 fatty acids originating from krill oil (phospholipid-rich) or fish oil (triglyceride-
rich) in rats of both genders using the Whole Body Fatty Acid Balance Method. 
Sprague Dawley rats (36 male, 36 female) were randomly assigned to have either a krill 
oil diet (EPA+DHA+DPA=1.38 mg/g of diet) or a fish oil diet (EPA+DHA+DPA=1.61 mg/g 
of diet) to constant ration for 6 weeks. The faeces, whole body and individual tissues 
were analysed for fatty acid content.  
Absorption of fatty acids was significantly greater in female rats, but was not affected 
by the oil type. It was estimated that most of EPA (>90%) and more than half of DHA 
(>60%) were β-oxidised in both diet groups. Most of the DPA was β-oxidised (57% and 
67% for female and male rats, respectively) in the fish oil group; however, for the krill 
oil group, the majority of DPA was deposited (82-83%). There was a significantly greater 
deposition of the n-3 LC-PUFA in rats fed krill oil compared with those fed fish oil, not 
due to a difference in bioavailability (absorption), but rather to a difference in metabolic 
fate (anabolism versus catabolism).  
Key words: Krill oil; EPA; DHA; DPA; Metabolic fate; Tissue deposition.  
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 Introduction  
The beneficial effects of marine oils, such as fish oil and krill oil, on human health and 
wellbeing are mostly attributed to the high content of n-3 LC-PUFA, predominantly 
eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3) and 
docosahexaenoic acid (DHA, 22:6n-3) (Kaur et al., 2011a, Burri et al., 2012, Harris et al., 
2009). As a result of these beneficial effects, there have been recommendations that 
individuals should increase their daily intake of n-3 LC-PUFA. Consequently, the use of 
food supplements in the form of fish oil capsules has become popular. In the last few 
years, krill oil has entered the market as an alternative source of omega-3 to traditional 
fish oil. It has been claimed by various industry sources, with no clearly documented 
evidence, that n-3 LC-PUFA from krill oil are much more “bioavailable” than those from 
fish oil. This has been attributed to differences in molecular structure and antioxidant 
content between these two marine sources. In fish oil, the n-3 LC-PUFA are mostly 
esterified in triglycerides (TAG), whereas in krill oil the fatty acids are largely found in 
phospholipids (PL), TAG and free fatty acids (FFA) (Tou et al., 2007). In addition, krill oil 
contains various antioxidants including astaxanthin and flavonoids which are not 
present in fish oil (Tou et al., 2007).  
There are several available studies comparing the effects of fish oil and krill oil in animals 
(Batetta et al., 2009, Di Marzo et al., 2010, Tou et al., 2011) and humans (Maki et al., 
2009, Ulven et al., 2011, Ramprasath et al., 2013, Laidlaw et al., 2014, Schuchardt et al., 
2011b). In general terms, the data do not show a consistently higher blood or tissue level 
of EPA or DHA in the krill oil fed groups compared with the fish oil fed groups. 
123 
 
Futhermore, a fairly common limitation of these studies was the failure to have identical 
doses of n-3 LC-PUFA between treatments. Additionally, little attention has been thus 
far focused on possible confounding effects originating by gender specific responses to 
dietary n-3 LC-PUFA intake, despite evidence of more efficient n-3 LC-PUFA metabolism 
in women, compared with men (Sarter et al., 2015, Howe et al., 2014, Lohner et al., 
2013). Accordingly, several rat studies examined the expression of enzymes involved in 
the biosynthesis of DHA from shorter chain omega-3 fatty acids, finding that female rats 
replete their DHA status more readily than males likely due to a higher expression of 
liver ∆5-desaturase and ∆6-desaturase enzymes (Kitson et al., 2012, Extier et al., 2010, 
Burdge et al., 2008). Nevertheless, there is a lack of information relative to possible 
gender differences with respect to n-3LC-PUFA bioavailability and deposition, when 
provided in the diet in different chemical forms. 
Salem and Kuratko (2014) recently reviewed papers comparing the bioavailability of fish 
oil and krill oil. They concluded that there was no evidence for greater bioavailability of 
n-3 LC-PUFA from krill oil versus fish oil and that more carefully controlled human trials 
must be performed to establish their relative efficacies after chronic administration. 
Following this review, Ghasemifard et al (2014) critically reviewed the methodology 
used in existing studies on the bioavailability of n-3 LC-PUFA in different forms, and 
highlighted that the mixed and inconclusive results currently available were likely be due 
to the implementation of different, and often not appropriate, methodologies.  
As recently discussed in the latter study (2014) , in pharmacology, bioavailability refers 
to the measurement of the extent to which a drug reaches the systemic circulation, and 
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is therefore a well-defined and standardised term (Kwan, 1997). Nevertheless, when 
used in nutrition science, there is no agreed definition for the term bioavailability, and 
it has become a sort of generic term used to estimate how much of a given nutrient is 
retained in the body. As argued by Ghasemifard et al (2014), in essence bioavailability is 
not different from the term “digestibility”, which is a well-defined term and its methods 
of evaluation are agreed and standardised. When it comes to n-3 LC-PUFA and related 
studies, bioavailability is often used referring to blood levels of n-3 LC-PUFA achieved 
after consuming an n-3 LC-PUFA dose, but rarely has the excretion of n-3 LC-PUFA been 
measured. Since n-3 LC-PUFA levels in blood are directly affected by a number of 
complex processes (including digestion, absorption and metabolism) and are also 
influenced by other external factors, such as the fat content of the diet, it has been 
suggested that the blood level is not a reliable measure of n-3 LC-PUFA bioavailability. 
Therefore, in the current paper we decided to minimise the use and reference to the 
term bioavailability, and more specifically focus on absorption, retention and metabolic 
fate.  
The Whole Body Fatty Acid Balance Method (Turchini et al., 2007) is rapidly gaining 
popularity and has been successfully implemented in a variety of animal species. It is 
envisaged it could be a more “efficient”, more reliable and a simple method to estimate 
and quantify an organism’s overall capacity to metabolize fatty acids, within the context 
of an integrated system. 
The aim of the current study was therefore to compare the metabolic fate (absorption, 
β-oxidation and tissue deposition) of dietary n-3 LC-PUFA originating from krill oil (PL-
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rich) or fish oil (TAG-rich) in male and female rats using the Whole Body Fatty Acid 
Balance Method. 
 
 Materials and Methods 
4.3.1 Diet and study design 
This study was performed following the Australian code for the care and use of animals 
for scientific purposes and the study was approved by the Deakin University Animal 
Welfare Committee (G29-2012). 
Seventy two 6-week old healthy, and sexually mature, male (n=36) and female (n=36) 
Sprague Dawley were purchased from Animal Resources Centre, Western Australia. Rats 
were housed in pairs (2 rats of the same gender per cage; 36 cages in total) and 
acclimatised for a week on ad libitum normal chow diet. The 36 cages were then 
randomly allocated into six groups of six cages each (three group per gender). One group 
of each gender was sacrificed at day 0 for the baseline data. The other four groups were 
fed two specifically prepared diets (10% fat by weight, Speciality Feed, Western 
Australia) which contained either krill oil or fish oil (both supplied by Swisse, Melbourne, 
Australia). The experimental design can therefore be described as a 2×2 factorial design, 
where the factors considered were gender (male vs female) and diet (krill oil diet vs fish 
oil diet), and thus originating 4 treatments: female fed krill oil; female fed fish oil; male 
fed krill oil; and male fed fish oil. Each treatment consisted of 6 replicate cages (n=6), 
and each cage (the experimental unit) contained a pair of rats of the same gender. The 
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two experimental diets were designed to be iso-proteic, iso-lipidic and to contain equal 
amounts of EPA+DHA+DPA, equating to ~1.5 mg/g of diet. However, the resulting 
manufactured diets had slightly different total amounts of these fatty acids (Table 4.1), 
with the krill oil diet recording EPA+DHA+DPA=1.38 mg/g of diet, and fish oil diet 
recording EPA+DHA+DPA=1.61 mg/g of diet. The fish oil used contained 88% TAG, 0.6% 
FFA, 4.8% DAG, 6.4% sterols and 0.1% PL, while the krill oil contained 18% TAG, 10% FFA, 
7.4% sterols and 65% PL (as determined using an automated Thin Layer Chromatography 
scanning instrument, Iatroscan). During the experimentation, animals were fed to fixed 
predetermined ration, which was adjusted weekly relative to body weight, for 6 weeks. 
For the computation of the food ration, a preliminary short trial was implemented over 
a period of three weeks, where 15 rats of similar size were fed ad libitum normal chow 
diet and total feed consumption was recorded. Then, using a regression equation 
comparing body weight (BW), the daily ration was estimated as Ration (% BW) = -0.0283 
BW + 16.6. Throughout the 6 weeks period, the rats were weighed (twice per week), and 
the faeces were collected every day during the last two weeks. After the 6 weeks, the 
rats were humanely sacrificed with CO2 overdose. Six rats of each group were used for 
analysis of the whole body lipids (one from each cage of two rats) and six rats were used 
for the analysis of the individual tissues (the other rat from the cage housing pairs of 
rats of the same gender). The collected faeces, whole body and tissues (liver, heart, 
white gastrocnemius muscle and perirenal adipose tissue) were analysed for fatty acid 
content. 
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Table 4-1. Dietary proximate composition and selected fatty acid concentrations (mg/g 
of diet). 
Composition (mg/g of diet)  Fish oil diet Krill oil diet  
Protein   194 194 
Fibre   84 84 
Fat   100 100 
 Fatty acid   
     16:0   38.49 36.02 
     18:0   3.75 3.41 
     18:1n-9  26.91 24.31 
     18:2n-6  7.83 7.13 
     18:3n-3 (ALA)  0.49 0.41 
     18:4n-3  0.14 0.15 
     20:3n-3  0 0 
     20:5n-3 (EPA)  0.88 0.84 
     22:5n-3 (DPA)  0.13 0.04 
     22:6n-3 (DHA)  0.59 0.51 
Values are expressed as the mean of triplicate analysis.  
 
4.3.2 Lipid analysis  
The whole body, tissues and faeces samples were homogenized, and the lipids extracted 
by dichloromethane:methanol (2:1), a modification of the method described by Folch et 
al (1957). Fatty acids derived from the lipids were methylated using an acid-catalysed 
trans-methylation (Christie, 2003). In brief, an aliquot of fatty acids derived from the 
lipids plus a known amount of internal standard of tricosanoic acid (C23:0 >99%; Nu-
Chek Prep, Inc.) were reacted with acetyl chloride/methanol to form fatty acid methyl 
128 
 
esters (FAME). The resulting FAME were separated and quantified using an Agilent 
Technologies 7890A gas chromatography system (Agilent Technologies; Santa Clara, CA, 
USA) equipped with a BPX70 capillary column (120 m, 0.25 mm internal diameter, 0.25 
μm film thickness; SGE Analytical Science, Australia), an Agilent Technologies 7693 
autosampler, a split injection system and a flame ionisation detector using established 
protocols (Norambuena et al., 2013). 
 
4.3.3 Lipid and fatty acid apparent digestibility  
Apparent digestibility of total lipid was measured according to Tou et al (2011) as [(lipid 
intake -faecal lipid)/(lipid intake)] × 100. Similarly, apparent digestibility of individual 
fatty acids was measured using the formula [(fatty acid intake - fatty acid excretion in 
faeces)/(fatty acid intake)] × 100. Lipid intake was determined as diet consumed per 
week × % lipid in the diet. Likewise, fatty acid intake was determined as diet consumed 
per week × % fatty acid in the diet. Faecal lipid and fatty acids were determined as total 
faeces excreted per week (pooled 7 days faecal samples) × % lipid and % fatty acids in 
the faeces respectively. Rats were housed in pairs and the faecal lipid data is presented 
as average digestibility of each rat pair over the last two weeks of the trial. 
 
4.3.4 Whole Body Fatty Acid Balance Method  
The fatty acid metabolism of rats was determined using the Whole Body Fatty Acid 
Balance Method, as conceived and described by Turchini et al (2007) with subsequent 
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developments (Turchini and Francis, 2009). Briefly, the first step of the method required 
that the net appearance or disappearance of each individual fatty acid be determined 
by the difference between total fatty acid accumulation (=final fatty acid content-initial 
fatty acid content) and the net fatty acid intake (=total fatty acid intake-fatty acid 
excretion in faeces), as initially proposed by Cunnane’s group (Cunnane et al., 1995, 
Cunnane and Yang, 1995, Cunnane and Anderson, 1997). Then, after the transformation 
of data from gram per animal per the duration of the trial to mol of fatty acid per gram 
of body weight per day, the subsequent second step involved a series of backwards 
computations along all the known fatty acid bioconversion pathways (Turchini et al., 
2007), therefore the fate of each individual fatty acid towards bioconversion, β-
oxidation or deposition was determined and quantified. Eventually, data relative to 
apparent in vivo enzyme activity could be reported as nmol of enzyme’s product per 
gram of body weight per day, and the in vivo metabolic fate (absorption, β-oxidation, 
bioconversion and tissue deposition) of each dietary fatty acid could be reported as a % 
relative to the dietary intake.  
 
4.3.5 Statistical analysis  
Data analysis was performed with Minitab Statistical Software (Version 14; Minitab Inc., 
USA). All data are reported as mean ± SD of 6 cages per treatment (n=6; N=24). 
Significant differences between experimental groups were tested using two-way 
ANOVA, assessing the effects of diets, gender and their interactions. Paired tests were 
performed with Tukey’s test. Statistical significance was considered for P<0.05.  
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 Results  
4.4.1 Weight of rat whole body and tissues 
There was no significant difference (P=0.303) in the body weights of female rats 
between the two dietary groups during the six weeks of experiment. The average body 
weights (± SD) of animals in fish oil and krill oil groups were 270 ± 20 g and 278 ± 15 g, 
respectively, at the end of the experiment. Similarly, there was no significant difference 
(P=0.957) in the body weights of male rats between the two dietary groups during the 
six weeks of experiment. The average body weights (± SD) of animals in fish oil and krill 
oil groups were 409 ± 28 g and 410 ± 31 g, respectively, at the end of the experiment. 
As male rats consumed more diet than female rats, they were significantly heavier (409 
± 29 vs 274 ± 18 g, P=0.000). 
In regard to the tissue weight, there was no significant difference in the tissue weights 
of rats between the two dietary groups during the six weeks of experiment. All tissue 
weights were significantly higher in male rats compared with female rats (Table 4.2).  
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Table 4-2. The effect of fish oil and krill oil diets on tissue weight over the six weeks of 
experiment. 
 Female rats Male rats    
Weight  
(mg/g of tissue) Krill oil Fish oil Krill oil Fish oil P(Diet) P(Gender) P(Diet*Gender) 
Liver 10.4 ± 0.2 10.6 ± 0.9 15.3 ± 0.8 17.3 ± 0.8 n.s 0.000 n.s 
Heart 1.0 ± 0.0 1.0 ± 0.1 1.4 ± 0.1 1.5 ± 0.1 n.s 0.000 n.s 
Perirenal 5.4 ± 1.6 5.3 ± 1.2 8.0 ± 2.3 6.7 ± 2.9 n.s 0.006 n.s 
White 
gastrocnemius  
1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 n.s 0.000 n.s 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not 
significant. 
 
 
 
 
4.4.2 Lipid content of rat whole body and tissues 
Whole body lipid content (mg/g of wet tissue of whole body) of rats at the conclusion of 
study (week 6) were significantly higher compared with the baseline data (P=0.001). 
Female rats had a tendency (P=0.053) towards higher whole body lipid content 
compared with male rats. There was no significant difference in the total amount of 
whole body lipid content between the two dietary treatments over the six weeks of 
experiment (P=0.404). Furthermore, the interaction of diet and gender was not 
significant (P=0.269).  
In regard to the tissue lipid content, both male and female rats had a greater liver lipid 
content (mg/ g tissue of wet tissue) over the six weeks of experiment compared with 
the baseline data (P<0.05). The total lipid content of the tissues did not differ between 
diet treatments. The lipid contents of liver, heart and muscle (mg/g tissue) were 
significantly higher in female rats compared with male rats (P<0.05; Table 4.3).  
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Table 4-3. The effect of fish oil and krill oil diets on the whole body and tissue lipid 
content over the six weeks of experiment. 
 Female rats Male rats    
Lipid content Krill oil Fish oil Krill oil Fish oil P(Diet) P(Gender) P(Diet*Gender) 
Whole body  
(mg/g whole body) 
149 ± 32 152 ± 28 140 ± 25 119 ± 13 n.s n.s n.s 
Tissues (mg/g tissue)        
Liver 68 ± 14 61 ± 6 49 ± 7 51 ± 6 n.s 0.001 n.s 
Heart 31 ± 1 29 ± 3 27 ± 2 29 ± 1 n.s 0.029 n.s 
Perirenal 778 ± 33 784 ± 38 886 ± 22 893 ± 27 n.s n.s n.s 
White gastrocnemius  25 ± 5 24 ± 3 22 ± 2 20 ± 3 n.s 0.041 n.s 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant.  
 
 
 
4.4.3 Lipid and fatty acid apparent digestibility  
The effect of fish oil and krill oil diets on apparent digestibility is shown in Table 4.4. 
There were no significant differences observed in total lipid apparent digestibility among 
the diet groups, with the values exceeding 96% in each case. There were small, but 
significant differences observed in total lipid and n-3 LC-PUFA apparent digestibility 
between genders, which was higher in female rats compared with male rats. It is not 
clear whether these small differences are biologically significant”. The relationship 
between statistical significance and biological significance of modified fatty acid 
digestibility is an interesting and not yet well addressed topic in vivo trial that deserves 
further investigations.  
However, there was a different pattern for n-3 LC-PUFA apparent digestibility, with the 
digestibility ranging from 84.2% (DPA, krill oil diet, male rats) to 99.6% (ALA and EPA, 
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krill oil diet, female rats), with the values for most of the fatty acids being in excess of 
98%. The largest differences in terms of both diet and gender were for DPA, whereby 
digestibility of these fatty acids was lowest in male rats fed the krill oil diet when 
compared with males fed the fish oil diet, and with male rats on both the krill oil and 
fish oil diets. 
 
Table 4-4. The effect of fish oil and krill oil diets on apparent digestibility (%) of lipids 
and n-3 PUFA. 
 Female rats Male rats    
 Krill oil Fish oil Krill oil Fish oil P(Diet) P(Gender) P(Diet*Gender) 
Total lipid 
n-3 PUFA 
96.8 ± 0.2 96.8 ± 0.1 96.3 ± 0.5 96.7 ± 0.3 n.s 0.016 n.s 
18:3n-3 (ALA) 99.6 ± 0.1 99.8 ± 0.1 99.4 ± 0.2 99.7 ± 0.1  0.000 0.003 n.s 
n-3 LC-PUFA        
20:5n-3 (EPA) 99.6 ± 0.9 99.4 ± 0.7 99.0 ± 0.1 99.4 ± 0.0 0.000 0.000 0.001 
22:5n-3 (DPA) 93.3 ± 2.3 97.1 ± 3.2 84.2 ± 8.4  96.9 ± 1.0 0.000 0.024 0.030 
22:6n-3 (DHA) 99.3 ± 0.2 98.8 ± 0.3 98.5 ± 0.4 98.8 ± 0.5 n.s 0.016 0.021 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant.  
 
 
4.4.4 The fatty acid concentration of the rat whole body and tissues  
As shown in Table 4.5, the whole body fatty acid concentration in female rats was 
significantly higher for all n-3 LC-PUFA compared with male rats at the end of 
experiment (P=0.000). The whole body EPA concentration was similar in rats fed either 
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fish oil diet or krill oil diet, for both genders. However, DPA and DHA concentrations 
were significantly higher in the fish oil fed group compared with the krill oil fed group 
for both gender at the end of the study period (P=0.022). Supplementation with omega-
3 diets (fish oil and krill oil) led to a significant increase in whole body EPA+DPA+DHA 
concentration compared with the baseline data over the six weeks of experiment (0.65 
mg/g whole body vs 1.26 and 1.18 in male rats fed fish and krill treatments, respectively 
and 0.71 mg/g whole body vs 1.72 and 1.52 in female rats fed fish and krill treatments, 
respectively). 
In terms of tissue concentrations, there were significant gender differences in the EPA 
and DHA concentrations (mg/g tissue) in liver, heart and adipose tissue, but not muscle 
tissue, with tissues from female rats having a higher level of these two fatty acids than 
male rats (Table 4.5). There were no effects of dietary treatment for EPA and DHA in any 
of these four tissues. 
Female rats had significantly higher concentrations of DPA than male rats in liver and 
heart tissue, but not in muscle or adipose tissue. Interestingly, there were significantly 
higher concentrations of DPA in liver and muscle tissue in krill oil fed rats compared with 
fish oil fed rats, but this difference was not observed in heart or adipose tissue. This data 
suggests tissue specific modulations of DPA metabolism, and is consistent with the 
recent study on male Sprague Dawley rats showing that an increased level of DPA was 
recorded in both liver and heart 2 days after the feeding of the DPA ceased (Ghasemi 
Fard et al., 2014). 
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Table 4-5. Selected whole body and tissue fatty acids (mg/g tissue) of rats fed either 
krill oil or fish oil during 6 weeks of experiment in both genders. 
 Female rats Male rats    
 Krill oil Fish oil Krill oil Fish oil P(Diet) P(Gender) P(Diet*Gender) 
Whole body        
20:5n-3 (EPA) 0.24 ± 0.05 0.29 ± 0.05 0.17 ± 0.02 0.16 ± 0.02 n.s 0.000 0.039 
22:5n-3 (DPA) 0.26 ± 0.07 0.32 ± 0.05 0.21 ± 0.02 0.22 ± 0.02 0.013 0.000 0.043 
22:6n-3 (DHA) 1.01 ± 0.08 1.11 ± 0.15 0.80 ± 0.06 0.88 ± 0.06 0.003 0.000 n.s 
Liver        
20:5n-3 (EPA) 0.69 ± 0.14 0.86 ± 0.17 0.57 ± 0.16 0.31 ± 0.04 n.s 0.000 0.001 
22:5n-3 (DPA) 0.39 ± 0.18 0.24 ± 0.07 0.26 ± 0.04 0.14 ± 0.02 0.004 0.008 n.s 
22:6n-3 (DHA) 2.26 ± 0.30 2.01 ± 0.62 1.77 ± 0.22 1.47 ± 0.32 n.s 0.005 n.s 
Heart        
20:5n-3 (EPA) 0.16 ± 0.02 0.18 ± 0.02 0.10 ± 0.07 0.09 ± 0.04 n.s 0.001 n.s 
22:5n-3 (DPA) 0.34 ± 0.04 0.29 ± 0.04 0.16 ± 0.13 0.21 ± 0.10 n.s 0.002 n.s 
22:6n-3 (DHA) 1.78 ± 0.14 1.90 ± 0.12 0.97 ± 0.77 1.55 ± 0.76 n.s 0.018 n.s 
White gastrocnemius muscle 
20:5n-3 (EPA) 0.18 ± 0.03 0.13 ± 0.04 0.13 ± 0.03 0.14 ± 0.04 n.s n.s 0.042 
22:5n-3 (DPA) 0.20 ± 0.02 0.14 ± 0.03 0.20 ± 0.03 0.15 ± 0.02 0.000 n.s n.s 
22:6n-3 (DHA) 1.04 ± 0.11 0.82 ± 0.23 0.94 ± 0.08 0.92 ± 0.10 n.s n.s n.s 
Perirenal adipose       
20:5n-3 (EPA) 0.15 ± 0.03 0.09 ± 0.02 0.06 ± 0.01 0.06 ± 0.02 n.s 0.001 n.s 
22:5n-3 (DPA) 0.15 ± 0.04 0.12 ± 0.02 0.10 ± 0.02 0.12 ± 0.06 n.s n.s n.s 
22:6n-3 (DHA) 0.17 ± 0.05 0.15 ± 0.04 0.09 ± 0.03 0.09 ± 0.03 n.s 0.000 n.s 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant.  
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4.4.5 EPA, DPA and DHA – Mass Balance 
Intake and excretion: Male rats consumed significantly more n-3 LC-PUFA (EPA, DPA and 
DHA) compared with female rats and excreted significantly more n-3 LC-PUFA (EPA, DPA 
and DHA). Between diets, n-3 LC-PUFA intake was higher in rats fed fish oil than krill oil; 
however, no significant differences in faecal excretion were observed.  
Accumulation: The main whole body n-3 LC-PUFA to be accumulated in both diet groups 
over the 6 weeks of the experiment was DHA (280-360 mg/animal), approximately 4 
times more than DPA and EPA (70-90 mg/animal). In terms of net accumulation, 
significantly more DHA and total n-3 LC-PUFA accumulated in male rats compared with 
females, with no effect of diet observed (Table 4.6).   
Appearance/disappearance: There was a net disappearance of all n-3 LC-PUFA in the 
experiment (intake greater than accumulation) in both diets and for both genders, 
except for DPA in male and female rats fed krill oil where a small net appearance was 
observed (Table 4.6). The differences in the net disappearance of all n-3 LC-PUFA were 
observed as a result of gender (male more than female, P=0.000) and diet (fish oil more 
than krill oil, P=0.000). 
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Table 4-6. n-3 LC-PUFA balance in rats fed either krill oil or fish oil during 6 weeks of 
experiment in both genders (mg per animal). 
 Female rats Male rats    
 Krill oil  Fish oil  Krill oil  Fish oil  P(Diet) P(Gender) P(Diet*Gender) 
Total intake (mg) 
20:5n-3 1110 ± 19 1240 ± 64 1428 ± 5 1661 ± 9 0.000 0.000 0.000 
22:5n-3 55 ± 1 177 ± 9 71 ± 0 237 ± 1 0.000 0.000 0.000 
22:6n-3 639 ± 11 823 ± 43 822 ± 3 1104 ± 6 0.000 0.000 0.000 
n-3 LC-PUFA 2582 ± 45 3175 ± 164 3322 ± 12 4256 ± 24 0.000 0.000 0.000 
Excretion (mg) 
20:5n-3 4 ± 0 7 ± 1  14 ± 1 10 ± 1 n.s 0.000 0.000 
22:5n-3 3 ± 1 5 ± 6 11 ± 6 8 ± 2 n.s 0.013 n.s 
22:6n-3 5 ± 1 10 ± 3 13 ± 4 13 ± 5 0.046 0.001 0.153 
n-3 LC-PUFA 23 ± 2 37 ± 12 57 ± 12 46 ± 9 n.s 0.000 0.004 
Initial body content (mg) 
20:5n-3 3.7 ± 0.1 3.6 ± 0.1 3.6 ± 0.2 3.4 ± 0.3 n.s 0.031 n.s 
22:5n-3 18.1 ± 0.5 17.6 ± 0.6 18.6 ± 1.1 17.7 ± 1.5 n.s n.s n.s 
22:6n-3 54.0 ± 1.4 52.3 ± 1.7 44.8 ± 2.6 42.7 ± 3.5 n.s 0.000 n.s 
n-3 LC-PUFA 177 ± 4 172 ± 5 170 ± 10 162 ± 13 n.s 0.035 n.s 
Final body content (mg) 
20:5n-3 68 ± 15 77 ± 16 68 ± 8 66 ± 9 n.s n.s n.s 
22:5n-3 74 ± 21 88 ± 14 86 ± 7 89 ± 8 n.s n.s n.s 
22:6n-3 288 ± 27 302 ± 49 328 ± 23 361 ± 28 n.s 0.001 n.s 
n-3 LC-PUFA 590 ± 90 637 ± 114 695 ± 62 723 ± 28 n.s 0.009 n.s 
Accumulation (mg) 
20:5n-3 65 ± 14 74 ± 16 65 ± 8 63 ± 9 n.s n.s n.s 
22:5n-3 56 ± 21 70 ± 14 68 ± 7 72 ± 9 n.s n.s n.s 
22:6n-3 229 ± 27 249 ± 49 284 ± 21 318 ± 28 n.s 0.000 n.s 
n-3 LC-PUFA 413 ± 90 465 ± 117 526 ± 58 561 ± 34 n.s 0.005 n.s 
Appearance/disappearance (mg) 
20:5n-3 -1041 ± 12 -1158 ± 55 -1350 ± 8 -1590 ± 13 0.000 0.000 0.000 
22:5n-3 4 ± 20 -101 ± 17 7 ± 10 -158 ± 8 0.000 0.000 0.000 
22:6n-3 -406 ± 26 -564 ± 33 -526 ± 19 -772 ± 23 0.000 0.000 0.000 
n-3 LC-PUFA -2146 ± 72 -2673± 109 -2739 ± 53 -3649 ± 33 0.000 0.000 0.000 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant.  
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4.4.6 EPA, DPA and DHA apparent in vivo metabolism 
The whole body method allowed the calculation of apparent in vivo fatty acid 
metabolism (excretion, β-oxidation, bioconversion or deposition) as shown in Table 4.5. 
The two most important pathways identified for the n-3 LC-PUFA in this study were β-
oxidation and deposition, which together accounted for more than 90% of the apparent 
in vivo metabolism (Table 4.7). 
The main fate of EPA and DHA was β-oxidation; for EPA it was 93-95%, while for DHA it 
ranged between (63-69%). There were significant diet effects for DHA β-oxidation which 
was higher in rats fed fish oil than those fed krill oil (P=0.002). Gender did not 
significantly affect DHA metabolism (Table 4.7).  
Apart from β-oxidation, deposition was the next main fate of the EPA and DHA. In the 
case of EPA, deposition amounted to less than 6% of the total metabolic activity, 
whereas in the case of DHA, deposition accounted for between 29 to 36% (Table 4.7). 
For EPA and DHA there were very similar trends between diets and gender; however, 
this was not the case for DPA. The main fate of DPA differed between the diet groups. 
In the case of the fish oil groups, most of the DPA was β-oxidised (57% and 67% for 
female and male rats, respectively). For the krill oil groups; however, the majority of DPA 
was deposited (82-83%) which contrasts with only 30-40% of the DPA being deposited 
in the fish oil groups. There was no significant difference in DPA deposition between 
genders. DPA was not further bio-converted to other n-3 LC-PUFA (namely 24:5n-3, 
24:6n-3 or DHA).  
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Table 4-7. Fate of n-3 LC-PUFA and EPA+DPA+DHA (% of total intake) in rats fed either 
fish oil or krill oil diets during 6 week experiment. 
 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant. 
n.d= not detected. 
 
The apparent in vivo enzyme activities (expressed as mmol of product per gram of body 
weight per day) are reported in Table 4.8. The apparent total elongase activity and total 
desaturase activities (Δ5-Desaturase, Δ6-Desaturase and Δ9-Desaturase) were 
significantly greater in rats fed krill oil supplemented diets compared with those fed fish 
oil supplemented diets. Apparent enzyme activities were also higher in male rats 
 Female rats Male rats    
 Krill oil  Fish oil  Krill oil  Fish oil  P(Diet) P(Gender) P(Diet*Gender) 
Excreted 
20:5n-3 (EPA) 0.7 ± 0.0 0.6 ± 0.0 0.9 ± 0.0 0.5 ± 0.0 0.011 0.000 0.000 
22:5n-3 (DPA) 6.3 ± 2.2 2.9 ± 0.3 14.9 ± 7.9 3.2 ± 1.0 0.000 0.025 0.031 
22:6n-3 (DHA) 0.7 ± 0.2 1.2 ± 0.3 1.5 ± 0.4 1.2 ± 0.5 n.s 0.016 0.021 
EPA+DPA+DHA 0.6 ± 0.1 0.9 ± 0.3 1.5 ± 0.3 1.1 ± 0.1 n.s 0.000 0.000 
β-oxidised 
20:5n-3 (EPA) 93.0 ± 2.4 93.4 ± 1.2 93.9 ± 0.8 95.6 ± 0.5 n.s 0.017 n.s 
22:5n-3 (DPA) 10.6 ± 13.1 57.4 ± 9.6 2.7 ± 6.5 66.6 ± 3.6 0.000 n.s 0.030 
22:6n-3 (DHA) 63.5 ± 4.2 68.6 ± 5.1 63.9 ± 2.4 69.9 ± 2.4 0.002 n.s n.s 
EPA+DPA+DHA 80.7 ± 2.7 82.0 ± 2.8 81.2 ± 1.4 84.4 ± 1.2 0.018 n.s n.s 
Bioconverted  
20:5n-3 (EPA) 0.7 ± 0.2 n.d 0.6 ± 0.4 n.d 0.017 n.s n.s 
22:5n-3 (DPA) n.d n.d n.d n.d - - - 
EPA+DPA 0.5 ± 0.1 n.d 0.4 ± 0.2 n.d 0.17 n.s n.s 
Deposited  
20:5n-3 (EPA) 5.8 ± 1.2 5.9 ± 1.1 4.5 ± 0.56 3.7 ± 0.5 n.s 0.000 n.s 
22:5n-3 (DPA) 83.0 ± 12.3 39.6 ± 7.2 82.3 ± 8.0 30.2 ± 3.8 0.000 n.s n.s 
22:6n-3 (DHA) 35.7 ± 4.1 30.2 ± 5.0 34.4 ± 2.5 28.8 ± 2.4 0.001 n.s n.s 
EPA+DPA+DHA 18.1 ± 2.2 17.0 ± 2.7 16.9 ± 1.1 14.5 ± 1.2 0.036 0.027 n.s 
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compared with female rats with the exception of Δ9-Desaturase, where no significant 
difference. 
Table 4-8. The apparent in vivo enzyme activities (mmol/g/day) in rats fed either fish 
oil or krill oil diets during 6 week experiment. 
  Female  Male      
  Krill Oil Fish Oil Krill Oil Fish Oil P(Diet) P(Gender) P(Diet*Gender) 
Elongation        
18:2n-6 to 20:n-6 3.7 ± 1.3 4.0 ± 1.3 5.2 ± 1.2 5.6 ± 0.7 n.s 0.003 n.s 
20:2n-6 to 22:2n-6 1.8 ± 0.3 0.61 ± 0.06 2.2 ± 0.2 2.4 ± 0.4 n.s 0.000 n.s 
18:3n-6 to 20:3n-6 41.4 ± 6.3 24.9 ± 10.4 64.9 ± 5.6 64.5 ± 4.6 0.008 0.000 n.s 
20:4n-6 to 22:4n-6 n.d 0.3 ± 0.4 1.9 ± 0.6 3.9 ± 0.8 0.000 0.000 n.s 
22:4n-6 to 24:4n-6 0.03 ± 0.07 0.18 ± 0.21 1.4 ± 0.6 1.9 ± 0.7 n.s 0.000 n.s 
18:3n-3 to 20:3n-3 0.4 ± 0.2 0.4 ± 0.2 0.8 ±0.3 2.1 ± 0.3 0.000 0.000 n.s 
20:3n-3 to 22:3n-3 n.d n.d n.d n.d - - - 
18:4n-3 to 20:4n-3 n.d n.d n.d n.d - - - 
20:5n-3 to 22:5n-3 3.6 ± 5.6 n.d 2.7 ± 2.1 n.d 0.018 n.s n.s 
22:5n-3 to 24:5n-3 n.d n.d n.d n.d - - - 
Δ9-desaturase        
14:0 to 14:1n-5 17.3 ± 11.5 23.2 ± 9.72 18.2 ±10.0 15.2 ± 3.0 n.s n.s n.s 
16:0 to 16:1n-7 838.3 ± 479.7 699.1 ±406.2 1010.2±490.3 359.3± 131.6 0.027 n.s n.s 
18:0 to 18:1n-9 n.d n.d n.d n.d - - n.s 
20:0 to 20:1n-11 1.7 ± 0.4 n.d 2.2 ± 0.5 n.d 0.000 n.s n.s 
22:0 to 22:1n-13 n.d n.d n.d n.d - - n.s 
Δ6-desaturase        
18:2n-6 to 18:3n-6 38.9 ± 7.0 10.1 ± 10.5 62.9 ± 5.5 45.8 ± 4.5 0.000 0.000 n.s 
24:4n-6 to 24:5n-6 0.03 ± 0.07 0.18 ± 0.21 1.40 ± 0.61 1.92 ± 0.74 n.s 0.000 n.s 
18:3n-3 to 18:4n-3 n.d n.d n.d n.d - - - 
24:5n-3 to 24:6n-3  n.d n.d n.d n.d - - - 
Δ5-desaturase        
20:3n-6 to 20:4n-6 35.6 ± 5.5 18.3 ± 9.5 56.9 ± 5.2 55.8 ± 5.3 0.003 0.000 0.007 
20:4n-3 to 20:5n-3 n.d n.d n.d n.d - - - 
Chain shortening        
24:5n-6 to 22:5n-6 0.03 ± 0.07 0.18 ± 0.21 1.40 ± 0.61 1.92 ± 0.74 n.s 0.000 n.s 
24:6n-3 to 22:6n-3 n.d n.d n.d n.d - - - 
Values are expressed as the mean ± SD of 6 cages per treatment (n=6, N=24). n.s = not significant.  
n.d= not detected.  
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 Discussion  
The aim of the current study was to compare the apparent bioavailability of n-3 LC-PUFA 
originating from krill oil (PL-rich) versus that from fish oil (TAG-rich) in both male and 
female rats. It was planned to feed identical amounts (1.5 mg/g) of n-3 LC-PUFA in each 
diet; however, once the diet had been manufactured and tested for the n-3 LC-PUFA 
content it was found the amounts were similar, but not identical (1.61 vs 1.38 mg/g, 
respectively). These are relatively small variations, normally encountered when 
formulating experimental diets, but for accuracy they have to be noted. Nevertheless, 
using the Whole Body Fatty Acid Balance Method, the difference in n-3 LC-PUFA intake 
is not influential since it is possible to express the results as a percentage of the total 
intake of n-3 LC-PUFA (see Table 4.7).  
During the 6 weeks of trial duration, no mortality was recorded, experimental diets were 
highly palatable, and all animals grew well. Lipid deposition in animals’ whole body and 
individual tissues was not affected by the dietary treatment. Accordingly, previous 
studies have reported no significant difference in body weight gain in mice (Burri et al., 
2011) or rats (Tou et al., 2011, Ferramosca et al., 2012) fed either krill oil or fish oil. In 
the present study, the only differences observed in performance, food intake and lipid 
deposition were, as expected, relative to gender. 
The n-3 LC-PUFA (EPA, DPA and DHA) concentrations in the tissues analysed showed 
some statistically significant differences. In liver, heart and perirenal adipose tissue, 
these differences were mainly affected by gender, with female animals recording higher 
n-3 LC-PUFA concentrations compared with males. For whole body, similar gender 
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differences were observed, but also a statistically significant effect of the oil was 
observed for DHA content, with animals fed fish oil recording higher DHA concentrations 
than animals fed krill oil. Nevertheless, while the results obtained by simply comparing 
tissue fatty acid profiles are interesting, they are admittedly of limited value towards 
achieving a better understanding of n-3 LC-PUFA bioavailability. In fact, the dietary 
intake of n-3 LC-PUFA provided by the two diets were similar, but also not identical, and 
differences between treatments observed could be partially due to dietary supply, 
rather than actual differences in bioavailability. Therefore, and as mentioned above, a 
much greater and more accurate understanding of the actual metabolic fate of n-3 LC-
PUFA provided by different oils can be achieved by observing the results of the Whole 
Body Fatty Acid Balance Method. 
The n-3 LC-PUFA in the diet were differently absorbed between the fish oil and krill oil 
groups and between genders (Table 4.4). Female animals recorded a higher apparent 
digestibility for total lipid, n-3 PUFA and n-3 LC-PUFA, compared with males. A marked 
effect on DPA digestibility by gender was observed for krill oil, with relatively low 
apparent digestibility values recorded in male rats fed the krill oil diet. On the other 
hand, DHA digestibility was not affected by the treatment, and was highly absorbed 
(>98%) by both males and females fed either diet. However, when n-3 LC-PUFA were 
considered all together (EPA+DPA+DHA) and reported as % of excreted fatty acids 
relative to total intake (Table 4.7), no differences were observed relative to diet 
treatment. Gender was found to have a direct effect on absorption (bioavailability), with 
female animals recording a significantly lower excretion (greater bioavailability). The 
excretion (expressed as % of the total dietary intake) of n-3 LC-PUFA in this study ranged 
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from 0.6 to 0.9% in females and from 1.1 to 1.5% in males. Tou et al (2011) observed no 
significant difference in EPA digestibility from krill oil and fish oil sources; however, they 
did report a higher DHA digestibility in female rats fed salmon oil compared with those 
fed krill oil. It is important to note here that in both the present study and that of Tou et 
al (2011) the differences between genders, although tested as statistically significant, 
were possibly of limited biological significance. Nevertheless we are short of likely 
explanations as to why gender can affect n-3 LC-PUFA absorption, and the present 
results warrant further specifically tailored studies. 
Once absorbed, the metabolic fate of n-3 LC-PUFA were significantly affected by diet 
and gender. Metabolic fate here refers to whether the n-3 LC-PUFA were deposited 
(anabolism) or were β-oxidised (catabolism). Deposited here refers to whether the n-3 
LC-PUFA were deposited as such, or were bio-converted by desaturation or chain 
elongation.  
A first important observation was that the major metabolic fate of n-3 LC-PUFA was 
towards catabolism (β-oxidation) accounting for over 80% of total dietary intake, 
whereas deposition accounted for only 14.5 to 18.6% of total dietary intake. It was found 
that for both genders, significantly more n-3 LC-PUFA were β-oxidised when originating 
from fish oil, compared with krill oil, with the average difference being 2.8%. Conversely, 
it was found that significantly more n-3 LC-PUFA were deposited when originating from 
krill oil, than from fish oil, in both genders, by a mean difference of 13.2%. As Cansell et 
al (2003) reported these two different forms of n-3 LC-PUFA (TAG and PL) led to different 
positional distributions of EPA and DHA in the chylomicron TAG. Therefore, positional 
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distribution of n-3 LC-PUFA may contribute to the different metabolic fate of n-3 LC-
PUFA following the feeding of fish oil versus krill oil. 
Furthermore, and independently from the dietary treatment, it was found that female 
rats deposited a significantly higher proportion of the dietary n-3 LC-PUFA intake than 
did male rats, with the mean difference for females and males being 10.3%. Therefore, 
the present study suggests the existence of gender specific differences with respect to 
n-3 LC-PUFA β-oxidation (higher in males) and deposition (higher in females), which 
coupled with the known higher omega-3 fatty acid bioconversion capability in females 
(Kitson et al., 2012, Extier et al., 2010, Burdge et al., 2008), can explain the commonly 
reported higher omega-3 status in females compared with males (Lohner et al., 2013, 
Sarter et al., 2015, Howe et al., 2014), and possibly due to the overall higher n-3 LC-PUFA 
requirements of females during pregnancy and lactation.    
Based on these data, it can be said that in this 6-week study a higher proportion of the 
n-3 LC-PUFA from krill oil were deposited in rat tissues (whole body) compared with n-
3 LC-PUFA originating from fish oil. This difference between deposition of n-3 LC-PUFA 
from krill oil and fish oil (13%) in a rat model was not of the order of the differences 
advertised in the marketing campaigns, which indicated the bioavailability of krill oil was 
3 to 9 times higher than fish oil in humans. Importantly, in the present study, it was also 
clearly shown that the bioavailability is in actuality the same, but the resultant metabolic 
fate is different. It should be noted that the energy from fat in test diets was lower than 
what the majority of humans generally would consume, so it is possible that the results 
may be different in diets with higher fat content. 
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To our knowledge, this is the first study to report the whole body bioavailability of n-3 
LC-PUFA from either fish oil or krill oil in the rat. A number of previous studies by 
Cunnane’s group, using the Whole Body Fatty Acid Balance Method, examined the 
accumulation and apparent β-oxidation of shorter chain PUFA in rats (linoleic acid and 
alpha-linolenic acid). Generally, these studies reported a very high proportion of these 
PUFA being readily β-oxidised in pregnant rats (Cunnane and Chen, 1995). Typically, 
studies on krill oil in rodents have looked at n-3 LC-PUFA levels in a number of tissues 
and compared n-3 LC-PUFA levels in these tissues in comparison with rats fed fish oil. 
For example, in a rat study by Batetta et al (2009), EPA and DHA concentrations in the 
PL fraction of liver and heart tissues were significantly increased in the krill fed rats 
compared with fish oil fed rats. Di Marzo et al (2010) reported that a significantly higher 
DHA level was found in brain PL of rats provided with krill oil compared with fish oil. In 
addition, some human studies reported that plasma (Ramprasath et al., 2013, Ulven et 
al., 2011) and RBC (Ramprasath et al., 2013) EPA and DHA proportions increased 
significantly in the krill oil group compared with fish oil group.    
One of the novel observations of this study was that a significantly higher proportion of 
n-3 LC-PUFA from dietary fish oil was β-oxidised compared with krill oil. A possible 
reason for this difference might relate to the fact that fish oil is basically composed of 
TAG molecules whereas krill oil is often rich in PL, as was the case in this study (65% PL). 
Accordingly, there is now emerging evidence from animal and human studies showing 
that, following digestion and absorption, the n-3 LC-PUFA fatty acids from PL partition 
differently to those from TAG. Specifically, animal studies comparing essentially pure PL 
preparations with TAG forms are generally consistent in showing different patterns of 
146 
 
incorporation of n-3 LC-PUFA into chylomicron and plasma lipids or lipoprotein fractions 
(Amate et al., 2001, Cansell et al., 2003, Cansell et al., 2006, Rossmeisl et al., 2012). 
Amate et al (2001) reported that arachidonic acid and DHA in TAG form partitioned 
preferentially into LDL-PL whereas arachidonic acid and DHA in PL partitioned into HDL-
PL. Rossmeisl et al (2012) reported EPA levels in liver PL were nearly double in mice fed 
PL compared with the group fed TAG in a 9 week study in mice fed DHA plus EPA either 
as TAG or PL form. Other data from the literature using either 14C or 13C-labelled DHA in 
PL or TAG form have reported differences in uptake into of the DHA into brain (Graf et 
al., 2010) or erythrocytes (Lemaitre-Delaunay et al., 1999, Brossard et al., 1997), in 
favour of PL form.  These examples emphasize that PL and TAG fatty acids are 
partitioned into tissue lipids in a different fashion. It is therefore conceivable that the 
greater tissue incorporation of n-3 LC-PUFA fatty acids such as DHA from krill oil (PL) 
means that the DHA is less easily available to enzymatic pathways leading to β-oxidation 
than the n-3 LC-PUFA from fish oil (TAG). 
Admittedly, there were a few limitations in this study that need to be reported. The first 
one was that the designed equal dose of n-3 LC-PUFA for fish oil and krill oil diets were 
not achieved during diets manufacturing (EPA+DHA+DPA level of krill oil and fish oil 
were 1.38 and 1.61 mg/g of diet, respectively), despite several attempts in trial batches 
to get the doses equal, prior to final formulation and manufacturing. Nevertheless, to 
counteract this error, metabolic fates of each fatty acid were computed and expressed 
as a percentage of total intake, and thus unaffected by the variation in dietary 
administration. The second one was that a longer term trial would have been necessary 
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to achieve any changes of n-3 LC-PUFA status in other tissues such as brain (Sinclair et 
al., 2007).  
In conclusion, this study showed that in this 6-week study a higher proportion of the 
dietary n-3 LC-PUFA from krill oil were deposited in rat tissues (whole body) compared 
with fish oil, by about 13%. However, and importantly, this study also demonstrated that 
this difference was not due to a difference in bioavailability (absorption), but to a 
difference in metabolic fate (anabolism vs catabolism). It was estimated that most of 
EPA (>90%) and more than half of DHA (>60%) were β-oxidised in both diet groups. Most 
of the DPA was β-oxidised (57% and 67% for female and male rats, respectively) in the 
fish oil group; however, for the krill oil group, the majority of DPA was deposited (82-
83%). Furthermore, a higher proportion of the dietary n-3 LC-PUFA was deposited in 
female rats (whole body) compared with male rats, by about 11%, independent of diet. 
This study proved that the β-oxidation and deposition, but not absorption, of long chain 
omega-3 fatty acids was affected by the oil source (krill oil or fish oil) in the rat.  
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 Abstract 
Based on the results from a human study which showed significantly reduced 
incorporation of DPA compared with EPA into chylomicrons, this study was designed to 
test if dietary DPA was significantly less absorbed than EPA. Male Sprague Dawley rats 
were randomly assigned to three groups of six, and were fed a semi synthetic high fat 
diet (23.5% fat) for 9 days. The test omega-3 fatty acids (EPA and DPA, 250 
mg/animal/day, free fatty acid form) or olive oil (250 mg/animal/day) were added to the 
high fat diet on days 5, 6 and 7. Dietary EPA and DPA appeared in the faeces on days 6, 
7 and 8, with the total amount of DPA excreted being 4.6-fold greater than that of EPA. 
The total amount of faecal fat did not differ significantly between the groups. At the 
conclusion of the study (day 9), it was found that liver DPA, EPA and total n-3 LC-PUFA 
levels were significantly increased by both DPA and EPA feeding compared with the olive 
oil fed control group. In the heart, DPA feeding increased the DPA content and both DPA 
and EPA feeding increased the total n-3 LC-PUFA levels. This study showed that DPA and 
EPA, both provided in free form, are metabolised differently, despite being chemically 
similar. 
Key words: 20:5n-3; 22:5n-3; Absorption; Excretion; Lipid metabolism; n-3 
polyunsaturated fatty acids (PUFA); Omega-3.  
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 Introduction 
Eicosapentaenoic acid (EPA, 20:5n-3), docosahexaenoic acid (DHA, 22:6n-3) and 
docosapentaenoic acid (DPA, 22:5n-3) are provided from dietary sources, mainly fish, 
fish oil products and to a lesser extent from ruminant meats. Traditionally, whilst EPA 
and DHA have been abundantly studied, little interest has been paid to DPA. However, 
recent studies in rats (Kaur et al., 2010, Holub et al., 2011, Kaur et al., 2013) and humans 
(Miller et al., 2013, Linderborg et al., 2013) suggest that EPA and DPA are metabolised 
differently.  
In rats, short-term supplementation with pure DPA significantly increased the 
concentration of DHA in liver and the concentration of EPA in the liver, heart and skeletal 
muscle, presumably by the process of retroconversion (Kaur et al., 2010); with the 
retroconversion from DPA to EPA being especially apparent in the kidney (Holub et al., 
2011). The synthesis, metabolism and biological effects of DPA have been reviewed by 
Kaur et al (2011a) and thereafter, two studies have investigated the metabolism of DPA 
in humans. In a randomized cross-over double blinded study by Miller et al (2013), 10 
female participants were provided a total of 8 grams of pure DPA or pure EPA over a 7-
day period. This study proved that DPA and EPA had different and specific incorporation 
patterns into plasma lipids and erythrocyte lipids in humans. Linderborg et al (2013) 
applied lipidomics to a postprandial cross-over study in which 2 grams of either pure 
EPA or pure DPA (as free fatty acids, FFA) were served with the breakfast to 10 healthy 
female subjects with a 1-week wash out between different supplements. It was found 
that following the breakfast containing DPA and olive oil, there was a significantly 
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reduced chylomicronemia compared with that observed in the EPA-olive oil breakfast 
and the control breakfast with olive oil alone. Lipidomics of chylomicron triacylglycerols 
(TAG) revealed that the EPA and DPA were incorporated into different TAG molecular 
species, namely EPA into 18:1:18:1:EPA and DPA into 16:0:18:1:DPA, with a significantly 
lower incorporation of DPA compared with EPA in the chylomicron TAG. They also 
reported that three out of ten participants felt sick in the stomach after having the DPA 
breakfast, and this led them to hypothesize that DPA might interfere with lipid digestion, 
absorption or clearance. However, in this study the lipid content of the faeces was not 
analysed.   
The present short-term study aimed to investigate whether DPA and EPA were 
metabolised equally or differently and thus, it was specificaly designed to assess the 
relative loss of DPA or EPA in faeces after equal dietary intake, and whether there was 
the incorporation of dietary DPA or EPA into tissues.   
 
 Materials and methods 
5.3.1 Diet and study design 
Twenty four 6-week old healthy male Sprague Dawley rats were housed in pairs and 
acclimatised for a week on ad libitum normal chow diet. The rats were then randomly 
divided into four groups of six rats each. The first group was sacrificed at day 0 for 
baseline data. The other groups were fed a specially prepared high fat diet (Speciality 
Feed, Western Australia; 22.5% protein, 23.5% fat, 10% total saturated fat, 8.3% 
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monounsaturated fat, 4.5% linoleic acid, 0.5% α-linolenic acid, and no detectable 
arachidonic acid, EPA, DPA or DHA) for 9 days; on days 5, 6 and 7 the groups of rats were 
fed either EPA, DPA or olive oil (250 mg/animal/day), soaked onto the high fat pellets. 
Using a micropipette, 500 mg of the two pure fatty acids or olive oil was applied daily 
for each pair of rats, before feed administration onto 6 pellets (equating to 4 grams 
total). These fortified pellets were then supplied as first feed in the morning to their 
respective allocated cages and it was verified that all fortified pellets were completely 
consumed by the rats within 1 hour since administration, daily. Subsequently, all animals 
were provided with the remainder of their normal daily ration (36 grams). The rats 
continued on the high fat diet on days 8 and 9. EPA (>99%; w/w) and DPA (>99%; w/w) 
were supplied in the FFA form (Nu-Chek Prep, Inc., MN, USA). Olive oil (Lupi, Italy) was 
used as a control. Daily, throughout the 9-day period, the rats were weighed, their food 
intake was monitored, and the faeces were collected. After the nine days, the rats were 
humanely euthanized with CO2 overdose. Blood was drawn and the heart and liver were 
removed and frozen at -80°C. 
The design of this fat absorption/excretion study was based on that reported by 
Jandacek et al (2004). In that study, it was shown that non-absorbable substances, such 
as olestra and calcium soaps of fatty acids were poorly absorbed compared with 
safflower oil, over a 2 to 3-day test period. The method was reported to be reproducible 
and consistent in both rats and mice. Thus, the number of animals in this study was set 
at 6 per group and duration of the experimental feeding of high fat diet at three days. 
In the study, the entire faecal output was collected from each cage (2 animals) and the 
amount of fat in the faeces was analysed on a per cage basis, for each day. 
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The study was performed following the Australian code of practice for care and use of 
animals for scientific purposes, and the study was approved by Deakin University Animal 
Welfare Committee (G28-2012). 
 
5.3.2 Lipid analysis  
Aliquots of liver, heart, plasma and faeces samples were homogenized, and the lipids 
were extracted by dichloromethane - methanol (2:1), essentially as described by Folch 
et al (1957). Fatty acids derived from the lipids were methylated using modified methods 
of Christie (2003). In brief, an aliquot of fatty acids derived from the lipids plus an 
internal standard of tricosanoic acid (C23:0 >99%; Nu-Chek Prep, Inc.) were reacted with 
acetyl chloride/methanol for 1 h at 100°C to form fatty acid methyl esters (FAME). The 
resulting FAME were separated and quantified by using a Shimadzu GC-2010 (Kyoto, 
Japan) equipped with a BPX70 capillary column (60 m x 0.25 mm internal diameter, 0.25 
μm film thickness (SGE Analytical Science, Australia), a splitless injector and a flame 
ionization detector. Each of the fatty acids was identified relative to known external 
standards (Tricosanoic acid, Sigma-Aldrich, Inc., St. Louis, MO, USA, and Nu-Chek Prep, 
Elysian, MN, USA), and the resulting peaks were then corrected by the theoretical 
relative Flame Ionization Detector response factors (Ackman, 2002) and quantified 
relative to the internal standard. 
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5.3.3 Statistical analysis  
Data analysis was performed with Minitab Statistical Software (Version 14; Minitab Inc., 
USA). Significant differences between experimental groups were tested using one way 
ANOVA. Paired tests were performed with Tukey’s test. Statistical significance was 
indicated by P<0.05.  
 
 Results 
5.4.1 Body weight 
There was no significant difference (P=0.203) in the body weights of the rats in the three 
experimental groups at the end of the study. The average body weights (± SD) of animals 
in olive oil, DPA and EPA groups were 379 (± 6), 366 (± 19) and 375 (± 9), respectively.  
 
5.4.2 The lipid content and fatty acid composition of the faeces 
There were no significant differences in the total amount of faecal fat between the three 
groups over the 9 day study (Table 5.1). The average percentage of lipids in the faeces 
(± SD) at day 9 in the olive oil, DPA and EPA groups was 2.89 (± 0.13), 2.92 (± 0.15) and 
2.95 (± 0.12), respectively.    
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Table 5-1. The amount of lipids in the faeces of rats fed high fat diet enriched with 
DPA, EPA or olive oil (250 mg/animal/day) at days 5 to 7. 
Day Olive oil feeding DPA feeding EPA feeding  
1 2.95 ± 0.00 2.97 ± 0.24 2.93 ± 0.34 
2 3.02 ± 0.12 2.92 ± 0.18 3.01 ± 0.07 
3 3.03 ± 0.07 2.73 ± 0.15 2.92 ± 0.29 
4 2.99 ± 0.13 2.99 ± 0.08 2.92 ± 0.09 
5 2.70 ± 0.05 2.94 ± 0.05 2.72 ± 0.12 
6 3.08 ± 0.11 3.17 ± 0.06 2.88 ± 0.10 
7 3.18 ± 0.05 3.28 ± 0.08 3.12 ± 0.10 
8 3.29 ± 0.11 3.21 ± 0.10 3.18 ± 0.06 
9 2.89 ± 0.13 2.92 ± 0.15 2.95 ± 0.12 
P value 0.166 0.236 0.296 
Values are g lipids in 100 g faeces wet weight ± SD, n=6. There are not significant differences 
between groups or between experimental days 
 
The fatty acid content of the faeces was affected by diet (Table 5.2). The content of DPA 
and EPA both increased significantly on days 6, 7 and 8 following feeding of these fatty 
acids on days 5-7. However, the oleic acid content was not affected by the 3-day 
provision of olive oil. The EPA supplementation was also associated with a small, but 
significant increase in the DHA content in faeces (days 7 and 8) compared with the olive 
oil or DPA supplementation (data not shown).  
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Table 5-2. DPA, EPA and OA content of rats faeces (mg/g wet weight) before (day 4), during (Day 5, 6 and 7) and after (Day 8 and 9) dietary 
supplementation of DPA, EPA and olive oil (250 mg/animal/day), respectively. 
Group FA excreted Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 P value 
DPA feeding DPA 0.03 ± 0.00a 0.03 ± 0.00a 0.44± 0.04b 0.29± 0.02b 0.28± 0.10b 0.03± 0.01 a 0.000 
EPA feeding EPA n.d n.d 0.04 ± 0.00a 0.09 ± 0.02a 0.09 ± 0.02a n.d 0.000 
Oleic acid OA 0.65 ± 0.07a 0.53 ± 0.04a 0.60 ± 0.06a 0.67 ± 0.02a 0.66 ± 0.05a 0.42± 0.03b 0.000 
Results are expressed as mean ± SD, n=6. Values with different letters differ significantly in each row (P< 0.05). n.d= not detected 
 
Table 5-3. Selected plasma fatty acids (μg/ml plasma) at day 9 of rats fed DPA, EPA or olive oil (250 mg/day) at days 5 to 7. 
Group Oleic acid EPA  DPA DHA n-3 LC-PUFA 20:4n-6 22:5n-6 n-6 LC-PUFA 
DPA feeding 376 ± 112 13 ± 8b 25 ± 7 84 ± 17 123 ± 90 472 ± 70 n.d2a 472 ± 70 
EPA feeding 525 ± 168 14 ± 3b 28 ± 8  105 ± 24 140 ± 20 553 ± 116 n.d2a 553 ± 116 
Olive oil feeding  654 ± 9 n.da 18 ± 8 101 ± 41   120 ± 10 611 ± 105 13 ± 2b 638 ± 127 
Baseline data1  718 ± 22 n.da 18 ± 7 80 ± 30 98 ± 9 432 ± 98 14 ± 4b 449 ± 87 
P value 0.173 0.013 0.328 0.525 0.432 0.352 0.046 0.330 
The rats were maintained on a high fat diet throughout the 9 days of the study. n-3 LC-PUFA: DPA+EPA+DHA; n-6 LC-PUFA: 20:4n-6 + 22:4n-6 + 22:5n-6. 
1Data from day 0. n.d= not detected. Values are mean ± SD, n=6. Values with different letters differ significantly in each column (P< 0.05).   
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There were no significant differences in the content of DPA or DHA between the groups 
measured at day 9 (Table 5.3). The level of EPA was significantly higher in DPA and EPA-
fed groups compared with olive oil group. There was no difference between treatments 
for the 20:4n-6 content in plasma. 
 
5.4.3 The lipid content and fatty acid composition of liver and heart  
There was no significant difference in the lipid content of liver (5.9% vs 6.3%) and heart 
(2.9% vs 2.7%) between DPA and EPA feeding groups, respectively.  
Both EPA and DPA supplementations significantly increased the DPA and EPA 
concentrations in liver compared with the olive oil supplementation (Table 5.4). There 
were similar levels of these fatty acids in both EPA and DPA-fed groups. The total amount 
of n-3 LC-PUFA (namely DPA, EPA and DHA concentrations pooled) was significantly 
increased by both EPA and DPA feeding compared with the olive oil feeding. There was 
no difference between treatments for the 20:4n-6 content in liver. 
In the heart, DPA concentration was significantly increased by the DPA feeding 
compared with the EPA and olive oil feeding. There were no significant increases in EPA 
or DPA concentrations following EPA supplementation. However, both EPA and DPA 
feeding significantly increased the total n-3 LC-PUFA concentration in the heart 
compared with the olive oil feeding or the baseline data. There was no difference 
between treatments for the 20:4n-6 content in heart. 
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Table 5-4. Selected liver and heart fatty acids (mg/g of tissue) of rats fed high fat diet with DPA, EPA or olive oil (250 mg/animal/day) at days 5 to 7. 
The rats were maintained on a high fat diet throughout the 9 days of the study. n-3 LC-PUFA: DPA+EPA+DHA; n-6 LC-PUFA: 20:4n-6 + 22:4n-6 + 22:5n-
6. 1Data from day 0. 2not detected. Values are mean ± SD, n=6. Values with different letters differ significantly in each column (P<0.05) 
Group Oleic acid EPA DPA DHA n-3 LC-PUFA 20:4n-6 22:5n-6 n-6 LC-PUFA 
Liver         
DPA feeding 10.88 ± 2.17b 0.20 ± 0.07b 0.64 ± 0.11b 1.62 ± 0.29ab 2.47 ±0.50b 4.34 ± 0.47b 0.06 ± 0.02a 4.61 ± 0.50b 
EPA feeding 11.64 ± 4.10b 0.27 ± 0.19b 0.66 ± 0.14b 2.05 ± 0.73b 2.98 ± 0.66b 4.74 ± 0.37b 0.07 ± 0.02a 5.03 ± 0.43b 
Olive oil feeding 13.54 ± 3.16b 0.08 ± 0.03a 0.32 ± 0.10a 1.50 ± 0.42ab 1.91 ± 0.40a 4.79 ± 0.34b 0.13 ± 0.04b 5.27 ± 0.27b 
Baseline data1  2.75 ± 0.32a 0.06 ± 0.00a 0.17 ± 0.00a 1.12 ± 0.14a 1.35 ± 0.09a 3.50 ± 0.10a 0.07 ± 0.01a 3.66 ± 0.10a 
P value  0.000 0.004 0.017 0.014 0.032 0.000 0.012 0.000 
Heart         
DPA feeding 1.59 ± 0.25 n.d2 1.33 ± 0.27b 2.56 ± 0.92ab 3.32 ± 0.46b 3.77 ± 0.27 0.23 ± 0.03 4.18 ± 0.44 
EPA feeding 1.80 ± 0.24 0.08 ± 0.05 0.85 ± 0.08a 2.94 ± 0.64b 3.87 ± 0.30b 4.16 ± 0.84 0.26 ± 0.04 4.42 ± 0.85 
Olive oil feeding 1.50 ± 0.22 n.d2 0.74 ± 0.14a 2.29 ± 0.64ab 3.03 ± 0.18a 4.30 ± 0.16 0.32 ± 0.02 4.99 ± 0.18 
Baseline data1  2.65 ± 1.05 n.d2 0.54 ± 0.04a 1.98 ± 0.38a  3.10 ± 0.16a 3.33 ± 0.50 0.33 ± 0.09 3.99 ± 0.75 
P value  0.236 0.157 0.002 0.037 0.042 0.100 0.098 0.165 
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 Discussion  
The present study sought to establish if short-term DPA feeding increased the excretion 
of DPA in faeces in rats relative to EPA. It was found that significantly more DPA was 
excreted in the DPA-fed group (0.4% of the dose fed) than EPA in the EPA-fed group 
(0.07% of the dose fed). It is interesting that despite the manifest poor apparent 
digestibility of DPA, the overall lipid digestibility seemed unaffected, as the total amount 
of lipids excreted in faeces was constant in all treatments and during the entire duration 
of the trial.  
This 4-fold increase in DPA excretion should clearly contribute to a reduced 
bioavailability of the DPA for possible subsequent tissue deposition, in comparison with 
EPA. 
The increased faecal excretion of DPA might offer empirical evidence explaining the 
reduced DPA incorporation into chylomicrons in the human study (Linderborg et al., 
2013). The reason for the increased DPA excretion is not clear, however the 
incorporation of FFA into chylomicrons involves a number of steps including absorption 
across gut mucosa, activation of the FFA into the CoA form and acylation to allow TAG 
formation.  
In the plasma, which was sampled at the conclusion of the study (day 9), the EPA content 
was increased for both the DPA and EPA-fed groups. Furthermore, an increased level of 
DPA was recorded in both liver and heart, 2 days after the feeding of the DPA ceased. 
Additionally, there was an increased level of EPA in the liver in the DPA-fed group, 
confirming the previously suggested occurrence of active retroconversion of DPA to EPA 
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(Kaur et al., 2010, Kaur et al., 2013, Holub et al., 2011). An interesting difference 
between DPA and EPA was noted in the heart, as DPA significantly increased heart DPA 
levels, whereas EPA did not increase heart EPA levels.  
Both DPA and EPA feeding increased the total n-3 LC-PUFA content of liver and heart to 
a similar extent, showing that the increased excretion of DPA, and thus reduced 
bioavailability, paradoxically did not affect its deposition in tissues, relative to EPA. A 
possible explanation for this could be that part of the absorbed EPA was then used in 
other metabolic (further bioconversion and/or eicosanoids production) or catabolic (β-
oxidation for energy production) processes, and thus resulted in similar tissue 
deposition/retention of that recorded for DPA, which was less absorbed, but then 
proportionally more efficiently retained.  Accordingly, it was recently reported, that DHA 
and DPA were conserved from β-oxidation to a significantly greater extent than EPA and 
oleic acid at 6 h in rats (Kaur et al., 2013).  
In this study, neither EPA nor DPA feeding significantly increased the DHA level in the 
liver or the heart compared with the olive oil group, though it should be admitted that 
the high variability in tissue levels for DHA reduced the possibility for detecting 
significant increases in DHA. In a previous 7-day study in rats with pure DPA, it was 
shown that there was a significantly increased concentration of DHA in liver (Kaur et al., 
2010). Recent research has started to uncover the complexity of elongation of DPA to 
24:5n-3 in different species (Gregory et al., 2013). 
In humans, DPA and EPA have demonstrated different and specific incorporation 
patterns in plasma lipids, red blood cell lipids and chylomicrons. In the study of Miller et 
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al (2013), the DPA and EPA did not partition identically into the plasma lipid fractions 
(cholesterol ester, phospholipid, TAG) or into erythrocyte phospholipids to the same 
extent. Furthermore, Linderborg et al (2013) revealed that the EPA and DPA were 
incorporated into the chylomicrons TAG to different extents (EPA more than DPA) and 
into different TAG molecular species. In the present study, there were different patterns 
of uptake of DPA and EPA in the heart, which further emphasises different rates and/or 
degrees of metabolism of these two n-3 fatty acids. 
In the present study and the human study reported (Linderborg et al., 2013), the DPA 
was fed in the FFA form. There have been no studies which have compared the 
bioavailability in humans of DPA-FFA versus other n-3 LC-PUFA. However, several studies 
have compared the bioavailability of n-3 FFA-forms with n-3 ethyl ester and TAG forms. 
In most cases, the FFA form was significantly more bioavailable (Beckermann et al., 
1990, Lawson and Hughes, 1988b, Davidson et al., 2012). Thus, it is plausible to suggest 
that the results observed in the present study, are not related to the fact the two n-3 
fatty acids were provided as FFA. 
Together, the data from rat and human studies are pointing to significant differences in 
how mammals process DPA compared with EPA, a finding which was not predicted from 
earlier work on n-3 LC-PUFA. In summary, in answer to the research question posed, the 
evidence available thus far, suggests that dietary DPA is less available than EPA, and 
proportionally more excreted in faeces. However, EPA is then more prone to catabolic 
processes compared with DPA, resulting in similar deposition rates for the two n-3 LC-
PUFA into tissues. 
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 Conclusions and Future Directions 
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Omega-3 polyunsaturated fatty acids are essential nutrients for health. They are needed 
for numerous normal body functions, such as controlling blood clotting and building cell 
membranes in the brain, and since our bodies cannot make n-3 LC-PUFA, they should be 
gained from food. It has been well documented by a plethora of studies that the 
ingestion of n-3 LC-PUFA can improve health and in some instances can contribute to 
preventing disease. However, little scientific attention has been paid on the actual 
bioavailability of n-3 LC-PUFA.  
In this thesis, several nutritional questions related to bioavailability of n-3 LC-PUFA have 
been answered by animal model. It is acknowledged that the rats used were growing, 
rather than having reached a constant weight. It is possible that a different result could 
have been obtained in rats of constant body weight. 
 
Question 1. How studies on the bioavailability of different n-3 LC-PUFA should be 
conducted to provide more consistent results, and which lipid form of omega-3 is more 
bioavailable?  
In nutrition science, there is no agreed definition for the term bioavailability, and it is a 
term used more or less loosely to broadly describe how much of a given nutrient 
administered orally is then actually retained in the body, after its digestion and 
absorption; and thus in essence it is not different from the term “digestibility”. In this 
thesis, we decided to refer to the term bioavailability, even if, as it has been described 
in Chapter 2, it should have a better and standard definition.  
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The available literature on the bioavailability of n-3 LC-PUFA is not consistent with 
considerable variability in the results, presumably due to high heterogeneity in the study 
designs. To gain more consistent results, the literature review reported in this thesis 
(Chapter 2) and in the publication in Progress Lipid Research suggested that researchers 
should pay attention to several factors as listed in Table 6.1. This set of criteria was used 
for animal studies conducted in this thesis and also recommended for conducting future 
studies on the bioavailability of n-3 LC-PUFA.  
Table 6-1. A set of criteria used in Chapters 3, 4 & 5 and to be considered in future 
studies 
 Factors Chapter 3 Chapter 4 Chapter 5 
1 Using a standard methodology √ √ √ 
2 Using equal amounts the n-3 LC-PUFA of 
the different diets 
x x x 
3 Providing the dose of n-3 LC-PUFA on a 
body weight basis 
√ √ √ 
4 Measuring the n-3 LC-PUFA excretion √ √ √ 
5 Controlling the total fat intake of 
subjects/animal’ diets 
√ √ √ 
6 Considering gender √ √ √ 
7 Considering age and number of 
participants/animals 
√ √ √ 
8 Reporting sufficient details of the 
analytical and quality control matters 
related to the measurements of 
levels/concentrations in plasma or red 
blood cells 
√ √ √ 
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Based on the available literature, the apparent bioavailability seems to be lowest for the 
ethyl ester form and highest for the free fatty acid form, whilst no conclusion can be 
made for the comparative differences between the triacylglycerol versus phospholipid 
forms, based on the animal and human data. 
 
Question 2. Which is a better feeding strategy (daily or weekly dose), to optimise n-3 
LC-PUFA bioavailability?    
In Chapter 3, the data from the animal experimental suggested that the weekly dose of 
n-3 LC-PUFA was more effective in increasing whole body n-3 LC-PUFA content 
compared with consuming n-3 LC-PUFA daily. Although more n-3 LC-PUFA was excreted 
in the weekly dose (Spike) group, there was significantly less β-oxidised and more 
deposited in rat whole body after the weekly dose of n-3 LC-PUFA. This indicated that 
there were significant differences in the fate of the n-3 LC-PUFA between treatments. 
Health Authorities recommend that for good health, at least one rich source of omega-
3 fatty acids in the diet per week is sufficient. These preliminary, novel and highly 
interesting findings support this recommendation and warrant further investigations, 
and in particular the need to be substantiated by conducting appropriate trials in 
humans.  
 
Question 3. What oil provides more bioavailable sources of omega-3 fatty acids? Fish oil 
or krill oil? 
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In Chapter 4, it was found that krill oil and fish oil have similar bioavailability 
(absorption), but they differed in their metabolic fate (anabolism vs catabolism). There 
was a significantly greater deposition of the n-3 LC-PUFA in the krill oil fed group 
compared with the fish oil fed group. This finding has not been reported previously and 
should be confirmed by a longer term animal trial in which other tissues such as brain 
could be studied. Furthermore, it would be of great interest to check this question in 
humans as several available studies comparing the effects of fish oil and krill oil in human 
have been inadequately designed as they failed to provide equal amounts the n-3 LC-
PUFA, failed to provide the dose of n-3 LC-PUFA on a body weight basis, failed to 
measure fatty acid excretion and failed to control the total fat intake.  
 
Question 4. Is the bioavailability of n-3 LC-PUFA different between sexes of rats? 
There is evidence of more efficient n-3 LC-PUFA metabolism in women compared with 
men. Also, several rat studies examined the expression of enzymes involved in the 
biosynthesis of DHA from shorter chain omega-3 fatty acids, finding that female rats 
replete their DHA status more readily than males. However, there is a lack of 
information relative to possible sex differences with respect to n-3 LC-PUFA 
bioavailability and deposition.  
In Chapter 4, it was found that there were significant sex differences in the EPA and DHA 
concentrations (mg/g tissue) in liver, heart and adipose tissue, but not muscle tissue, 
with tissues from female rats having a higher level of these two fatty acids than male 
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rats. Absorption of fatty acids was significantly greater in female rats. It was estimated 
that most of EPA (>90%) and more than half of DHA (>60%) were β-oxidised in both diet 
groups. There was a significantly greater deposition of n-3 LC-PUFA in the whole body 
of female rats than male rats. These data suggested beneficial and perhaps unique 
findings; however, more extensive research is required to investigate the bioavailability 
of n-3 LC-PUFA between female and male subjects.  
 
Question 5. Would different n-3 LC-PUFA be deposited or excreted similarly in the rat? 
In Chapter 5, it was reported DPA and EPA were metabolised differently, despite being 
chemically similar. The total amount of DPA excreted being 4.6-fold greater than that of 
EPA, however the total amount of faecal fat did not differ significantly between the 
groups. At the conclusion of this short study, it was found that liver DPA, EPA and total 
n-3 LC-PUFA levels were significantly increased by both DPA and EPA feeding compared 
with the olive oil fed control group. In the heart, DPA feeding increased the DPA content 
and both DPA and EPA feeding increased the total n-3 LC-PUFA levels. It is possible that 
the duration used in this study was not long enough to cause a change in liver and heart 
DHA levels. Future studies should investigate the effect of long-term supplementation 
of DPA and EPA in animals. There is also a need to investigate the bioavailability of DPA 
and EPA in humans to test findings reported here, mainly whether DPA is significantly 
more excreted than EPA. 
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To test findings reported in this thesis, in humans, the following study design is 
proposed keeping in mind the issues have been raised in the review paper (Progress in 
Lipid Research) Chapter 2, as well as in other literature.  
Objectives: 
1. To test the effect of fish oil versus krill oil on bioavailability of n-3 LC-PUFA in 
humans, 
2. To test if there are gender effects in the bioavailability of n-3 LC-PUFA in humans, 
3. To test if a daily or weekly dose of n-3 LC-PUFA in humans leads to differences in 
bioavailability. 
 
The key features of the design are as follows: 
a. Recruiting male and female subjects with low red cell long chain omega-3 fatty 
acid levels. This can be achieved by diet screening and measurement of n-3 LC-
PUFA status prior to enrolment, 
b. Measuring faecal excretion of lipids and n-3 LC-PUFA, 
c. Conducting a post-prandial study at the start of a long-term study, 
d. Conducting the long-term study for a sufficiently long time to reach an 
equilibrated state. 
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For objectives 1 and 2 (follow each step). For objective 3 omit step 4. 
Step 1: Recruit male and female subjects with low baseline red blood cell n-3 LC-
PUFA status (for example vegetarians), in order to have a low starting blood omega-
3 level to maximise the possibility of seeing a significant rise in n-3 LC-PUFA in tissues 
analysed, 
Step 2: Recruit a sufficiently large enough sample to be able to deal with the 
variability in blood omega-3 responses as outlined by Harris and Thomas (2010) and 
Flock et al (2013) (age, physical activity, gender, starting omega-3 level in blood), 
Step 3: Recruit subjects with similar body mass, so that the same dose per kg body 
weight per gender can be used. Otherwise the dose of n-3 LC-PUFA on a body weight 
basis should be provided, 
Step 4: Conduct a post-prandial study on day 1 of the long-term trial in male and 
female subjects fed fish oil and krill oil, measuring the post-prandial response to the 
oils in chylomicrons, non-chylomicrons and plasma. Take blood samples for at least 
8 hours to account for possible differences in the rates of absorption of n-3 LC-PUFA 
from TAG (fish oil) and phospholipid (krill oil) forms, 
Step 5: Use red blood cell n-3 LC-PUFA levels as proxy for bioavailability and if 
feasible take an adipose tissue biopsy and muscle biopsy at the start and finish of 
the study. While these might seem invasive procedures, they are collected in 
nutrition studies with appropriately trained staff (Dasarathy et al., 2015, Veno et al., 
2013, Jans et al., 2012). In order to monitor excretion of fatty acids, collect faeces at 
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the start (for 24 hours) of the study and every month (24 hour sample) thereafter 
until the conclusion, 
Step 6: Design a minimum of six-month study to be able to monitor steady changes 
of n-3 LC-PUFA status in the various compartments (Browning et al., 2014). 
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